Patent Application
20170107229
The present invention relates to substituted tetrahydropyridothienopyrimidine compounds of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.
The present invention relates to chemical compounds that inhibit MKNK1 kinase (also known as MAP Kinase interacting Kinase, Mnk1) and/or MKNK2 kinase (also known as MAP Kinase interacting Kinase, Mnk2).
Human MKNKs comprise a group of four proteins encoded by two genes (Gene symbols: MKNK1 and MKNK2) by alternative splicing. The b-forms lack a MAP kinase-binding domain situated at the C-terminus. The catalytic domains of the MKNK1 and MKNK2 are very similar and contain a unique DFD (Asp-Phe-Asp) motif in subdomain VII, which usually is DFG (Asp-Phe-Gly) in other protein kinases and suggested to alter ATP binding [Jauch et al., Structure 13, 1559-1568, 2005 and Jauch et al., EMBO J25, 4020-4032, 2006]. MKNK1a binds to and is activated by ERK and p38 MAP Kinases, but not by JNK1. MKNK2a binds to and is activated only by ERK. MKNK1b has low activity under all conditions and MKNK2b has a basal activity independent of ERK or p38 MAP Kinase. [Buxade M et al., Frontiers in Bioscience 5359-5374, May 1, 2008]
MKNKs have been shown to phosphorylate eukaryotic initiation factor 4E (eIF4E), heterogeneous nuclear RNA-binding protein A1 (hnRNP A1), polypyrimidine-tract binding protein-associated splicing factor (PSF), cytoplasmic phospholipase A2 (cPLA2) and Sprouty 2 (hSPRY2) [Buxade M et al., Frontiers in Bioscience 5359-5374, May 1, 2008].
eIF4E is an oncogene that is amplified in many cancers and is phosphorylated exclusively by MKNKs proteins as shown by KO-mouse studies [Konicek et al., Cell Cycle 7:16, 2466-2471, 2008; Ueda et al., Mol Cell Biol 24, 6539-6549, 2004]. eIF4E has a pivotal role in enabling the translation of cellular mRNAs. eIF4E binds the 7-methylguanosine cap at the 5′ end of cellular mRNAs and delivers them to the ribosome as part of the eIF4F complex, also containing eIF4G and eIF4A. Though all capped mRNAs require eIF4E for translation, a pool of mRNAs is exceptionally dependent on elevated eIF4E activity for translation. These so-called “weak mRNAs” are usually less efficiently translated due to their long and complex 5′UTR region and they encode proteins that play significant roles in all aspects of malignancy including VEGF, FGF-2, c-Myc, cyclin D1, survivin, BCL-2, MCL-1, MMP-9, heparanase, etc. Expression and function of eIF4E is elevated in multiple human cancers and directly related to disease progression [Konicek et al., Cell Cycle 7:16, 2466-2471, 2008].
MKNK1 and MKNK2 are the only kinases known to phosphorylate eIF4E at Ser209. Overall translation rates are not affected by eIF4E phosphorylation, but it has been suggested that eIF4E phosphorylation contributes to polysome formation (i.e. multiple ribosome on a single mRNA) that ultimately enables more efficient translation of “weak mRNAs” [Buxade M et al., Frontiers in Bioscience 5359-5374, May 1, 2008]. Alternatively, phosphorylation of eIF4E by MKNK proteins might facilitate eIF4E release from the 5′ cap so that the 48S complex can move along the “weak mRNA” in order to locate the start codon [Blagden S P and Willis A E, Nat Rev Clin Oncol. 8(5):280-91, 2011]. Accordingly, increased eIF4E phosphorylation predicts poor prognosis in non-small cell lung cancer patients [Yoshizawa et al., Clin Cancer Res. 16(1):240-8, 2010]. Further data point to a functional role of MKNK1 in carcinogenesis, as overexpression of constitutively active MKNK1, but not of kinase-dead MKNK1, in mouse embryo fibroblasts accelerates tumor formation [Chrestensen C. A. et al., Genes Cells 12, 1133-1140, 2007]. Moreover, increased phosphorylation and activity of MKNK proteins correlate with overexpression of HER2 in breast cancer [Chrestensen, C. A. et al., J. Biol. Chem. 282, 4243-4252, 2007]. Constitutively active, but not kinase-dead, MKNK1 also accelerated tumor growth in a model using Ep-Myc transgenic hematopoietic stem cells to produce tumors in mice. Comparable results were achieved, when an eIF4E carrying a S209D mutation was analyzed. The S209D mutation mimicks a phosphorylation at the MKNK1 phosphorylation site. In contrast a non-phosphorylatable form of eIF4E attenuated tumor growth [Wendel H G, et al., Genes Dev. 21(24):3232-7, 2007]. A selective MKNK inhibitor that blocks eIF4E phosphorylation induces apoptosis and suppresses proliferation and soft agar growth of cancer cells in vitro. This inhibitor also suppresses outgrowth of experimental B16 melanoma pulmonary metastases and growth of subcutaneous HCT116 colon carcinoma xenograft tumors without affecting body weight [Konicek et al., Cancer Res. 71(5):1849-57, 2011]. Screening of a cohort of pancreatic ductal adenocarcinoma patients by immunohistochemistry showed that eIF4E phosphorylation correlated with disease grade, early onset of disease and worse prognosis. In addition it was suggested based on preclinical in vitro findings that the MNK/eIF4E pathway represents an escape route utilized by pancreatic ductal adenocarcinoma cells to withstand chemotherapeutic treatments (e.g Gemcitabine) [Adesso L, et al., Oncogene. 2012 Jul. 16]. Furthermore, it was observed that Rapamycin activated MKNK1 kinase activity in multiple myeloma cell lines and primary specimens by a MKNK-dependent mechanism. Pharmacological inhibition of MKNK activity or genetic silencing of MKNK1 prevented a rapalog-induced upregulation of c-myc IRES activity. Although Rapamycin, used alone, had little effect on myc protein expression, when combined with a MKNK inhibitor, myc protein expression was abrogated. These data provide a rationale for therapeutically targeting MKNK kinases for combined treatment with mTOR inhibitors [Shi Y et al., Oncogene. 2012 Feb. 27]. In summary, eIF4E phosphorylation through MKNK protein activity can promote cellular proliferation and survival and is critical for malignant transformation. Inhibition of MKNK activity may provide a tractable cancer therapeutic approach.
Furthermore it has been found that MKNK1 is an acinar cell-specific kinase required for exocrine pancreatic secretion [Cendrowski J, Sanchez-Arevalo Lobo V J, Sendler M, et al. Gut; Published Online First: Jul. 18, 2014; doi:10.1136/gutjnl-2013-306068].
WO2009/33581(A1) discloses tetrahydropyridothieno[2,3-d]-pyrimidine derivatives as EGFR tyrosine kinase inhibitors.
WO2010/023181(A1), WO2011/104334(A1), WO2011/104337(A1), WO2011/104338(A1) and WO2011/104340(A1) (Boehringer Ingelheim) relate to thienopyrimidin-4-amines for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2.
US2010/120805A1 discloses fused bicyclic or tricyclic pyrimidine compounds as tyrosine kinase inhibitors.
Certain tetrahydropyridothieno[2,3-d]-pyrimidine derivatives were found to irreversibly inhibit EGFR tyrosine kinase (Mostafa M. Hamed et al., Med Chem Comm, 2013, vol. 4, p. 1202-1207).
US2010/298297A1 discloses tetrahydropyridothieno[2,3-d]-pyrimidine derivatives showing anti-proliferative activity in tumor cell proliferation assays.
Specific substituted tetrahydropyridothienopyrimidine compounds of general formula (I) of the present invention as defined herein, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same, as described and defined herein, and as hereinafter referred to as “compounds of the present invention”, or their pharmacological activity have not been disclosed so far.
It has now been found, and this constitutes the basis of the present invention, that said compounds of the present invention have surprising and advantageous properties.
In particular, said compounds of the present invention have surprisingly been found to effectively inhibit MKNK kinases and may therefore be used for the treatment or prophylaxis of diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, or inappropriate cellular inflammatory responses or diseases which are accompanied with uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, or inappropriate cellular inflammatory responses, particularly in which the uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, or inappropriate cellular inflammatory responses is mediated by MKNK kinases, such as, for example, haematological tumours, solid tumours, and/or metastases thereof, e.g. leukaemias and myelodysplastic syndrome, malignant lymphomas, head and neck tumours including brain tumours and brain metastases, tumours of the thorax including non-small cell and small cell lung tumours, gastrointestinal tumours, endocrine tumours, mammary and other gynaecological tumours, urological tumours including renal, bladder and prostate tumours, skin tumours, and sarcomas, and/or metastases thereof.
The present invention covers compounds of general formula (I):
in which:
The present invention further relates to methods of preparing compounds of general formula (I), to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.
The terms as mentioned in the present text have preferably the following meanings: The term “halogen atom”, “halo-” or “Hal-” is to be understood as meaning a fluorine, chlorine, bromine or iodine atom, preferably a fluorine, chlorine or bromine atom.
The term “C1-C6-alkyl” is to be understood as preferably meaning a linear or branched, saturated, monovalent hydrocarbon group having 1, 2, 3, 4, 5 or 6 carbon atoms, e.g. a methyl, ethyl, propyl, butyl, pentyl, hexyl, iso-propyl, iso-butyl, sec-butyl, tert-butyl, iso-pentyl, 2-methylbutyl, 1-methylbutyl, 1-ethylpropyl, 1,2-dimethylpropyl, neo-pentyl, 1,1-dimethylpropyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 2-ethylbutyl, 1-ethylbutyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 2,3-dimethylbutyl, 1,3-dimethylbutyl, or 1,2-dimethylbutyl group, or an isomer thereof. Particularly, said group has 1, 2, 3 or 4 carbon atoms (“C1-C4-alkyl”), e.g. a methyl, ethyl, propyl, butyl, iso-propyl, iso-butyl, sec-butyl, tert-butyl group; even more particularly 1, 2 or 3 carbon atoms (“C1-C3-alkyl”), e.g. a methyl, ethyl, n-propyl- or iso-propyl group.
The term “C1-C10-alkylene” is to be understood as preferably meaning a linear or branched, saturated, bivalent hydrocarbon group having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, e.g. a methylene, ethylene, n-propylene, n-butylene, n-pentylene, 2-methylbutylene, n-hexylene, 3-methylpentylene group, or an isomer thereof. Particularly, said group is linear and has 2, 3, 4 or 5 carbon atoms (“C2-C5-alkylene”), e.g. an ethylene, n-propylene, n-butylene, n-pentylene group, more particularly 3 or 4 carbon atoms (“C3-C4-alkylene”), e.g. an n-propylene or n-butylene group.
The term “halo-C1-C6-alkyl” is to be understood as preferably meaning a linear or branched, saturated, monovalent hydrocarbon group in which the term “C1-C6-alkyl” is defined supra, and in which one or more hydrogen atoms is replaced by a halogen atom, in identically or differently, i.e. one halogen atom being independent from another. Particularly, said halogen atom is F. Said halo-C1-C6-alkyl group is, for example, —CF3, —CHF2, —CH2F, —CF2CF3 or —CH2CF3.
The term “C1-C6-alkoxy” is to be understood as preferably meaning a linear or branched, saturated, monovalent, hydrocarbon group of formula —O—(C1-C6-alkyl), in which the term “C1-C6-alkyl” is defined supra, e.g. a methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, tert-butoxy, sec-butoxy, pentoxy, iso-pentoxy, or n-hexoxy group, or an isomer thereof.
The term “halo-C1-C6-alkoxy” is to be understood as preferably meaning a linear or branched, saturated, monovalent C1-C6-alkoxy group, as defined supra, in which one or more of the hydrogen atoms is replaced, in identically or differently, by a halogen atom. Particularly, said halogen atom is F. Said halo-C1-C6-alkoxy group is, for example, —OCF3, —OCHF2, —OCH2F, —OCF2CF3 or —OCH2CF3.
The term “C1-C6-alkoxy-C1-C6-alkyl” is to be understood as preferably meaning a linear or branched, saturated, monovalent C1-C6-alkyl group, as defined supra, in which one or more of the hydrogen atoms is replaced, in identically or differently, by a C1-C6-alkoxy group, as defined supra, e.g. methoxyalkyl, ethoxyalkyl, propyloxyalkyl, iso-propoxyalkyl, butoxyalkyl, iso-butoxyalkyl, tert-butoxyalkyl, sec-butoxyalkyl, pentyloxyalkyl, iso-pentyloxyalkyl, hexyloxyalkyl group, or an isomer thereof.
The term “halo-C1-C6-alkoxy-C1-C6-alkyl” is to be understood as preferably meaning a linear or branched, saturated, monovalent C1-C6-alkoxy-C1-C6-alkyl group, as defined supra, in which one or more of the hydrogen atoms is replaced, in identically or differently, by a halogen atom. Particularly, said halogen atom is F. Said halo-C1-C6-alkoxy-C1-C6-alkyl group is, for example, —CH2CH2OCF3, —CH2CH2OCHF2, —CH2CH2OCH2F, —CH2CH2OCF2CF3 or —CH2CH2OCH2CF3.
The term “C2-C6-alkenyl” is to be understood as preferably meaning a linear or branched, monovalent hydrocarbon group, which contains one or more double bonds, and which has 2, 3, 4, 5 or 6 carbon atoms, particularly 2 or 3 carbon atoms (“C2-C3-alkenyl”), it being understood that in the case in which said alkenyl group contains more than one double bond, then said double bonds may be isolated from, or conjugated with, each other. Said alkenyl group is, for example, a vinyl, allyl, (E)-2-methylvinyl, (Z)-2-methylvinyl, homoallyl, (E)-but-2-enyl, (Z)-but-2-enyl, (E)-but-1-enyl, (Z)-but-1-enyl, pent-4-enyl, (E)-pent-3-enyl, (Z)-pent-3-enyl, (E)-pent-2-enyl, (Z)-pent-2-enyl, (E)-pent-1-enyl, (Z)-pent-1-enyl, hex-5-enyl, (E)-hex-4-enyl, (Z)-hex-4-enyl, (E)-hex-3-enyl, (Z)-hex-3-enyl, (E)-hex-2-enyl, (Z)-hex-2-enyl, (E)-hex-1-enyl, (Z)-hex-1-enyl, iso-propenyl, 2-methylprop-2-enyl, 1-methylprop-2-enyl, 2-methylprop-1-enyl, (E)-1-methylprop-1-enyl, (Z)-1-methylprop-1-enyl, 3-methylbut-3-enyl, 2-methylbut-3-enyl, 1-methylbut-3-enyl, 3-methylbut-2-enyl, (E)-2-methylbut-2-enyl, (Z)-2-methylbut-2-enyl, (E)-1-methylbut-2-enyl, (Z)-1-methylbut-2-enyl, (E)-3-methylbut-1-enyl, (Z)-3-methylbut-1-enyl, (E)-2-methylbut-1-enyl, (Z)-2-methylbut-1-enyl, (E)-1-methylbut-1-enyl, (Z)-1-methylbut-1-enyl, 1,1-dimethylprop-2-enyl, 1-ethylprop-1-enyl, 1-propylvinyl, 1-isopropylvinyl, 4-methylpent-4-enyl, 3-methylpent-4-enyl, 2-methylpent-4-enyl, 1-methylpent-4-enyl, 4-methylpent-3-enyl, (E)-3-methylpent-3-enyl, (Z)-3-methylpent-3-enyl, (E)-2-methylpent-3-enyl, (Z)-2-methylpent-3-enyl, (E)-1-methylpent-3-enyl, (Z)-1-methylpent-3-enyl, (E)-4-methylpent-2-enyl, (Z)-4-methylpent-2-enyl, (E)-3-methylpent-2-enyl, (Z)-3-methylpent-2-enyl, (E)-2-methylpent-2-enyl, (Z)-2-methylpent-2-enyl, (E)-1-methylpent-2-enyl, (Z)-1-methylpent-2-enyl, (E)-4-methylpent-1-enyl, (Z)-4-methylpent-1-enyl, (E)-3-methylpent-1-enyl, (Z)-3-methylpent-1-enyl, (E)-2-methylpent-1-enyl, (Z)-2-methylpent-1-enyl, (E)-1-methylpent-1-enyl, (Z)-1-methylpent-1-enyl, 3-ethylbut-3-enyl, 2-ethylbut-3-enyl, 1-ethylbut-3-enyl, (E)-3-ethylbut-2-enyl, (Z)-3-ethylbut-2-enyl, (E)-2-ethylbut-2-enyl, (Z)-2-ethylbut-2-enyl, (E)-1-ethylbut-2-enyl, (Z)-1-ethyl but-2-enyl, (E)-3-ethylbut-1-enyl, (Z)-3-ethylbut-1-enyl, 2-ethylbut-1-enyl, (E)-1-ethyl but-1-enyl, (Z)-1-ethylbut-1-enyl, 2-propylprop-2-enyl, 1-propylprop-2-enyl, 2-isopropylprop-2-enyl, 1-isopropylprop-2-enyl, (E)-2-propylprop-1-enyl, (Z)-2-propylprop-1-enyl, (E)-1-propylprop-1-enyl, (Z)-1-propylprop-1-enyl, (E)-2-isopropylprop-1-enyl, (Z)-2-isopropylprop-1-enyl, (E)-1-isopropyl prop-1-enyl, (Z)-1-isopropylprop-1-enyl, (E)-3,3-dimethylprop-1-enyl, (Z)-3,3-dimethylprop-1-enyl, 1-(1,1-dimethylethyl)ethenyl, buta-1,3-dienyl, penta-1,4-dienyl, or hexa-1,5-dienyl group. Particularly, said group is vinyl or allyl.
The term “C2-C6-alkynyl” is to be understood as preferably meaning a linear or branched, monovalent hydrocarbon group which contains one or more triple bonds, and which contains 2, 3, 4, 5 or 6 carbon atoms, particularly 2 or 3 carbon atoms (“C2-C3-alkynyl”). Said C2-C6-alkynyl group is, for example, ethynyl, prop-1-ynyl, prop-2-ynyl, but-1-ynyl, but-2-ynyl, but-3-ynyl, pent-1-ynyl, pent-2-ynyl, pent-3-ynyl, pent-4-ynyl, hex-1-ynyl, hex-2-ynyl, hex-3-ynyl, hex-4-ynyl, hex-5-ynyl, 1-methylprop-2-ynyl, 2-methylbut-3-ynyl, 1-methylbut-3-ynyl, 1-methylbut-2-ynyl, 3-methylbut-1-ynyl, 1-ethylprop-2-ynyl, 3-methylpent-4-ynyl, 2-methylpent-4-ynyl, 1-methylpent-4-ynyl, 2-methylpent-3-ynyl, 1-methylpent-3-ynyl, 4-methylpent-2-ynyl, 1-methylpent-2-ynyl, 4-methylpent-1-ynyl, 3-methylpent-1-ynyl, 2-ethylbut-3-ynyl, 1-ethylbut-3-ynyl, 1-ethylbut-2-ynyl, 1-propylprop-2-ynyl, 1-isopropylprop-2-ynyl, 2,2-dimethylbut-3-ynyl, 1,1-dimethylbut-3-ynyl, 1,1-dimethylbut-2-ynyl, or 3,3-dimethylbut-1-ynyl group. Particularly, said alkynyl group is ethynyl, prop-1-ynyl, or prop-2-ynyl.
The term “C3-C6-cycloalkyl” is to be understood as meaning a saturated, monovalent, and monocyclic hydrocarbon ring which contains 3, 4, 5 or 6 carbon atoms. Said C3-C6-cycloalkyl group is for example a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl hydrocarbon ring.
The term “C3-C6-cycloalkyloxy” refers to a (C3-C6-cycloalkyl)-O— group in which “C3-C6-cycloalkyl” is as defined herein. Examples include, but are not limited to, cyclopropanoxy and cyclobutanoxy.
The term “C4-C6-cycloalkenyl” is to be understood as preferably meaning a non-aromatic, monovalent, and monocyclic hydrocarbon ring which contains 4, 5 or 6 carbon atoms and one or two double bonds, in conjugation or not, as the size of said cycloalkenyl ring allows. Said C4-C10-cycloalkenyl group is for example a cyclobutenyl, cyclopentenyl, or cyclohexenyl hydrocarbon ring.
The term “3- to 10-membered heterocycloalkyl”, is to be understood as meaning a saturated, monovalent, mono- or bicyclic hydrocarbon ring which contains 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms, and one or more heteroatom-containing groups selected from —C(═O)—, —O—, —S—, —S(═O)—, —S(═O)2—, —N(Ra)—, in which Ra represents a hydrogen atom or a C1-C6-alkyl group; it being possible for said heterocycloalkyl group to be attached to the rest of the molecule via any one of the carbon atoms or, if present, the nitrogen atom. Heterospirocycloalkyl, heterobicycloalkyl and bridged heterocycloalkyl, as defined infra, are also included within the scope of this definition.
The term “heterospirocycloalkyl” is to be understood as meaning a saturated, monovalent bicyclic hydrocarbon radical in which the two rings share one common ring carbon atom, and wherein said bicyclic hydrocarbon radical contains 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms, and one or more heteroatom-containing groups selected from C(═O), O, S, S(═O), S(═O)2, NRa, in which Ra represents a hydrogen atom or a C1-C6-alkyl- or C3-C7-cycloalkyl- group; it being possible for said heterospirocycloalkyl- group to be attached to the rest of the molecule via any one of the carbon atoms or, if present, the nitrogen atom. Said heterospirocycloalkyl-group is, for example, azaspiro[2.3]hexyl-, azaspiro[3.3]heptyl-, oxaazaspiro[3.3]heptyl-, thiaazaspiro[3.3]heptyl-, oxaspiro[3.3]heptyl-, oxazaspiro[5.3]nonyl-, oxazaspiro[4.3]octyl-, oxazaspiro[5.5]undecyl-, diazaspiro[3.3]heptyl-, thiazaspiro[3.3]heptyl-, thiazaspiro[4.3]octyl-, or azaspiro[5.5]decyl-.
The term “heterobicycloalkyl” is to be understood as meaning a saturated, monovalent bicyclic hydrocarbon radical in which the two rings share two immediately adjacent ring atoms, and wherein said bicyclic hydrocarbon radical contains 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms, and one or more heteroatom-containing groups selected from C(═O), O, S, S(═O), S(═O)2, NRa, in which Ra represents a hydrogen atom or a C1-C6-alkyl- or C3-C7-cycloalkyl-group; it being possible for said heterobicycloalkyl- group to be attached to the rest of the molecule via any one of the carbon atoms or, if present, the nitrogen atom. Said heterobicycoalkyl- group is, for example, azabicyclo[3.3.0]octyl-, azabicyclo[4.3.0]nonyl-, diazabicyclo[4.3.0]nonyl-, oxazabicyclo[4.3.0]nonyl-, thiazabicyclo[4.3.0]nonyl-, or azabicyclo[4.4.0]decyl-.
The term “bridged heterocycloalkyl” is to be understood as meaning a saturated, monovalent bicyclic hydrocarbon radical in which the two rings share two common ring atoms which are not immediately adjacent, and wherein said bicyclic hydrocarbon radical contains 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms, and one or more heteroatom-containing groups selected from C(═O), O, S, S(═O), S(═O)2, NRa, in which Ra represents a hydrogen atom, or a C1-C6-alkyl- or C3-C7-cycloalkyl- group; it being possible for said bridged heterocycloalkyl- group to be attached to the rest of the molecule via any one of the carbon atoms or, if present, the nitrogen atom. Said bridged heterocycloalkyl- group is, for example, azabicyclo[2.2.1]heptyl-, oxazabicyclo[2.2.1]heptyl-, thiazabicyclo[2.2.1]heptyl-, diazabicyclo[2.2.1]heptyl-, azabicyclo[2.2.2]octyl-, diazabicyclo[2.2.2]octyl-, oxazabicyclo[2.2.2]octyl-, thiazabicyclo[2.2.2]octyl-, azabicyclo[3.2.1]octyl-, diazabicyclo[3.2.1]octyl-, oxazabicyclo[3.2.1]octyl-, thiazabicyclo[3.2.1]octyl-, azabicyclo[3.3.1]nonyl-, diazabicyclo[3.3.1]nonyl-, oxazabicyclo[3.3.1]nonyl-, thiazabicyclo[3.3.1]nonyl-, azabicyclo[4.2.1]nonyl-, diazabicyclo[4.2.1]nonyl-, oxazabicyclo[4.2.1]nonyl, thiazabicyclo[4.2.1]nonyl-, azabicyclo[3.3.2]decyl-, diazabicyclo[3.3.2]decyl-, oxazabicyclo[3.3.2]decyl-, thiazabicyclo[3.3.2]decyl-, or azabicyclo[4.2.2]decyl-.
Particularly, said 3- to 10-membered heterocycloalkyl can contain 2, 3, 4, or 5 carbon atoms, and one or more of the above-mentioned heteroatom-containing groups (a “3- to 6-membered heterocycloalkyl”), more particularly said 3- to 10-membered heterocycloalkyl can contain 4 or 5 carbon atoms, and one or more of the above-mentioned heteroatom-containing groups (a “5- to 6-membered heterocycloalkyl”).
Particularly, without being limited thereto, said 3- to 10-membered heterocycloalkyl can be a 4-membered ring, such as an azetidinyl, oxetanyl, or a 5-membered ring, such as tetrahydrofuranyl, dioxolinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl or a 6-membered ring, such as tetrahydropyranyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, or trithianyl, or a 7-membered ring, such as a diazepanyl ring, for example.
Said 3- to 10-membered heterocycloalkyl can be bicyclic, such as, without being limited thereto, a 5,5-membered ring, e.g. a hexahydrocyclopenta[c]pyrrol-2(1H)-yl ring, or a 5,6-membered bicyclic ring, e.g. a hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl ring.
The term “4- to 10-membered heterocycloalkenyl”, is to be understood as meaning an non-aromatic, unsaturated, monovalent, mono- or bicyclic hydrocarbon ring which contains 3, 4, 5, 6, 7, 8 or 9 carbon atoms, and one or more heteroatom-containing groups selected from —C(═O)—, —O—, —S—, —S(═O)—, —S(═O)2—, —N(Ra)—, in which Ra represents a hydrogen atom or a C1-C6-alkyl group; it being possible for said heterocycloalkenyl group to be attached to the rest of the molecule via any one of the carbon atoms or, if present, the nitrogen atom. Examples of said heterocycloalkenyl are e.g. 4H-pyranyl, 2H-pyranyl, 3H-diazirinyl, 2,5-dihydro-1H-pyrrolyl, [1,3]dioxolyl, 4H-[1,3,4]thiadiazinyl, 2,5-dihydrofuranyl, 2,3-dihydrofuranyl, 2,5-dihydrothiophenyl, 2,3-dihydrothiophenyl, 4,5-dihydrooxazolyl, or 4H-[1,4]thiazinyl group.
The term “aryl” is to be understood as preferably meaning a monovalent, aromatic or partially aromatic, mono-, bi- or tricyclic hydrocarbon ring having 6, 7, 8, 9, 10, 11, 12, 13 or 14 carbon atoms (a “C6-C14-aryl” group), particularly a ring having 6 carbon atoms (a “C6-aryl” group), e.g. a phenyl group; or a biphenyl group, or a ring having 9 carbon atoms (a “C9-aryl” group), e.g. an indanyl or indenyl group, or a ring having 10 carbon atoms (a “C10-aryl” group), e.g. a tetralinyl, dihydronaphthyl, or naphthyl group, or a ring having 13 carbon atoms, (a “C13-aryl” group), e.g. a fluorenyl group, or a ring having 14 carbon atoms, (a “C14-aryl” group), e.g. an anthranyl group. Preferably, the aryl group is a phenyl group.
The term “heteroaryl” is understood as preferably meaning a monovalent, monocyclic, bicyclic or tricyclic aromatic ring system having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring atoms (a “5- to 14-membered heteroaryl” group), particularly 5 or 6 or 9 or 10 atoms, and which contains at least one heteroatom which may be identical or different, said heteroatom being such as oxygen, nitrogen or sulfur, and in addition in each case can be benzocondensed. Particularly, heteroaryl is selected from thienyl, furanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, thia-4H-pyrazolyl etc., and benzo derivatives thereof, such as, for example, benzofuranyl, benzothienyl, benzoxazolyl, benzisoxazolyl, benzimidazolyl, benzotriazolyl, indazolyl, indolyl, isoindolyl, etc.; or pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, etc., and benzo derivatives thereof, such as, for example, quinolinyl, quinazolinyl, isoquinolinyl, etc.; or azocinyl, indolizinyl, purinyl, etc., and benzo derivatives thereof; or cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthpyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, xanthenyl, or oxepinyl, etc.
In general, and unless otherwise mentioned, the heteroarylic or heteroarylenic radicals include all the possible isomeric forms thereof, e.g. the positional isomers thereof. Thus, for some illustrative non-restricting example, the term pyridinyl or pyridinylene includes pyridin-2-yl, pyridin-2-ylene, pyridin-3-yl, pyridin-3-ylene, pyridin-4-yl and pyridin-4-ylene; or the term thienyl or thienylene includes thien-2-yl, thien-2-ylene, thien-3-yl and thien-3-ylene.
The term “C1-C6”, as used throughout this text, e.g. in the context of the definition of “C1-C6-alkyl”, “C1-C6-haloalkyl”, “C1-C6-alkoxy”, or “C1-C6-haloalkoxy” is to be understood as meaning an alkyl group having a finite number of carbon atoms of 1 to 6, i.e. 1, 2, 3, 4, 5, or 6 carbon atoms. It is to be understood further that said term “C1-C6” is to be interpreted as any sub-range comprised therein, e.g. C1-C6, C2-C5, C3-C4, C1-C2, C1-C3, C1-C4, C1-C5; particularly C1-C2, C1-C3, C1-C4, C1-C5, C1-C6; more particularly C1-C4; in the case of “C1-C6-haloalkyl” or “C1-C6-haloalkoxy” even more particularly C1-C2.
Similarly, as used herein, the term “C2-C6”, as used throughout this text, e.g. in the context of the definitions of “C2-C6-alkenyl” and “C2-C6-alkynyl”, is to be understood as meaning an alkenyl group or an alkynyl group having a finite number of carbon atoms of 2 to 6, i.e. 2, 3, 4, 5, or 6 carbon atoms. It is to be understood further that said term “C2-C6” is to be interpreted as any sub-range comprised therein, e.g. C2-C6, C3-C5, C3-C4, C2-C3, C2-C4, C2-C5; particularly C2-C3.
Further, as used herein, the term “C3-C6”, as used throughout this text, e.g. in the context of the definition of “C3-C6-cycloalkyl”, is to be understood as meaning a cycloalkyl group having a finite number of carbon atoms of 3 to 6, i.e. 3, 4, 5 or 6 carbon atoms. It is to be understood further that said term “C3-C6” is to be interpreted as any sub-range comprised therein, e.g. C3-C6, C4-C5, C3-C5, C3-C4, C4-C6, C5-C6; particularly C3-C6.
The term “substituted” means that one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
The term “optionally substituted” means optional substitution with the specified groups, radicals or moieties.
As used herein, the term “one or more”, e.g. in the definition of the substituents of the compounds of the general formulae of the present invention, is understood as meaning “one, two, three, four or five, particularly one, two, three or four, more particularly one, two or three, even more particularly one or two”.
As used herein, the term “leaving group” refers to an atom or a group of atoms that is displaced in a chemical reaction as stable species taking with it the bonding electrons. Preferably, a leaving group is selected from the group comprising: halo, in particular chloro, bromo or iodo, methanesulfonyloxy, p-toluenesulfonyloxy, trifluoromethanesulfonyloxy, nonafluorobutanesulfonyloxy, (4-bromo-benzene)sulfonyloxy, (4-nitro-benzene)sulfonyloxy, (2-nitro-benzene)-sulfonyloxy, (4-isopropyl-benzene)sulfonyloxy, (2,4,6-tri-isopropyl-benzene)-sulfonyloxy, (2,4,6-trimethyl-benzene)sulfonyloxy, (4-tertbutyl-benzene)sulfonyloxy, benzenesulfonyloxy, and (4-methoxy-benzene)sulfonyloxy.
As used herein, the term “protective group” is a protective group attached to a nitrogen in intermediates used for the preparation of compounds of the general formula (I). Such groups are introduced e.g. by chemical modification of the respective amino group in order to obtain chemoselectivity in a subsequent chemical reaction. Protective groups for amino groups are descibed for example in T.W. Greene and P.G.M. Wuts in Protective Groups in Organic Synthesis, 3rd edition, Wiley 1999; more specifically, said groups can be selected from substituted sulfonyl groups, such as mesyl-, tosyl- or phenylsulfonyl-, acyl groups such as benzoyl, acetyl or tetrahydropyranoyl-, or carbamate based groups, such as tert.-butoxycarbonyl (Boc), or can include silicon, as in e.g. 2-(trimethylsilyl)ethoxymethyl (SEM).
The invention includes all suitable isotopic variations of a compound of the invention. An isotopic variation of a compound of the invention is defined as one in which at least one atom is replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually or predominantly found in nature. Examples of isotopes that can be incorporated into a compound of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulphur, fluorine, chlorine, bromine and iodine, such as 2H (deuterium), 3H (tritium), 11C, 13C, 14C, 15N, 17O, 18O, 32P, 33P, 33S, 34S, 35S, 36S, 18F, 36Cl, 82Br, 123I, 124I, 129I and 131I, respectively. Certain isotopic variations of a compound of the invention, for example, those in which one or more radioactive isotopes such as 3H or 14C are incorporated, are useful in drug and/or substrate tissue distribution studies. Tritiated and carbon-14, i.e., 14C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements and hence may be preferred in some circumstances. Isotopic variations of a compound of the invention can generally be prepared by conventional procedures known by a person skilled in the art such as by the illustrative methods or by the preparations described in the examples hereafter using appropriate isotopic variations of suitable reagents.
Where the plural form of the word compounds, salts, polymorphs, hydrates, solvates and the like, is used herein, this is taken to mean also a single compound, salt, polymorph, isomer, hydrate, solvate or the like.
By “stable compound’ or “stable structure” is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
The compounds of this invention may contain one or more asymmetric centre, depending upon the location and nature of the various substituents desired. Asymmetric carbon atoms may be present in the (R) or (S) configuration, resulting in racemic mixtures in the case of a single asymmetric centre, and diastereomeric mixtures in the case of multiple asymmetric centres. In certain instances, asymmetry may also be present due to restricted rotation about a given bond, for example, the central bond adjoining two substituted aromatic rings of the specified compounds.
The compounds of the present invention may contain sulphur atoms which are asymmetric, such as an asymmetric sulphoxide or sulphoximine group, of structure:
for example, in which * indicates atoms to which the rest of the molecule can be bound.
Substituents on a ring may also be present in either cis or trans form. It is intended that all such configurations (including enantiomers and diastereomers), are included within the scope of the present invention.
Preferred compounds are those which produce the more desirable biological activity. Separated, pure or partially purified isomers and stereoisomers or racemic or diastereomeric mixtures of the compounds of this invention are also included within the scope of the present invention. The purification and the separation of such materials can be accomplished by standard techniques known in the art.
Pure stereoisomers can be obtained by resolution of racemic mixtures according to conventional processes, for example, by the formation of diastereoisomeric salts using an optically active acid or base or formation of covalent diastereomers. Examples of appropriate acids are tartaric, diacetyltartaric, ditoluoyltartaric and camphorsulfonic acid. Mixtures of diastereoisomers can be separated into their individual diastereomers on the basis of their physical and/or chemical differences by methods known in the art, for example, by chromatography or fractional crystallisation. The optically active bases or acids are then liberated from the separated diastereomeric salts. A different process for separation of optical isomers involves the use of chiral chromatography (e.g., chiral HPLC columns), with or without conventional derivatisation, optimally chosen to maximise the separation of the enantiomers. Suitable chiral HPLC columns are manufactured by Daicel, e.g., Chiracel OD and Chiracel OJ among many others, all routinely selectable. Enzymatic separations, with or without derivatisation, are also useful. The optically active compounds of this invention can likewise be obtained by chiral syntheses utilizing optically active starting materials.
In order to limit different types of isomers from each other reference is made to IUPAC Rules Section E (Pure Appl Chem 45, 11-30, 1976).
The present invention includes all possible stereoisomers of the compounds of the present invention as single stereoisomers, or as any mixture of said stereoisomers, e.g. (R) or (S) isomers, or (E) or (Z) isomers, in any ratio. Isolation of a single stereoisomer, e.g. a single enantiomer or a single diastereomer, of a compound of the present invention may be achieved by any suitable state of the art method, such as chromatography, especially chiral chromatography, for example.
Further, the compounds of the present invention may exist as tautomers. For example, any compound of the present invention which contains a pyrazole moiety as a heteroaryl group for example can exist as a 1H tautomer, or a 2H tautomer, or even a mixture in any amount of the two tautomers, or a triazole moiety for example can exist as a 1H tautomer, a 2H tautomer, or a 4H tautomer, or even a mixture in any amount of said 1H, 2H and 4H tautomers, namely:
The present invention includes all possible tautomers of the compounds of the present invention as single tautomers, or as any mixture of said tautomers, in any ratio.
Further, the compounds of the present invention can exist as N-oxides, which are defined in that at least one nitrogen of the compounds of the present invention is oxidised. The present invention includes all such possible N-oxides.
The present invention also relates to useful forms of the compounds as disclosed herein, such as metabolites, hydrates, solvates, prodrugs, salts, in particular pharmaceutically acceptable salts, and co-precipitates.
The compounds of the present invention can exist as a hydrate, or as a solvate, wherein the compounds of the present invention contain polar solvents, in particular water, methanol or ethanol for example as structural element of the crystal lattice of the compounds. The amount of polar solvents, in particular water, may exist in a stoichiometric or non-stoichiometric ratio. In the case of stoichiometric solvates, e.g. a hydrate, hemi-, (semi-), mono-, sesqui-, di-, tri-, tetra-, penta- etc. solvates or hydrates, respectively, are possible. The present invention includes all such hydrates or solvates.
Further, the compounds of the present invention can exist in free form, e.g. as a free base, or as a free acid, or as a zwitterion, or can exist in the form of a salt. Said salt may be any salt, either an organic or inorganic addition salt, particularly any pharmaceutically acceptable organic or inorganic addition salt, customarily used in pharmacy.
The term “pharmaceutically acceptable salt” refers to a relatively non-toxic, inorganic or organic acid addition salt of a compound of the present invention. For example, see S. M. Berge, et al. “Pharmaceutical Salts,” J. Pharm. Sci. 1977, 66, 1-19.
A suitable pharmaceutically acceptable salt of the compounds of the present invention may be, for example, an acid-addition salt of a compound of the present invention bearing a nitrogen atom, in a chain or in a ring, for example, which is sufficiently basic, such as an acid-addition salt with an inorganic acid, such as hydrochloric, hydrobromic, hydroiodic, sulfuric, bisulfuric, phosphoric, or nitric acid, for example, or with an organic acid, such as formic, acetic, acetoacetic, pyruvic, trifluoroacetic, propionic, butyric, hexanoic, heptanoic, undecanoic, lauric, benzoic, salicylic, 2-(4-hydroxybenzoyl)-benzoic, camphoric, cinnamic, cyclopentanepropionic, digluconic, 3-hydroxy-2-naphthoic, nicotinic, pamoic, pectinic, persulfuric, 3-phenylpropionic, picric, pivalic, 2-hydroxyethanesulfonate, itaconic, sulfamic, trifluoromethanesulfonic, dodecylsulfuric, ethanesulfonic, benzenesulfonic, para-toluenesulfonic, methanesulfonic, 2-naphthalenesulfonic, naphthalinedisulfonic, camphorsulfonic acid, citric, tartaric, stearic, lactic, oxalic, malonic, succinic, malic, adipic, alginic, maleic, fumaric, D-gluconic, mandelic, ascorbic, glucoheptanoic, glycerophosphoric, aspartic, sulfosalicylic, hemisulfuric, or thiocyanic acid, for example.
Further, another suitably pharmaceutically acceptable salt of a compound of the present invention which is sufficiently acidic, is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically acceptable cation, for example a salt with N-methyl-glucamine, dimethyl-glucamine, ethyl-glucamine, lysine, dicyclohexylamine, 1,6-hexadiamine, ethanolamine, glucosamine, sarcosine, serinol, tris-hydroxy-methyl-aminomethane, aminopropandiol, sovak-base, 1-amino-2,3,4-butantriol, or with a quarternary ammonium salt, such as tetramethylammonium, tetraethylammonium, tetra(n-propyl)ammonium, tetra (n-butyl)ammonium, or N-benzyl-N,N,N-trimethylammonium.
Those skilled in the art will further recognise that acid addition salts of the claimed compounds may be prepared by reaction of the compounds with the appropriate inorganic or organic acid via any of a number of known methods. Alternatively, alkali and alkaline earth metal salts of acidic compounds of the invention are prepared by reacting the compounds of the invention with the appropriate base via a variety of known methods.
The present invention includes all possible salts of the compounds of the present invention as single salts, or as any mixture of said salts, in any ratio.
Furthermore, the present invention includes all possible crystalline forms, or polymorphs, of the compounds of the present invention, either as single polymorphs, or as a mixture of more than one polymorphs, in any ratio.
In accordance with a first aspect, the present invention covers compounds of general formula (I):
in which:
In a preferred embodiment, the invention relates to compounds of formula (I), supra, in which
wherein * indicates the point of attachment of said groups with the rest of the molecule.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, in which A represents a group selected from:
wherein * indicates the point of attachment of said groups with the rest of the molecule.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, in which A represents a group selected from:
wherein * indicates the point of attachment of said groups with the rest of the molecule.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein A represents
wherein * indicates the point of attachment of said group with the rest of the molecule.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein A represents
wherein * indicates the point of attachment of said group with the rest of the molecule.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein A represents
wherein * indicates the point of attachment of said group with the rest of the molecule.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein A represents
wherein * indicates the point of attachment of said group with the rest of the molecule.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein A represents
wherein * indicates the point of attachment of said group with the rest of the molecule.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein A represents
wherein * indicates the point of attachment of said group with the rest of the molecule.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein A represents
wherein * indicates the point of attachment of said group with the rest of the molecule.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein A represents
wherein * indicates the point of attachment of said group with the rest of the molecule.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R1 represents a hydrogen atom or a group selected from: C1-C6-alkyl-, C3-C6-cycloalkyl-, 3- to 10-membered heterocycloalkyl-, cyano-, and —(CH2)q—X—(CH2)p—R4; wherein said C1-C6-alkyl-, C3-C6-cycloalkyl-, and 3- to 10-membered heterocycloalkyl-group is optionally substituted, identically or differently, with 1, 2, 3, 4 or 5 R3 groups.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R1 represents a hydrogen atom or a group selected from: C1-C6-alkyl- and —(CH2)q—X—(CH2)p—R4; wherein said C1-C6-alkyl- group is optionally substituted, identically or differently, with 1, 2, 3, 4 or 5 R3 groups.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R1 represents a group selected from: —C(═O)—R4, —C(═O)—O—R4, —C(═O)—N(R4a)—R4, —S(═O)2—R4, and —CH2—N(R4a)—R4.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R1 represents a group selected from: —C(═O)—R4, —C(═O)—O—R4, —C(═O)—N(R4a)—R4, —S(═O)2—R4, —(CH2)p—R4 and —CH2—N(R4a)—R4.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R1 represents a hydrogen atom.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R1 represents a C1-C6-alkyl- group, wherein said C1-C6-alkyl- group is optionally substituted, identically or differently, with 1, 2, 3, 4 or 5 R3 groups.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R1 represents a halo-C1-C3-alkyl- group.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R1 represents F3C—CH2— group.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R1 represents —(CH2)q—X—(CH2)p—R4.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R1 represents —X—R4.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R1 represents —CH2—CH2—X—R4.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R1 represents —(CH2)p—R4.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R1 represents —C(═O)—O—R4.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R1 represents —C(═O)—R4.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R1 represents —C(═O)—N(R4a)R4.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R1 represents —S(═O)2—R4.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R1 represents —CH2—CH2—N(R4a)R4.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R1 represents —CH2—CH2—C(═O)N(R4a)R4.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein X represents a bond or a bivalent group selected from:
—O—, —S—, —S(═O)—, —S(═O)2—, —S(═O)—N(R4a)—, —N(R4a)—S(═O)—, —S(═O)2—N(R4a)—, —N(R4a)—S(═O)2—, —S(═O)(═NR4a)—, —C(═O)—, —N(R4a)—, —C(═O)—O—, —O—C(═O)—, —C(═S)—O—, —O—C(═S)—, —C(═O)—N(R4a)—, and —N(R4a)—C(═O)—.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein X represents a bond or a bivalent group selected from: —S(═O)2—, —C(═O)—, —N(R4a)—, —C(═O)—O—, and —C(═O)—N(R4a)—.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein X represents —S(═O)2—.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein X represents —C(═O)—.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein X represents —N(R4a)—.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein X represents —C(═O)—O—.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein X represents —C(═O)—N(R4a)—.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein X represents a bond.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R2 represents a hydrogen atom or a halogen atom or a group selected from:
hydroxy-, cyano-, C1-C6-alkyl-, halo-C1-C6-alkyl, C1-C6-alkoxy-, halo-C1-C6-alkoxy-, C3-C6-cycloalkyl-, C3-C6-cycloalkyloxy-, (3- to 10-membered heterocycloalkyl)-, (3- to 10-membered heterocycloalkyl)-O—, —N(R4a)R4b, —SR4a, —SCF3 and —SF5.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R2 represents a hydrogen atom or a halogen atom or a group selected from: hydroxy-, cyano-, halo-C1-C3-alkyl, C1-C3-alkoxy-, halo-C1-C3-alkoxy-, C3-C6-cycloalkyloxy-, (3- to 10-membered heterocycloalkyl)-O—, —N(R4a)R4b, —SR4a, —SCF3 and —SF5.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R2 represents a hydrogen atom or a halogen atom or a group selected from: C1-C3-alkoxy- and —SR4a.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R2 represents —O—CH3 or —S—CH3.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R2 represents a hydrogen atom.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R2 represents a halogen atom.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R2 represents a bromine atom or a chlorine atom.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R2 represents a C1-C6-alkoxy- group.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R2 represents a C1-C3-alkoxy- group.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R2 represents a methoxy group.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R2 represents —SR4a.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R2 represents —S—CH3.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R3 represents a halogen atom.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R3 represents a fluorine atom.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R3 represents a —C(═O)—NR5aR5b group.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R4a represents a C1-C6-alkyl- group.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R4a represents a C1-C3-alkyl- group.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R4a represents a hydrogen atom or a methyl group.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R4a represents a methyl group.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R4a represents a hydrogen atom.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R4b represents a C1-C6-alkyl- group.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R4b represents a C1-C3-alkyl- group.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R4b represents a hydrogen atom or a methyl group.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R4b represents a methyl group.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R4b represents a hydrogen atom.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R4 represents a C1-C6-alkyl- group, wherein said C1-C6-alkyl- group is optionally substituted, identically or differently, with 1, 2, 3, 4 or 5 R6 groups.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R4 represents a C1-C4-alkyl- group, wherein said C1-C4-alkyl- group is optionally substituted, identically or differently, with 1, 2, 3, 4 or 5 halogen atoms, preferably with fluorine atoms.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R4 represents a C1-C4-alkyl- group, wherein said C1-C4-alkyl- group is optionally substituted, identically or differently, with one R5—S(═O)2— group.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R4 represents a group selected from C1-C6-alkyl-, C3-C6-cycloalkyl-, 3- to 10-membered heterocycloalkyl- and heteroaryl-; wherein said C1-C6-alkyl-, C3-C6-cycloalkyl-, 3- to 10-membered heterocycloalkyl- and heteroaryl- group is optionally substituted, identically or differently, with 1, 2, 3, 4 or 5 R6 groups.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R4 represents a group selected from C1-C6-alkyl-, 3- to 10-membered heterocycloalkyl-, and heteroaryl-; wherein said C1-C6-alkyl- is optionally substituted, identically or differently, with 1, 2, 3, 4 or 5 R6 groups.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R4 represents a group selected from C3-C6-cycloalkyl-, 3- to 10-membered heterocycloalkyl- and heteroaryl-; wherein said C3-C6-cycloalkyl-, 3- to 10-membered heterocycloalkyl- and heteroaryl- group is optionally substituted, identically or differently, with 1, 2, 3, 4 or 5 R6 groups.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R4 represents a 3- to 10-membered heterocycloalkyl- group, wherein said 3- to 10-membered heterocycloalkyl- group is optionally substituted, identically or differently, with 1, 2, 3, 4 or 5 R6 groups.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R4 represents a 4- to 7-membered heterocycloalkyl- group selected from azetidinyl-, oxetanyl-, pyrrolidinyl-, tetrahydrofuranyl-, piperidinyl-, piperazinyl-, morpholinyl-, tetrahydropyranyl-, azepinyl-, oxazepinyl- and diazepinyl-, wherein said 4- to 7-membered heterocycloalkyl- group is optionally substituted, identically or differently, with 1, 2, 3, 4 or 5 R6 groups.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R4 represents a 3- to 10-membered heterocycloalkyl- group, wherein said 3- to 10-membered heterocycloalkyl- group is optionally substituted, identically or differently, with one or two C1-C3-alkyl- groups.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R4 represents a 4- to 7-membered heterocycloalkyl- group, wherein said 4- to 7-membered heterocycloalkyl- group is optionally substituted, identically or differently, with one or two C1-C3-alkyl- groups.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R4 represents a 4- to 7-membered heterocycloalkyl- group selected from azetidinyl-, oxetanyl-, pyrrolidinyl-, tetrahydrofuranyl-, piperidinyl-, piperazinyl-, morpholinyl-, tetrahydropyranyl-, azepinyl-, oxazepinyl- and diazepinyl-, wherein said 4- to 7-membered heterocycloalkyl- group is optionally substituted, identically or differently, with one or two C1-C3-alkyl- groups.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R4 represents a 5- to 6-membered heterocycloalkyl- group selected from pyrrolidinyl-, tetrahydrofuranyl-, piperidinyl-, piperazinyl-, morpholinyl-, tetrahydropyranyl-, wherein said 5- to 6-membered heterocycloalkyl- group is optionally substituted, identically or differently, with one or two C1-C3-alkyl- groups.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R4 represents a heteroaryl- group, wherein said heteroaryl- group is optionally substituted, identically or differently, with 1 or 2 R6 groups.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R4 represents a heteroaryl- group selected from thienyl, furanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, thia-4H-pyrazolyl; wherein said heteroaryl- group is optionally substituted, identically or differently, with 1 or 2 R6 groups.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R4 represents a heteroaryl- group selected from pyrrolyl-, imidazolyl-, isoxazolyl-, oxazolyl-, pyrazolyl- and oxadiazolyl-; wherein said heteroaryl- group is optionally substituted, identically or differently, with 1 or 2 R6 groups.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R4 represents a heteroaryl- group selected from pyrrolyl and imidazolyl; wherein said heteroaryl- group is optionally substituted, identically or differently, with 1 or 2 R6 groups.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R4 represents a group selected from:
wherein * indicates the point of attachment of said groups with the rest of the molecule.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R4 represents a group selected from:
wherein * indicates the point of attachment of said groups with the rest of the molecule.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein N(R4a)R4 together represent a 3- to 10-membered heterocycloalkyl- group, said group being optionally substituted, identically or differently, with 1, 2, 3, 4 or 5 R6 groups.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein N(R4a)R4 together represent a 3- to 10-membered heterocycloalkyl- group, said group being optionally substituted, identically or differently, one or two C1-C3-alkyl- groups.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein N(R4a)R4 together represent a 4- to 7-membered heterocycloalkyl- group, said group being optionally substituted, identically or differently, one or two C1-C3-alkyl- groups.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein N(R4a)R4 together represent a group selected from:
wherein * indicates the point of attachment of said groups with the rest of the molecule.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein N(R4a)R4 together represent a group selected from:
wherein * indicates the point of attachment of said groups with the rest of the molecule.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R5a represents a hydrogen atom.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R5a represents a C1-C6-alkyl- group.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R5a represents a C1-C3-alkyl- group.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R5a represents a methyl- group.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R5b represents a hydrogen atom.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R5b represents a C1-C6-alkyl- group.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R5b represents a C1-C3-alkyl- group.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R5b represents a methyl- group.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R5a represents a methyl- group and R5b represents a methyl- group.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R5c represents a hydrogen atom.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R5c represents a C1-C6-alkyl- group.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R5c represents a C1-C3-alkyl- group.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R5 represents a hydrogen atom.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R5 represents a C1-C6-alkyl- group.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R5 represents a C1-C3-alkyl- group.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R6 represents a halogen atom or a group selected from: C1-C6-alkyl-, R5—S(═O)2—.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R6 represents a halogen atom or a group selected from: C1-C3-alkyl-, R5—S(═O)2—.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R6 represents a fluorine atom or a group selected from: methyl-, H3C—S(═O)2—.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R6 represents a halogen atom or a group selected from: C1-C6-alkyl-, C1-C6-alkoxy-, R5—S(═O)2— and —C(═O)—NR5aR5b.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R6 represents a halogen atom or a group selected from: C1-C3-alkyl-, C1-C3-alkoxy-, R5—S(═O)2— and —C(═O)—NR5aR5b.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R6 represents a fluorine atom or a group selected from: methyl-, ethoxy-, H3C—S(═O)2— and —C(═O)—N(CH3)2.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R6 represents a halogen atom, preferably a fluorine atom.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R6 represents a C1-C6-alkyl- group.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R6 represents a C1-C3-alkyl- group.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R6 represents a methyl group.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R6 represents a R5—S(═O)2— group.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R6 represents a H3C—S(═O)2— group.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein p represents 0.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein q represents 0.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein q represents 1 or 2.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein q represents 2.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein p represents 0 and q represents 0.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein p represents 0 and q represents 2.
It is to be understood that the present invention relates also to any combination of the preferred embodiments described above. Some examples of combinations are given hereinafter. However, the invention is not limited to these combinations.
In a preferred embodiment, the invention relates to compounds of formula (I), supra, in which:
In another preferred embodiment, the invention relates to compounds of formula (I), supra, in which:
In another preferred embodiment, the invention relates to compounds of formula (I), supra, in which:
In another preferred embodiment, the invention relates to compounds of formula (I), supra, in which:
In another preferred embodiment, the invention relates to compounds of formula (I), supra, in which:
In another preferred embodiment, the invention relates to compounds of formula (I), supra, in in which:
In another preferred embodiment, the invention relates to compounds of formula (I), supra, in in which:
In another preferred embodiment, the invention relates to compounds of formula (I), supra, in in which:
In another preferred embodiment, the invention relates to compounds of formula (I), supra, in in which:
It is to be understood that the present invention relates to any sub-combination within any embodiment or aspect of the present invention of compounds of general formula (I), supra.
More particularly still, the present invention covers compounds of general formula (I) which are disclosed in the Examples section of this text, infra.
In accordance with another aspect, the present invention covers methods of preparing compounds of the present invention, said methods comprising the steps as described in the Experimental Section herein.
In a preferred embodiment, the present invention relates to a method of preparing compounds of general formula (I), supra, in which method an intermediate compound of general formula (II):
in which R1 is as defined for general formula (I), supra, and LG represents a leaving group, preferably a chlorine atom;
is allowed to react with an intermediate compound of general formula (IV):
A-NH2 (IV)
in which A is as defined for general formula (I), supra.
In another aspect, the present invention relates to intermediate compounds which are useful for the preparation of the compounds of general formula (I), supra.
In particular, the present invention relates to intermediate compounds of general formula (II)
in which R1 is as defined for general formula (I), supra, and LG represents a leaving group, preferably a chlorine atom.
Compounds of general formula (I), wherein A and R1 have the meaning as given for general formula (I), supra, can be synthesized according to a general procedure depicted in Scheme 1 starting from synthons of the formula (IX) wherein R′ stands for R1 or a protective group PG.
The different routes exemplified in Scheme 1 allow variations either in A or in R1 on the last synthetic step. The coupling of compounds of formula (IV) with synthons such as (II) or (VI) can be accomplished by reacting the two reactants in a suitable solvent, such as ethanol or a related lower aliphatic alcohol of the formula C1-C4-alkyl-OH or a cyclic ether, such as tetrahydrofuran or 1,4-dioxane, optionally in the presence of an acid such as hydrochloric acid. The compounds of formula (IV) can be used either as free base or as corresponding salt with organic or inorganic acids. Alternatively, such amination reactions can be performed using catalysis by metals, such as palladium (see e.g. J. Y. Yoon et al., Synthesis 2009, (5), 815, and literature cited therein), to give compounds of formulae (I) or (III). Amines of formulae (Ia) or (V), in which A has the meaning as given for general formula (I) and LG represents a leaving group can be converted to compounds of general formula (I) in accordance with common general knowledge of a person skilled in the art of organic synthesis. Said amines of formulae (Ia) or (V) can be reacted with widely commercially available carboxylic acid chlorides, carbamic chlorides, carbonochloridates, sulfonyl chlorides or compounds of formula LG-R1, in which LG represents a leaving group, to form amides, ureas, carbamates, sulfonamides or amines, respectively. Alternatively, amines of formulae (Ia) or (V) can be reacted with phosgene or triphosgene to form carbamic chlorides that can be converted further to carbamates or ureas by the reaction with alcohols or amines, respectively. Alternatively, amines of formulae (Ia) or (V) can be reacted with carboxylic acids, which are widely commercially available, with a suitable coupling agent, such as HATU, TBTU, or 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide (also known as T3P), to form amides.
Substituents R1 can also be introduced by a reductive amination reaction reacting amines of formulae (Ia) or (V) with aldehydes and a suitable reducing agent, for example sodium tris(acetato-kappaO)(hydrido)borate or sodium cyanoborohydride.
Amines of formulae (Ia) or (V) can be used either as free base or as corresponding salt with organic or inorganic acids.
Modification of any of the substituents, A and R1 can be achieved before and/or after the exemplified transformation. However, also other routes may be used to synthesise the target compounds, in accordance with common general knowledge of a person skilled in the art of organic synthesis.
Said modifications can be such as the introduction of protecting groups, cleavage of protecting groups, reduction or oxidation of functional groups, formation or cleavage of esters or carboxamides, halogenation, metallation, substitution or other reactions known to a person skilled in the art. These transformations include those which introduce a functionality which allows for further interconversion of substituents. Appropriate protecting groups and their introduction and cleavage are well-known to a person skilled in the art (see for example T.W. Greene and P.G.M. Wuts in Protective Groups in Organic Synthesis, 3rd edition, Wiley 1999). Further, it is possible that two or more successive steps may be performed without work-up being performed between said steps, e.g. a “one-pot” reaction, as it is well-known to a person skilled in the art.
Intermediate compounds of the general formula (VI), wherein R′ represents R1 or a protective group PG and wherein LG stands for a leaving group, are known to the person skilled in the art and can be readily prepared as shown in Scheme 1 by a so-called Gewald thiophene synthesis (for a seminal publication see e.g. K. Gewald et al., Chem. Ber. 1966, 94, 99), starting from ketones of the general formula (IX), to give the intermediate thiophene derivatives (VIII), wherein RE represents a C1-C6-alkyl group.
Said intermediates are then cyclised to the hydroxy-thienopyrimidines (VII), which are in equilibrium with their respective pyrimidone tautomers, employing a suitable C1 synthon such as formamide. The resulting hydroxypyrimidines (VII) are then transferred into compounds of the general formula (VI), in which LG represents a leaving group like, for example, a halogen atom as, for example, a chlorine or bromine atom, by suitable procedures known to the person skilled in the art, such as treatment by reacting the alcohol with a halogenation agent like, for example, phosphorus trichloride or phosphorus tribromide with or without an additional inert solvent as, for example, toluene at temperatures ranging from room temperature to the boiling point of the solvent, for example. Compounds of formula (VI) in which LG represents a leaving group like, for example, an alkylsulfonate as, for example, methanesulfonate or trifluoromethanesulfonate or 1,1,2,2,3,3,4,4,4-nonafluorobutane-1-sulfonate or an arylsulfonate like, for example, benzenesulfonate or 4-methylbenzenesulfonate can be synthesised from compounds of formula (VII), by reacting the alcohol with a suitable alkylsulfonyl halide as, for example, methanesulfonyl chloride or trifluoromethanesulfonyl chloride or 1,1,2,2,3,3,4,4,4-nonafluorobutane-1-sulfonyl fluoride or by reacting the alcohol with a suitable arylsulfonyl halide as, for example, benzenesulfonyl chloride or 4-methylbenzenesulfonyl chloride in an inert solvent like, for example, tetrahydrofuran or toluene or dichloromethane optionally in the presence of a suitable base like, for example, triethylamine or pyridine or N,N-dimethylpyridin-4-amine at temperatures ranging from −40° C. to the boiling point of the solvent, for example. An instructive exemplary protocol for the sequence outlined in Scheme 1 can be found in WO 2005/010008, example 14, steps 1 to 3.
Synthons of the formula (IV), are known to the person skilled in the art, are commercially available with a wide range of substituents, or can be synthesised in analogy to procedures known to the person skilled in the art. As a representative example, the synthesis of 5-aminoindazole synthons of the formula (IVa) in which R3 represents a C1-C6-alkoxy group has been described inter alia by means of diazotation of the corresponding ortho-toluidines, followed by cyclisation to the indazole (see e.g. H. D. Porter and W. D. Peterson, Org. Syn., Coll. Vol. 3 (1955), 660, or U.S. Pat. No. 5,444,038). Recently, the synthesis of substituted indazoles suitable as intermediates via reaction of ortho-fluorobenzaldehydes with hydrazine hydrate has been described (see e.g. R. C. Wheeler et al., Org. Process Res. Dev 2011, 15, 565, for a related publication see also K. Lukin et al., J. Org. Chem. 2006, 71, 8166). Both processes typically yield indazoles featuring an amine precursor, such as a nitro group, which can be readily converted into the desired indazole-5-amine by reduction (see e.g. J. Med. Chem. 2003, 46, 5663).
As an example of said synthetic approach, Scheme 2 outlines the preparation of indazole intermediates of the formula (IVa), which constitute a subset of the compounds of formula (IV). Nitration of 2-fluoro-4-hydroxybenzaldehyde (XIII, CAS-No. 348-27-6) using nitric acid in sulfuric acid gives rise to the corresponding 5-nitro-benzaldehyde (XII), which can be subsequently cyclised e.g. by reacting with hydrazine hydrate in a suitable solvent, such as an aliphatic alcohol of the formula C1-C4-alkyl-OH, e.g. ethanol, preferentially at elevated temperature. The resulting 5-nitro-1H-indazol-6-ol (XI) can be chemoselectively O-alkylated, for example, by applying a so-called Mitsunobu reaction (Mitsunobu, O. Synthesis 1981, 1, 1-28) with an aliphatic alcohol C1-C6-alkyl-OH, a suitable trialkyl or triaryl phosphane, such as triphenylphosphane, and a suitable dialkyl azodicarboxylate, such as diisopropyl azodicarboxylate, in a suitable solvent, such as a cyclic ether, e.g. tetrahydrofuran, resulting in 6-alkoxy-5-nitro-(1H)-indazoles of the formula (X), which can be reduced to the corresponding 6-aminoindazole derivatives of formula (IVa) by reduction methods well known to the person skilled in the art, e.g. by reaction with a palladium/charcoal catalyst in a suitable solvent such as methanol, ethanol, or tetrahydrofuran.
As another example of said synthetic approach, Scheme 3 outlines the preparation of pyrazolo[1,5-a]pyridin-5-amine intermediates of the formula (IVb), in which R2 has the meaning as defined supra and which constitute a subset of the compounds of formula (IV). Scheme 3 exemplifies one route that allows variations and modifications in R2 starting from commercially available 4-amino-pyridines of the formula (XIX). The amino group in (XIX) may be optionally protected by a suitable protective group (PG) like, for example, a tert-butyloxycarbonyl- or a allyloxycarbonyl-group, to give compounds of the formula (XVIII). N-Amination to compounds of the formula (XVIII) is achieved by reacting compounds of the formula (XVIII) with commercially available aminooxy-sulfonyl compounds of the formula (XVII) in which Ar represents a optionally substituted aryl group, like, for example, 2-[(aminooxy)sulfonyl]-1,3,5-trimethylbenzene. Alternatively, an N-amination can also be achieved by reacting compounds of the formula (XVIII) with O-(2,4-dinitrophenyl)hydroxylamine.
Compounds of the formula (XVI) react with propiolate compounds of formula (XV), in which RE represents a hydrogen atom or a C1-C6-alkyl group, optionally in the presence of an organic or inorganic base to compounds of formula (XIV). Cleavage of the ester (RE=hydrogen), decarboxylation and removal of the protective group (PG) gives access to compounds of formula (IVb).
Optionally, two or more successive steps may be performed without work-up being performed between said steps, e.g. a “one-pot” reaction, as it is well-known to a person skilled in the art.
However, also other routes may be used to synthesise the target compounds (IVb) in accordance with common general knowledge of a person skilled in the art of organic synthesis. The order of transformations exemplified in Scheme 3 is also not intended to be limiting. In addition, interconversion of any of the substituents as defined herein for R2, PG and RE can be achieved before and/or after the exemplified transformations as described supra.
In the present text, in particular in the Experimental Section, for the synthesis of intermediates and of examples of the present invention, when a compound is mentioned as a salt form with the corresponding base or acid, the exact stoichiometric composition of said salt form, as obtained by the respective preparation and/or purification process, is, in most cases, unknown.
Unless specified otherwise, suffixes to chemical names or structural formulae such as “hydrochloride”, “trifluoroacetate”, “sodium salt”, or “x HCl”, “x CF3COOH”, “x Na+”, for example, are to be understood as not a stoichiometric specification, but solely as a salt form.
This applies analogously to cases in which synthesis intermediates or example compounds or salts thereof have been obtained, by the preparation and/or purification processes described, as solvates, such as hydrates with (if defined) unknown stoichiometric composition.
The IUPAC names of the examples and intermediates were generated using the program ‘ACD/Name batch version 12.01’ from ACD LABS, and were adapted if needed.
A mixture comprising 1.02 g (3.12 mmol) tert-butyl 4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine-7(6H)-carboxylate (prepared according to WO2009/33581), 560 mg 6-(methylsulfanyl)-1H-indazol-5-amine (prepared according to intermediate example 1a), 25 mL ethanol, 435 μL N,N-diethylethanamine and 195 μL hydrochloric acid (4N) was heated at 100° C. for 16 hours. 2 equivalents N,N-diethylethanamine were added and stirring was continued at 23° C. The precipitate was filtered off, washed with ethanol and dried to give 795 mg (66%) of the title compound. 1H-NMR (DMSO-d6): δ=2.44 (3H), 2.62-2.74 (1H), 3.03-3.15 (4H), 3.95 (2H), 7.39 (1H), 7.94 (1H), 8.05 (1H), 8.13 (1H), 8.22 (1H), 12.98-13.04 (1H) ppm.
A mixture comprising 100 mg (478 mmol) 6-(methylsulfanyl)-5-nitro-1H-indazole (prepared according to intermediate example 1b), 20 mL ethanol and 25 mg palladium on charcoal (10%) was shaken at 23° C. under an atmosphere of hydrogen for 5 hours. The catalyst and solvents were removed to give 76 mg (89%) of the title compound.
A mixture comprising 1.00 g (4.05 mmol) 5-nitro-6-(trifluoromethoxy)-1H-indazole (prepared according to intermediate example 1c), 20 mL N,N-dimethylformamide and 851 mg sodium methanethiolate was heated at 100° C. overnight. The mixture was poured into water, the precipitate collected, washed with water and dried. The crude product was purified by chromatography to give 368 mg (43%) of the title compound.
A mixture comprising 11.73 g (46.3 mmol) 2-fluoro-5-nitro-4-(trifluoromethoxy)benzaldehyde (prepared according to intermediate example 1d), 50 mL N,N-dimethylacetamide and 11.3 mL hydrazine hydrate was heated at 120° C. for 3 hours. The mixture was poured into water the precipitate was collected and purified by chromatography to give 3.44 g (30%) of the title compound A and 340 mg (3%) of the title compound B.
A solution of 28.20 g (135.5 mmol) 2-fluoro-4-(trifluoromethoxy)benzaldehyde (CAS-No: 1227628-83-2) in 150 mL concentrated sulfuric acid was cooled to −15° C. A mixture comprising 20 mL concentrated nitric acid and 40 mL sulfuric acid was added slowly. After 1 hour the mixture was poured into ice-water. The precipitate was filtered, washed with water and hexane and dried to give 34.87 g (100%) of the title compound.
A mixture comprising 80 mg (246 μmol) tert-butyl 4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine-7(6H)-carboxylate (prepared according to WO2009/33581), 44 mg 6-(methylsulfanyl)-1H-indazol-5-amine (prepared according to intermediate example 1a), 2 mL ethanol and 34 μL N,N-diethylethanamine was heated at 100° C. for 16 hours. 2 equivalents N,N-diethylethanamine were added and stirring was continued at 23° C. The crude product was purified by chromatography to give 17.7 mg (12%) of the title compound.
1H-NMR (DMSO-d6): δ=1.45 (9H), 2.44 (3H), 3.18-3.25 (2H), 3.69-3.76 (2H), 4.64-4.71 (2H), 7.35-7.38 (1H), 7.82-7.88 (1H), 8.02-8.06 (1H), 8.23 (2H), 12.98-13.04 (1H) ppm.
A mixture comprising 100 mg (307 μmol) tert-butyl 4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine-7(6H)-carboxylate (prepared according to WO2009/33581), 51 mg 6-amino-1,3-benzothiazol-2(3H)-one (CAS-No: 56354-98-4), 2 mL dimethyl sulfoxide and 160 μL N-ethyl-N-isopropylpropan-2-amine was heated at 100° C. for 16 hours. The crude product was purified by chromatography and crystallisation to give 40.5 mg (36%) of the title compound.
1H-NMR (DMSO-d6): δ=1.45 (9H), 3.20 (2H), 3.69 (2H), 4.68 (2H), 7.11 (1H), 7.47 (1H), 7.84 (1H), 8.25 (1H), 8.38 (1H), 11.87 (1H) ppm.
100 mg (307 μmol) tert-butyl 4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine-7(6H)-carboxylate (prepared according to WO2009/33581) were transformed in analogy to example 3 using 6-methoxy-1H-indazol-5-amine to give after working up and purification 23.8 mg (16%) of the title compound.
1H-NMR (DMSO-d6): δ=1.46 (9H), 3.20 (2H), 3.78 (2H), 3.98 (3H), 4.68 (2H), 7.10 (1H), 8.01 (1H), 8.18 (1H), 8.47 (1H), 8.69 (1H), 12.87 (1H) ppm.
100 mg (307 μmol) tert-butyl 4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine-7(6H)-carboxylate (prepared according to WO2009/33581) were transformed in analogy to example 3 using 1H-indazol-5-amine to give after working up and purification 70.5 mg (52%) of the title compound.
1H-NMR (DMSO-d6): δ=1.46 (9H), 3.24 (2H), 3.71 (2H), 4.68 (2H), 7.49-7.56 (2H), 8.00 (1H), 8.06 (1H), 8.27 (1H), 8.35 (1H), 13.04 (1H) ppm.
100 mg (307 μmol) tert-butyl 4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine-7(6H)-carboxylate (prepared according to WO2009/33581) were transformed in analogy to example 3 using 1H-pyrazolo[3,4-b]pyridin-5-amine (CAS-No. 942185-01-5) to give after working up and purification 41.0 mg (30%) of the title compound.
1H-NMR (DMSO-d6): δ=1.44 (9H), 3.24 (2H), 3.71 (2H), 4.68 (2H), 8.14 (1H), 8.33 (1H), 8.38 (1H), 8.40 (1H), 8.62 (1H), 13.61 (1H) ppm.
100 mg (307 μmol) tert-butyl 4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine-7(6H)-carboxylate (prepared according to WO2009/33581) were transformed in analogy to example 3 using 1H-pyrazolo[3,4-c]pyridin-5-amine (CAS-No. 1049672-75-4) to give after working up and purification 14.8 mg (11%) of the title compound.
1H-NMR (DMSO-d6): δ=1.45 (9H), 3.24 (2H), 3.71 (2H), 4.68 (2H), 8.14 (1H), 8.34 (1H), 8.38 (1H), 8.39 (1H), 8.62 (1H), 13.61 (1H) ppm.
569 mg (1.75 mmol) tert-butyl 4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine-7(6H)-carboxylate (prepared according to WO2009/33581) were transformed in analogy to example 1 using 6-methoxy-1H-indazol-5-amine to give after working up and purification 527 mg (78%) of the title compound.
1H-NMR (DMSO-d6): δ=3.01-3.13 (4H), 3.94 (2H), 3.97 (3H), 7.09 (1H), 7.99 (1H), 8.19 (1H), 8.46 (1H), 8.79 (1H), 12.86 (1H) ppm.
A mixture comprising 100 mg (257 μmol) N-(6-methoxy-1H-indazol-5-yl)-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-4-amine (prepared according to example 8), 4.0 mL N,N-dimethylformamide, 55.6 mg 4-(methylsulfonyl)butanoic acid (CAS-No: 148928-08-9), 134 μL N-ethyl-N-isopropylpropan-2-amine and 143 mg N-[({[(1E)-1-cyano-2-ethoxy-2-oxoethylidene]amino}oxy)(morpholin-4-yl)methylene]-N-methylmethanaminium hexafluorophosphate was stirred at 23° C. for 16 hours. The mixture was poured into an aqueous saturated sodium hydrogencarbonate solution, the precipitate was filtered off and purified by chromatography to give 42.0 mg (32%) of the title compound.
1H-NMR (DMSO-d6): δ=1.91-2.02 (2H), 2.57-2.74 (2H), 2.96-3.00 (3H), 3.08-3.21 (3H), 3.24-3.31 (1H), 3.85-3.94 (2H), 3.95-4.03 (3H), 4.77-4.86 (2H), 7.10 (1H), 8.00 (1H), 8.17 (1H), 8.46-8.51 (1H), 8.66-8.77 (1H), 12.87 (1H) ppm.
75 mg (244 μmol) 4-chloro-7-(2,2,2-trifluoroethyl)-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine (prepared according to intermediate example 10a) were transformed in analogy to example 2 using 1H-pyrazolo[3,4-b]pyridin-5-amine (CAS-No. 942185-01-5) to give after working up and purification 25.2 mg (99%) of the title compound.
1H-NMR (DMSO-d6): δ=3.05-3.13 (2H), 3.28 (2H), 3.46 (2H), 4.00 (2H), 8.15 (1H), 8.32-8.42 (3H), 8.63 (1H), 13.59-13.66 (1H) ppm.
A mixture comprising 213 mg (737 μmol) 7-(2,2,2-trifluoroethyl)-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-4-ol (prepared according to intermediate example 10b) and 2.32 mL phenylphosphonic dichloride (90%) was heated at 110° C. for 16 hours. Tetrahydrofuran was added followed by an aqueous sodium hydrogencarbonate solution until pH 7 was adjusted. The mixture was extracted with ethyl acetate, the organic layer was washed with brine and dried over magnesium sulfate. After filtration and removal of the solvents 226 mg (94%) of the title compound were isolated that was used without further purification.
A mixture comprising 1.84 g (5.97 mmol) ethyl 2-amino-6-(2,2,2-trifluoroethyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylate (prepared according to intermediate example 10c), 12.4 mL N,N-dimethylacetamide and 1.55 g imidoformamide acetate (1:1) (CAS-No: 3473-63-0) was stirred at 135° C. for 4 hours. The solvents were removed and the residue was purified by chromatography to give 864 mg (50%) of the title compound.
A mixture comprising 1.00 g (5.52 mmol) 1-(2,2,2-trifluoroethyl)piperidin-4-one (CAS-No: 81363-14-6), 587 μL ethyl cyanoacetate, 186 mg sulfur, 481 μL morpholine and 9.1 mL ethanol was stirred at 23° C. for 16 hours. The precipitate was filtered off, washed with ethanol and dried to give 1.84 g (max 100%) of the title compound as crude product that was used without further purification.
75 mg (244 μmol) 4-chloro-7-(2,2,2-trifluoroethyl)-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine (prepared according to intermediate example 10a) were transformed in analogy to example 2 using 6-(methylsulfanyl)-1H-indazol-5-amine (prepared according to intermediate example 1a) to give after working up and purification 59.4 mg (54%) of the title compound.
1H-NMR (DMSO-d6): δ=2.44 (3H), 3.07-3.14 (2H), 3.25 (2H), 3.46 (2H), 3.99 (2H), 7.38 (1H), 7.92 (1H), 8.05 (1H), 8.18 (1H), 8.24 (1H), 13.01 (1H) ppm.
75 mg (244 μmol) 4-chloro-7-(2,2,2-trifluoroethyl)-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine (prepared according to intermediate example 10a) were transformed in analogy to example 2 using 6-methoxy-1H-indazol-5-amine to give after working up and purification 68.2 mg (64%) of the title compound.
1H-NMR (DMSO-d6): δ=3.12-3.25 (4H), 3.47 (2H), 3.96-4.04 (5H), 7.10 (1H), 8.00 (1H), 8.21 (1H), 8.49 (1H), 8.78 (1H), 12.87 (1H) ppm.
80 mg (270 μmol) 4-chloro-N,N-dimethyl-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine-7(6H)-carboxamide (prepared according to intermediate example 13a) were transformed in analogy to example 3 using 1H-pyrazolo[3,4-b]pyridin-5-amine (CAS-No. 942185-01-5) to give after working up and purification 30.2 mg (27%) of the title compound.
1H-NMR (DMSO-d6): δ=2.84 (6H), 3.31 (2H), 3.53 (2H), 4.50 (2H), 8.15 (1H), 8.34 (1H), 8.39 (1H), 8.43 (1H), 8.64 (1H), 13.63 (1H) ppm.
A mixture comprising 1.00 g (3.81 mmol) 4-chloro-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine hydrochloride (prepared according to US2010/298297), 20 mL dimethyl sulfoxide, 926 μL pyridine, 466 mg N,N-dimethylpyridin-4-amine and 562 μL dimethylcarbamic chloride was stirred at 23° C. for 16 hours. The mixture was poured into water and extracted with dichloromethane. The organic layer was washed with brine and dried over sodium sulfate. After filtration and removal of the solvents the residue was purified by chromatography to give 533 mg (47%) of the title compound.
80 mg (270 μmol) 4-chloro-N,N-dimethyl-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine-7(6H)-carboxamide (prepared according to intermediate example 13a) were transformed in analogy to example 3 using 1H-pyrazolo[3,4-c]pyridin-5-amine (CAS-No. 1049672-75-4) to give after working up and purification 65.4 mg (58%) of the title compound.
1H-NMR (DMSO-d6): δ=2.84 (6H), 3.32 (2H), 3.54 (2H), 4.48 (2H), 8.25 (1H), 8.45 (1H), 8.56 (1H), 8.65 (1H), 8.86 (1H), 13.55 (1H) ppm.
80 mg (270 μmol) 4-chloro-N,N-dimethyl-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine-7(6H)-carboxamide (prepared according to intermediate example 13a) were transformed in analogy to example 3 using 1H-indazol-5-amine to give after working up and purification 50.7 mg (45%) of the title compound.
1H-NMR (DMSO-d6): δ=2.83 (6H), 3.31 (2H), 3.52 (2H), 4.49 (2H), 7.49-7.55 (2H), 8.00 (1H), 8.06 (1H), 8.28 (1H), 8.34 (1H), 13.04 (1H) ppm.
80 mg (270 μmol) 4-chloro-N,N-dimethyl-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine-7(6H)-carboxamide (prepared according to intermediate example 13a) were transformed in analogy to example 3 using 6-methoxy-1H-indazol-5-amine to give after working up and purification 33.7 mg (28%) of the title compound.
1H-NMR (DMSO-d6): δ=2.83 (6H), 3.26 (2H), 3.59 (2H), 3.99 (3H), 4.50 (2H), 7.10 (1H), 8.01 (1H), 8.18 (1H), 8.47 (1H), 8.69 (1H), 12.87 (1H) ppm.
80 mg (270 μmol) 4-chloro-N,N-dimethyl-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine-7(6H)-carboxamide (prepared according to intermediate example 13a) were transformed in analogy to example 3 using 6-amino-1,3-benzothiazol-2(3H)-one to give after working up and purification 46.2 mg (38%) of the title compound.
1H-NMR (DMSO-d6): δ=2.83 (6H), 3.27 (2H), 3.50 (2H), 4.48 (2H), 7.11 (1H), 7.47 (1H), 7.84 (1H), 8.25 (1H), 8.37 (1H), 11.86 (1H) ppm.
100 mg (338 μmol) 1-(4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)-2-methylpropan-1-one (prepared according to intermediate example 18a) were transformed in analogy to example 3 using 6-amino-1,3-benzothiazol-2(3H)-one to give after working up and purification 62.1 mg (41%) of the title compound.
1H-NMR (DMSO-d6): δ=1.02+1.09 (6H), 2.95-3.10 (1H), 3.18+3.29 (2H), 3.83+3.87 (2H), 4.79+4.91 (2H), 7.10+7.13 (1H), 7.44+7.46 (1H), 7.84 (1H), 8.24+8.26 (1H), 8.38 (1H), 11.87 (1H) ppm.
A mixture comprising 1.00 g (3.81 mmol) 4-chloro-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine hydrochloride (prepared according to US2010/298297), 30 mL dichloromethane, 1.60 mL N,N-diethylethanamine, 46.6 mg N,N-dimethylpyridin-4-amine and 562 μL 2-methylpropanoyl chloride was stirred at 23° C. for 2 hours. The mixture was poured into water and extracted with dichloromethane. The organic layer was washed with brine and dried over sodium sulfate. After filtration and removal of the solvents the residue was purified by chromatography to give 954 mg (85%) of the title compound.
100 mg (338 μmol) 1-(4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)-2-methylpropan-1-one (prepared according to intermediate example 18a) were transformed in analogy to example 3 using 1H-indazol-5-amine to give after working up and purification 22.3 mg (16%) of the title compound.
1H-NMR (DMSO-d6): δ=1.03-1.09 (6H), 3.03 (1H), 3.23+3.32 (2H), 3.81-3.92 (2H), 4.79+4.91 (2H), 7.48-7.56 (2H), 8.00 (1H), 8.07 (1H), 8.28 (1H), 8.36 (1H), 13.04 (1H) ppm.
100 mg (338 μmol) 1-(4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)-2-methylpropan-1-one (prepared according to intermediate example 18a) were transformed in analogy to example 3 using 1H-pyrazolo[3,4-c]pyridin-5-amine (CAS-No. 1049672-75-4) to give after working up and purification 79.2 mg (57%) of the title compound.
1H-NMR (DMSO-d6): δ=1.02+1.09 (6H), 2.95-3.14 (1H), 3.22+3.34 (2H), 3.86+3.92 (2H), 4.80+4.92 (2H), 8.25 (1H), 8.49 (1H), 8.57 (1H), 8.65 (1H), 8.86 (1H), 13.55 (1H) ppm.
100 mg (338 μmol) 1-(4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)-2-methylpropan-1-one (prepared according to intermediate example 18a) were transformed in analogy to example 3 using 1H-pyrazolo[3,4-b]pyridin-5-amine (CAS-No. 942185-01-5) to give after working up and purification 28.6 mg (20%) of the title compound.
1H-NMR (DMSO-d6): δ=1.03+1.09 (6H), 2.96-3.10 (1H), 3.24+3.33 (2H), 3.86+3.90 (2H), 4.81+4.92 (2H), 8.15 (1H), 8.36 (1H), 8.39 (1H), 8.42 (1H), 8.63 (1H), 13.64 (1H) ppm.
100 mg (338 μmol) 1-(4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)-2-methylpropan-1-one (prepared according to intermediate example 18a) were transformed in analogy to example 3 using 6-methoxy-1H-indazol-5-amine to give after working up and purification 26.0 mg (17%) of the title compound.
1H-NMR (DMSO-d6): δ=1.03+1.09 (6H), 3.00+3.09 (1H), 3.13-3.39 (2H), 3.88-4.04 (5H), 4.79+4.92 (2H), 7.10 (1H), 8.01 (1H), 8.17+8.19 (1H), 8.49 (1H), 8.71+8.73 (1H), 12.87 (1H) ppm.
100 mg (329 μmol) 4-chloro-7-(methylsulfonyl)-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine (prepared according to intermediate example 23a) were transformed in analogy to example 2 using 1H-pyrazolo[3,4-c]pyridin-5-amine (CAS-No. 1049672-75-4) to give after working up and purification 105.6 mg (76%) of the title compound.
1H-NMR (DMSO-d6): δ=3.00 (3H), 3.39 (2H), 3.61 (2H), 4.59 (2H), 8.24 (1H), 8.53 (1H), 8.57 (1H), 8.62 (1H), 8.86 (1H), 13.53 (1H) ppm.
1.00 g (3.81 mmol) 4-chloro-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine hydrochloride (prepared according to US2010/298297) were transformed in analogy to intermediate example 18a using methanesulfonyl chloride to give after working up and purification 781 mg (67%) of the title compound.
100 mg (295 μmol) (4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)(morpholin-4-yl)methanone (prepared according to intermediate example 24a) were transformed in analogy to example 2 using 1H-pyrazolo[3,4-c]pyridin-5-amine (CAS-No. 1049672-75-4) to give after working up and purification 81.2 mg (60%) of the title compound. 1H-NMR (DMSO-d6): δ=3.23 (4H), 3.31 (2H), 3.57 (2H), 3.61 (4H), 4.52 (2H), 8.23 (1H), 8.43 (1H), 8.55 (1H), 8.63 (1H), 8.84 (1H), 13.52 (1H) ppm.
1.00 g (3.81 mmol) 4-chloro-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine hydrochloride (prepared according to US2010/298297) were transformed in analogy to intermediate example 18a using morpholine-4-carbonyl chloride to give after working up and purification 1.01 g (78%) of the title compound.
100 mg (307 μmol) tert-butyl 4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine-7(6H)-carboxylate (prepared according to WO2009/33581) were transformed in analogy to example 3 using 6-bromo-1H-indazol-5-amine (e.g. Pharmablock, Inc. Sunnyvale, Calif., USA) to give after working up and purification 16.5 mg (11%) of the title compound.
1H-NMR (DMSO-d6): δ=1.46 (9H), 3.23 (2H), 3.74 (2H), 4.69 (2H), 7.94 (1H), 8.03 (1H), 8.14 (1H), 8.26 (1H), 8.38 (1H), 13.21 (1H) ppm.
2.51 g (7.70 mmol) tert-butyl 4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine-7(6H)-carboxylate (prepared according to WO2009/33581) were transformed in analogy to example 1 using 6-chloro-1H-indazol-5-amine to give after working up and purification 2.11 g (64%) of the title compound.
1H-NMR (DMSO-d6): δ=3.11 (4H), 3.99 (2H), 7.76 (1H), 8.14 (2H), 8.26 (1H), 8.27 (1H), 13.21 (1H) ppm.
A mixture comprising 100 mg (280 μmol) N-(6-chloro-1H-indazol-5-yl)-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-4-amine (prepared according to example 26), 3 mL dimethyl sulfoxide, 59 μL N-ethyl-N-isopropylpropan-2-amine and 30 μL 2-methylpropanoyl chloride was stirred at 23° C. for 2.5 days. The solvent was removed and the residue was purified by chromatography to give 70.0 mg (55%) of the title compound.
1H-NMR (DMSO-d6): δ=2.82 (6H), 3.27 (2H), 3.54 (2H), 4.49 (2H), 7.77 (1H), 8.08 (1H), 8.14 (1H), 8.27 (1H), 8.35 (1H), 13.21 (1H) ppm.
3.00 g (9.21 mmol) tert-butyl 4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine-7(6H)-carboxylate (prepared according to WO2009/33581) were transformed in analogy to example 1 using 6-bromo-1H-indazol-5-amine to give after working up and purification 2.32 g (55%) of the title compound.
1H-NMR (DMSO-d6): δ=3.10 (4H), 3.99 (2H), 7.94 (1H), 8.09 (1H), 8.14 (1H), 8.23 (1H), 8.27 (1H), 13.21 (1H) ppm.
100 mg (249 μmol) N-(6-bromo-1H-indazol-5-yl)-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-4-amine (prepared according to example 28) were transformed in analogy to example 27 to give after working up and purification 65.5 mg (56%) of the title compound.
1H-NMR (DMSO-d6): δ=2.82 (6H), 3.29 (2H), 3.54 (2H), 4.49 (2H), 7.93 (1H), 8.03 (1H), 8.13 (1H), 8.25 (1H), 8.36 (1H), 13.20 (1H) ppm.
50 mg (168 μmol) 4-chloro-N,N-dimethyl-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine-7(6H)-carboxamide (prepared according to intermediate example 13a) were transformed in analogy to example 3 using pyrazolo[1,5-a]pyridin-5-amine (CAS-No: 1101120-37-9) to give after working up and purification 19.0 mg (18%) of the title compound.
1H-NMR (DMSO-d6): δ=2.84 (6H), 3.32 (2H), 3.52 (2H), 4.51 (2H), 6.51 (1H), 7.15 (1H), 7.93 (1H), 8.11 (1H), 8.47 (1H), 8.54 (1H), 8.63 (1H) ppm.
100 mg (273 μmol) (4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)[(2R,6S)-2,6-dimethylmorpholin-4-yl]methanone (prepared according to intermediate example 31a) were transformed in analogy to intermediate example 3 using 6-amino-1,3-benzothiazol-2(3H)-one to give after working up and purification 53.5 mg (38%) of the title compound.
1H-NMR (DMSO-d6): δ=1.09 (6H), 2.55 (2H), 3.27 (2H), 3.48-3.63 (6H), 4.53 (2H), 7.11 (1H), 7.47 (1H), 7.84 (1H), 8.25 (1H), 8.37 (1H), 11.86 (1H) ppm.
To a solution comprising 1.00 g (3.81 mmol) 4-chloro-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine hydrochloride (prepared according to US2010/298297), 40 mL dichloromethane and 1.60 mL N,N-diethylethanamine were added 1.19 g trichloroacetic anhydride at 0° C. The mixture was stirred at 0° C. for 0.5 hours, 1.88 mL (2R,6S)-2,6-dimethylmorpholine were added and stirring was continued at 23° C. for 2 hours. 1.0 mL N,N-diethylethanamine were added, the solvents removed and the residue purified by chromatography to give 825 mg (59%) of the title compound.
100 mg (273 μmol) (4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)[(2R,6S)-2,6-dimethylmorpholin-4-yl]methanone (prepared according to intermediate example 31a) were transformed in analogy to intermediate example 3 using 6-methoxy-1H-indazol-5-amine to give after working up and purification 17.4 mg (11%) of the title compound.
1H-NMR (DMSO-d6): δ=1.10 (6H), 2.55 (2H), 3.26 (2H), 3.48-3.67 (6H), 3.98 (3H), 4.54 (2H), 7.10 (1H), 8.01 (1H), 8.18 (1H), 8.46 (1H), 8.67 (1H), 12.87 (1H) ppm.
100 mg (273 μmol) (4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)[(2R,6S)-2,6-dimethylmorpholin-4-yl]methanone (prepared according to intermediate example 31a) were transformed in analogy to intermediate example 3 using 1H-indazol-5-amine to give after working up and purification 58.4 mg (44%) of the title compound.
1H-NMR (DMSO-d6): δ=1.10 (6H), 2.55 (2H), 3.31 (2H), 3.49-3.62 (6H), 4.53 (2H), 7.52 (2H), 8.00 (1H), 8.06 (1H), 8.28 (1H), 8.34 (1H), 13.03 (1H) ppm.
100 mg (273 μmol) (4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)[(2R,6S)-2,6-dimethylmorpholin-4-yl]methanone (prepared according to intermediate example 31a) were transformed in analogy to intermediate example 3 using 1H-pyrazolo[3,4-c]pyridin-5-amine (CAS-No. 1049672-75-4) to give after working up and purification 68.9 mg (52%) of the title compound.
1H-NMR (DMSO-d6): δ=1.10 (6H), 2.50-2.60 (4H), 3.49-3.63 (6H), 4.52 (2H), 8.25 (1H), 8.47 (1H), 8.56 (1H), 8.65 (1H), 8.86 (1H), 13.55 (1H) ppm.
100 mg (273 μmol) (4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)[(2R,6S)-2,6-dimethylmorpholin-4-yl]methanone (prepared according to intermediate example 31a) were transformed in analogy to intermediate example 3 using 1H-pyrazolo[3,4-b]pyridin-5-amine (CAS-No. 942185-01-5) to give after working up and purification 40.1 mg (30%) of the title compound.
1H-NMR (DMSO-d6): δ=1.10 (6H), 2.56 (2H), 3.33 (2H), 3.49-3.62 (6H), 4.55 (2H), 8.15 (1H), 8.34 (1H), 8.39 (1H), 8.43 (1H), 8.64 (1H), 13.63 (1H) ppm.
80 mg (263 μmol) 4-chloro-7-(methylsulfonyl)-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine (prepared according to intermediate example 23a) were transformed in analogy to example 3 using pyrazolo[1,5-a]pyridin-5-amine to give after working up and purification 10.9 mg (10%) of the title compound.
1H-NMR (DMSO-d6): δ=3.03 (3H), 3.40 (2H), 3.60 (2H), 4.61 (2H), 6.53 (1H), 7.15 (1H), 7.94 (1H), 8.14 (1H), 8.47 (1H), 8.57 (1H), 8.65 (1H) ppm.
100 mg (329 μmol) 4-chloro-7-(methylsulfonyl)-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine (prepared according to intermediate example 23a) were transformed in analogy to example 3 using 6-methoxy-1H-indazol-5-amine to give after working up and purification 94.4 mg (63%) of the title compound.
1H-NMR (DMSO-d6): δ=3.03 (5H), 3.67 (2H), 4.00 (3H), 4.58 (2H), 7.11 (1H), 8.01 (1H), 8.21 (1H), 8.50 (1H), 8.74 (1H), 12.87 (1H) ppm.
100 mg (329 μmol) 4-chloro-7-(methylsulfonyl)-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine (prepared according to intermediate example 23a) were transformed in analogy to example 3 using 1H-indazol-5-amine to give after working up and purification 61.1 mg (44%) of the title compound.
1H-NMR (DMSO-d6): δ=3.03 (3H), 3.39 (2H), 3.59 (2H), 4.58 (2H), 7.50-7.57 (2H), 8.02 (1H), 8.07 (1H), 8.29 (1H), 8.37 (1H), 13.05 (1H) ppm.
100 mg (329 μmol) 4-chloro-7-(methylsulfonyl)-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine (prepared according to intermediate example 23a) were transformed in analogy to example 3 using 6-amino-1,3-benzothiazol-2(3H)-one to give after working up and purification 110 mg (73%) of the title compound.
1H-NMR (DMSO-d6): δ=3.02 (3H), 3.35 (2H), 3.58 (2H), 4.58 (2H), 7.13 (1H), 7.47 (1H), 7.86 (1H), 8.26 (1H), 8.40 (1H), 11.87 (1H) ppm.
100 mg (329 μmol) 4-chloro-7-(methylsulfonyl)-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine (prepared according to intermediate example 23a) were transformed in analogy to example 3 using 1H-pyrazolo[3,4-b]pyridin-5-amine (CAS-No. 942185-01-5) to give after working up and purification 35.1 mg (25%) of the title compound.
1H-NMR (DMSO-d6): δ=3.04 (3H), 3.40 (2H), 3.61 (2H), 4.59 (2H), 8.16 (1H), 8.37 (1H), 8.41 (1H), 8.43 (1H), 8.65 (1H), 13.64 (1H) ppm.
100 mg (295 μmol) (4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)(morpholin-4-yl)methanone (prepared according to intermediate example 24a) were transformed in analogy to example 3 using 6-amino-1,3-benzothiazol-2(3H)-one to give after working up and purification 52.6 mg (36%) of the title compound.
1H-NMR (DMSO-d6): δ=3.17-3.30 (6H), 3.54 (2H), 3.62 (4H), 4.54 (2H), 7.11 (1H), 7.47 (1H), 7.84 (1H), 8.25 (1H), 8.37 (1H), 11.85 (1H) ppm.
100 mg (295 μmol) (4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)(morpholin-4-yl)methanone (prepared according to intermediate example 24a) were transformed in analogy to example 3 using 6-methoxy-1H-indazol-5-amine to give after working up and purification 39.8 mg (29%) of the title compound.
1H-NMR (DMSO-d6): δ=3.19-3.30 (6H), 3.62 (6H), 3.98 (3H), 4.55 (2H), 7.10 (1H), 8.01 (1H), 8.17 (1H), 8.46 (1H), 8.67 (1H), 12.88 (1H) ppm.
100 mg (295 μmol) (4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)(morpholin-4-yl)methanone (prepared according to intermediate example 24a) were transformed in analogy to example 3 using 1H-indazol-5-amine to give after working up and purification 67 mg (50%) of the title compound.
1H-NMR (DMSO-d6): δ=3.22 (4H), 3.29 (2H), 3.54 (2H), 3.61 (4H), 4.53 (2H), 7.48-7.53 (2H), 7.98 (1H), 8.04 (1H), 8.25 (1H), 8.33 (1H), 13.01 (1H) ppm.
100 mg (295 μmol) (4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)(morpholin-4-yl)methanone (prepared according to intermediate example 24a) were transformed in analogy to example 3 using 1H-pyrazolo[3,4-b]pyridin-5-amine (CAS-No. 942185-01-5) to give after working up and purification 37.7 mg (28%) of the title compound.
1H-NMR (DMSO-d6): δ=3.24 (4H), 3.32 (2H), 3.57 (2H), 3.63 (4H), 4.56 (2H), 8.15 (1H), 8.34 (1H), 8.38 (1H), 8.43 (1H), 8.64 (1H), 13.62 (1H) ppm.
3.00 g (9.21 mmol) tert-butyl 4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine-7(6H)-carboxylate (prepared according to WO2009/33581) were transformed in analogy to example 1 using 6-methoxy-1H-pyrazolo[3,4-b]pyridin-5-amine to give after working up and purification 2.94 g (81%) of the title compound.
1H-NMR (DMSO-d6): δ=3.09-3.30 (4H), 4.02 (2H), 4.07 (3H), 7.99 (2H), 8.43 (1H), 8.91 (1H), 13.14 (1H) ppm.
80 mg (217 μmol) N-[6-(Methylsulfanyl)-1H-indazol-5-yl]-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-4-amine (prepared according to example 1) were transformed in analogy to example 27 using dimethylcarbamic chloride to give after working up and purification 60.0 mg (63%) of the title compound.
1H-NMR (DMSO-d6): δ=2.43 (3H), 2.81 (6H), 3.27 (2H), 3.53 (2H), 4.48 (2H), 7.36 (1H), 7.85 (1H), 8.03 (1H), 8.20 (1H), 8.21 (1H), 12.99 (1H) ppm.
80 mg (217 μmol) N-[6-(methylsulfanyl)-1H-indazol-5-yl]-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-4-amine (prepared according to example 1) were transformed in analogy to example 27 using morpholine-4-carbonyl chloride to give after working up and purification 70.0 mg (67%) of the title compound.
1H-NMR (DMSO-d6): δ=2.44 (3H), 3.23 (4H), 3.29 (2H), 3.58 (2H), 3.62 (4H), 4.55 (2H), 7.36 (1H), 7.84 (1H), 8.04 (1H), 8.23 (2H), 13.01 (1H) ppm.
80 mg (217 μmol) N-[6-(methylsulfanyl)-1H-indazol-5-yl]-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-4-amine (prepared according to example 1) were transformed in analogy to example 27 using methanesulfonyl chloride to give after working up and purification 35.0 mg (36%) of the title compound.
1H-NMR (DMSO-d6): δ=2.45 (3H), 3.03 (3H), 3.36 (2H), 3.62 (2H), 4.57 (2H), 7.38 (1H), 7.89 (1H), 8.05 (1H), 8.26 (1H), 8.27 (1H), 13.02 (1H) ppm.
100 mg (280 μmol) N-(6-chloro-1H-indazol-5-yl)-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-4-amine (prepared according to example 26) were transformed in analogy to example 27 using methanesulfonyl chloride to give after working up and purification 14.5 mg (12%) of the title compound.
1H-NMR (DMSO-d6): δ=3.02 (3H), 3.34 (2H), 3.61 (2H), 4.57 (2H), 7.77 (1H), 8.12 (1H), 8.14 (1H), 8.29 (1H), 8.36 (1H), 13.20 (1H) ppm.
100 mg (283 μmol) N-(6-methoxy-1H-pyrazolo[3,4-b]pyridin-5-yl)-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-4-amine (prepared according to example 45) were transformed in analogy to example 27 using methanesulfonyl chloride to give after working up and purification 6.5 mg (5%) of the title compound.
1H-NMR (DMSO-d6): δ=3.02 (3H), 3.33 (2H), 3.65 (2H), 4.02 (3H), 4.57 (2H), 8.01 (1H), 8.12 (1H), 8.45 (1H), 8.80 (1H), 13.37 (1H) ppm.
100 mg (280 μmol) N-(6-chloro-1H-indazol-5-yl)-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-4-amine (prepared according to example 26) were transformed in analogy to example 27 using morpholine-4-carbonyl chloride to give after working up and purification 77.7 mg (58%) of the title compound.
1H-NMR (DMSO-d6): δ=3.22 (4H), 3.27 (2H), 3.57 (2H), 3.61 (4H), 4.54 (2H), 7.75 (1H), 8.06 (1H), 8.12 (1H), 8.26 (1H), 8.34 (1H), 13.18 (1H) ppm.
100 mg (283 μmol) N-(6-methoxy-1H-pyrazolo[3,4-b]pyridin-5-yl)-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-4-amine (prepared according to example 45) were transformed in analogy to example 27 using morpholine-4-carbonyl chloride to give after working up and purification 36.3 mg (25%) of the title compound.
1H-NMR (DMSO-d6): δ=3.19-3.27 (6H), 3.55-3.65 (6H), 4.00 (3H), 4.54 (2H), 8.00 (1H), 8.09 (1H), 8.40 (1H), 8.70 (1H), 13.36 (1H) ppm.
100 mg (249 μmol) N-(6-bromo-1H-indazol-5-yl)-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-4-amine (prepared according to example 28) were transformed in analogy to example 27 using morpholine-4-carbonyl chloride to give after working up and purification 63.7 mg (50%) of the title compound.
1H-NMR (DMSO-d6): δ=3.22 (4H), 3.28 (2H), 3.57 (2H), 3.61 (4H), 4.54 (2H), 7.92 (1H), 8.00 (1H), 8.12 (1H), 8.24 (1H), 8.36 (1H), 13.18 (1H) ppm.
100 mg (257 μmol) N-(6-methoxy-1H-indazol-5-yl)-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-4-amine (prepared according to example 8) were transformed in analogy to example 9 using 3,3,3-trifluoropropanoic acid to give after working up and purification 15.0 mg (13%) of the title compound.
1H-NMR (DMSO-d6): δ=3.22+3.32 (2H), 3.75-3.97 (4H), 3.99+4.02 (3H), 4.83+4.87 (2H), 7.11+7.12 (1H), 8.01+8.02 (1H), 8.16+8.19 (1H), 8.49+8.51 (1H), 8.70+8.77 (1H), 12.88 (1H) ppm.
A mixture comprising 100 mg (283 μmol) N-(6-methoxy-1H-pyrazolo[3,4-b]pyridin-5-yl)-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-4-amine (prepared according to example 45), 2.27 mL dimethylsulfoxide, 123 μL N-ethyl-N-isopropylpropan-2-amine, 32 μL 2-methylpropanoic acid and 250 μL 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide solution (50% in N,N-dimethylformamide) was stirred at 60° C. for 2.5 days. The solvents were removed and the residue purified by chromatography to give 10.8 mg (9%) of the title compound.
1H-NMR (DMSO-d6): δ=1.01+1.08 (6H), 2.98+3.06 (1H), 3.15+3.27 (2H), 3.89+3.94 (2H), 4.02 (3H), 4.77+4.90 (2H), 8.01 (1H), 8.07 (1H), 8.42 (1H), 8.79 (1H), 13.33 (1H) ppm.
100 mg (280 μmol) N-(6-chloro-1H-indazol-5-yl)-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-4-amine (prepared according to example 26) were transformed in analogy to example 55 to give after working up and purification 10.0 mg (8%) of the title compound.
1H-NMR (DMSO-d6): δ=1.03+1.09 (6H), 3.03 (1H), 3.20+3.29 (2H), 3.87+3.92 (2H), 4.80+4.92 (2H), 7.78 (1H), 8.07-8.20 (2H), 8.30 (1H), 8.37 (1H), 13.22 (1H) ppm.
100 mg (249 μmol) N-(6-bromo-1H-indazol-5-yl)-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-4-amine (prepared according to example 28) were transformed in analogy to example 55 to give after working up and purification 16.4 mg (13%) of the title compound.
1H-NMR (DMSO-d6): δ=1.03+1.09 (6H), 3.03 (1H), 3.21+3.32 (2H), 3.88+3.92 (2H), 4.80+4.92 (2H), 7.94 (1H), 8.06 (1H), 8.14 (1H), 8.28 (1H), 8.37+8.38 (1H), 13.21 (1H) ppm.
75 mg (204 μmol) (4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)[(2R,6S)-2,6-dimethylmorpholin-4-yl]methanone (prepared according to intermediate example 31a) were transformed in analogy to example 2 using pyrazolo[1,5-a]pyridin-5-amine (CAS-No: 1101120-37-9) to give after working up and purification 24.1 mg (24%) of the title compound.
1H-NMR (DMSO-d6): δ=1.10 (6H), 2.56 (2H), 3.31 (2H), 3.48-3.63 (6H), 4.56 (2H), 6.51 (1H), 7.15 (1H), 7.93 (1H), 8.11 (1H), 8.47 (1H), 8.54 (1H), 8.63 (1H) ppm.
A mixture comprising 100 mg (307 μmol) tert-butyl 4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine-7(6H)-carboxylate (prepared according to WO2009/33581), 50.4 mg 6-methoxy-1H-pyrazolo[3,4-b]pyridin-5-amine (prepared according to intermediate example 59a), 2 mL ethanol and 53.5 μL N-ethyl-N-isopropylpropan-2-amine was heated at reflux for 2 days. The crude product was purified by chromatography and crystallisation to give 32.0 mg (23%) of the title compound.
1H-NMR (DMSO-d6): δ=1.46 (9H), 3.21 (2H), 3.76 (2H), 4.02 (3H), 4.69 (2H), 8.03 (1H), 8.12 (1H), 8.43 (1H), 8.73 (1H), 13.40 (1H) ppm.
A mixture comprising 4.00 g (20.6 mmol) 6-methoxy-5-nitro-1H-pyrazolo[3,4-b]pyridine (prepared according to intermediate example 59b), 120 mL ethanol, 120 mL tetrahydrofurane and 1.10 g palladium on charcoal (10%) was stirred at 23° C. under an atmosphere of hydrogen overnight. The catalyst and solvents were removed to give 3.26 g (96%) of the title compound.
At 0° C. 2.2 mL fuming nitric acid was carefully added to 6.8 mL acetic anhydride. 1.00 g (mmol) 6-methoxy-1H-pyrazolo[3,4-b]pyridine (CAS-No. 1260664-24-1) was added in portions, the mixture was stirred at 10° C. for 22 hours and poured on ice. Sodium hydrocarbonate was carefully added until a pH between 2 and 3 was obtained and the mixture was extracted with dichloromethane. The organic layer was washed with brine and dried over sodium sulphate. After filtration and removal of the solvent, the residue was purified by chrystallization to give 640 mg (39%) of the title compound.
A mixture comprising 100 mg (295 μmol) 4-chloro-7-[2-(morpholin-4-yl)ethyl]-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine (prepared according to intermediate example 60a), 79.2 mg 1H-pyrazolo[3,4-c]pyridin-5-amine and 4 mL ethanol a was heated at 150° C. for 8 hours. The crude product was purified by chromatography to give 42.0 mg (31%) of the title compound.
1H-NMR (DMSO-d6): δ=2.42 (4H), 2.53 (2H), 2.70 (2H), 2.91 (2H), 3.23 (2H), 3.57 (4H), 3.80 (2H), 8.26 (1H), 8.39 (1H), 8.56 (1H), 8.68 (1H), 8.86 (1H), 13.55 (1H) ppm.
A mixture comprising 2.06 g 4-(2-chloroethyl)morpholine, 50 mL acetone and 8.23 g sodium iodide was stirred at 50° C. for 2 days and added to a mixture comprising 1.50 g (5.72 mmol) 4-chloro-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine hydrochloride (prepared according to US2010/298297), 45 mL dichloromethane, 2.39 mL N,N-diethylethanamine and 140 mg N,N-dimethylpyridin-4-amine. Stirring was continued at 23° C. for 16 hours, the solvents were removed and the residue was purified by chromatography and crystallization to give 645 mg (33%) of the title compound.
100 mg (295 μmol) 4-chloro-7-[2-(morpholin-4-yl)ethyl]-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine (prepared according to intermediate example 60a), were transformed in analogy to example 60 using 1H-indazol-5-amine to give after working up and purification 57.2 mg (42%) of the title compound.
1H-NMR (DMSO-d6): δ=2.43 (4H), 2.54 (2H), 2.70 (2H), 2.87 (2H), 3.23 (2H), 3.58 (4H), 3.78 (2H), 7.49-7.57 (2H), 8.02 (1H), 8.06 (1H), 8.20 (1H), 8.34 (1H), 13.03 (1H) ppm.
100 mg (295 μmol) 4-chloro-7-[2-(morpholin-4-yl)ethyl]-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine (prepared according to intermediate example 60a), were transformed in analogy to example 60 using 6-methoxy-1H-indazol-5-amine to give after working up and purification 64.7 mg (43%) of the title compound.
1H-NMR (DMSO-d6): δ=3.02 (2H), 3.16 (2H), 3.21 (4H), 3.28 (4H), 3.81 (4H), 3.99 (3H), 4.02 (2H), 7.12 (1H), 8.02 (1H), 8.22 (1H), 8.50 (1H), 8.76 (1H), 12.89 (1H) ppm.
100 mg (295 μmol) 4-chloro-7-[2-(morpholin-4-yl)ethyl]-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine (prepared according to intermediate example 60a), were transformed in analogy to example 60 using 6-amino-1,3-benzothiazol-2(3H)-one to give after working up and purification 40.2 mg (28%) of the title compound.
1H-NMR (DMSO-d6): δ=2.42 (4H), 2.54 (2H), 2.69 (2H), 2.86 (2H), 3.19 (2H), 3.57 (4H), 3.77 (2H), 7.11 (1H), 7.47 (1H), 7.85 (1H), 8.17 (1H), 8.36 (1H), 11.84 (1H), ppm.
100 mg (295 μmol) 4-chloro-7-[2-(morpholin-4-yl)ethyl]-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine (prepared according to intermediate example 60a), were transformed in analogy to example 60 using 1H-pyrazolo[3,4-b]pyridin-5-amine to give after working up and purification 42.0 mg (31%) of the title compound.
1H-NMR (DMSO-d6): δ=2.43 (4H), 2.53 (2H), 2.70 (2H), 2.89 (2H), 3.24 (2H), 3.58 (4H), 3.79 (2H), 8.15 (1H), 8.34 (1H), 8.35 (1H), 8.41 (1H), 8.64 (1H), 13.63 (1H) ppm.
100 mg (283 μmol) N-(6-methoxy-1H-pyrazolo[3,4-b]pyridin-5-yl)-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-4-amine (prepared according to example 45) were transformed in analogy to example 27 using dimethylcarbamic chloride to give after working up and purification 34.5 mg (28%) of the title compound.
1H-NMR (DMSO-d6): δ=2.83 (6H), 3.26 (2H), 3.57 (2H), 4.02 (3H), 4.50 (2H), 8.02 (1H), 8.11 (1H), 8.42 (1H), 8.74 (1H), 13.39 (1H) ppm.
75 mg (214 μmol) (4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)(1-methylpiperidin-4-yl)methanone (prepared according to intermediate example 66a) were transformed in analogy to example 3 using 6-amino-1,3-benzothiazol-2(3H)-one to give after working up and purification 25.1 mg (23%) of the title compound.
1H-NMR (DMSO-d6): δ=1.53-1.72 (4H), 1.94 (2H), 2.15 (3H), 2.65 (2H), 2.78 (2H), 3.17 (1H), 3.82+3.86 (2H), 4.78+4.90 (2H), 7.06 (1H), 7.37 (1H), 7.75 (1H), 8.18 (1H), 8.36 (1H), 11.84 (1H) ppm.
500 mg (1.91 mmol) 4-chloro-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine hydrochloride (prepared according to US2010/298297) were transformed in analogy to intermediate example 18a using 1-methylpiperidine-4-carbonyl chloride to give after working up and purification 589 mg (73%) of the title compound.
75 mg (214 μmol) (4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)(1-methylpiperidin-4-yl)methanone (prepared according to intermediate example 66a) were transformed in analogy to example 3 using 1H-pyrazolo[3,4-b]pyridin-5-amine to give after working up and purification 15.7 mg (16%) of the title compound.
1H-NMR (DMSO-d6): δ=1.54-1.73 (4H), 1.94 (2H), 2.15 (3H), 2.67 (2H), 2.79 (2H), 3.23 (1H), 3.85+3.69 (2H), 4.80+4.92 (2H), 8.15 (1H), 8.34 (1H), 8.39 (1H), 8.31-8.55 (1H), 8.63 (1H), 13.62 (1H) ppm.
75 mg (214 μmol) (4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)(1-methylpiperidin-4-yl)methanone (prepared according to intermediate example 66a) were transformed in analogy to example 3 using 6-methoxy-1H-indazol-5-amine to give after working up and purification 21.9 mg (20%) of the title compound.
1H-NMR (DMSO-d6): δ=1.51-1.71 (4H), 1.94 (2H), 2.14 (3H), 2.61-2.84 (3H), 3.09-3.32 (2H), 3.89+3.93 (2H), 3.97 (3H), 4.76+4.90 (2H), 7.08 (1H), 7.99 (1H), 8.14 (1H), 8.45 (1H), 8.64+8.69 (1H), 12.86 (1H) ppm.
75 mg (214 μmol) (4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)(1-methylpiperidin-4-yl)methanone (prepared according to intermediate example 66a) were transformed in analogy to example 3 using 1H-indazol-5-amine to give after working up and purification 24.7 mg (25%) of the title compound.
1H-NMR (DMSO-d6): δ=1.52-1.70 (4H), 1.92 (2H), 2.14 (3H), 2.65 (1H), 2.76 (2H), 3.20 (1H), 3.28 (1H), 3.81+3.86 (2H), 4.77+4.90 (2H), 7.46-7.56 (2H), 7.98 (1H), 8.05 (1H), 8.26 (1H), 8.34 (1H), 13.03 (1H) ppm.
45 mg (134 μmol) (4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)(piperidin-1-yl)methanone (prepared according to intermediate example 70a) were transformed in analogy to example 3 using 6-methoxy-1H-indazol-5-amine to give after working up and purification 35.4 mg (62%) of the title compound.
1H-NMR (DMSO-d6): δ=1.54 (6H), 3.21 (4H), 3.25 (2H), 3.58 (2H), 3.97 (3H), 4.49 (2H), 7.10 (1H), 8.01 (1H), 8.18 (1H), 8.46 (1H), 8.66 (1H), 12.88 (1H) ppm.
100 mg (381 μmol) 4-chloro-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine hydrochloride (prepared according to US2010/298297) were transformed in analogy to intermediate example 18a using piperidine-1-carbonyl chloride to give after working up and purification 132 mg (97%) of the title compound.
39 mg (120 μmol) 3-(4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)-N,N-dimethylpropanamide (prepared according to intermediate example 71a) were transformed in analogy to example 2 using 6-methoxy-1H-indazol-5-amine to give after working up and purification 21.0 mg (37%) of the title compound.
1H-NMR (DMSO-d6): δ=2.59 (2H), 2.80 (2H), 2.81 (3H), 2.92 (2H), 3.00 (3H), 3.17 (2H), 3.76 (2H), 3.98 (3H), 7.09 (1H), 7.99 (1H), 8.18 (1H), 8.47 (1H), 8.78 (1H), 12.84 (1H) ppm.
100 mg (381 μmol) 4-chloro-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine hydrochloride (prepared according to US2010/298297) were transformed in analogy to intermediate example 18a using 3-chloro-N,N-dimethylpropanamide to give after working up and purification 41.9 mg (25%) of the title compound.
50 mg (155 μmol) (4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)(pyrrolidin-1-yl)methanone (prepared according to intermediate example 72a) were transformed in analogy to example 2 using 6-methoxy-1H-indazol-5-amine to give after working up and purification 35.1 mg (62%) of the title compound.
1H-NMR (DMSO-d6): δ=1.80 (4H), 3.24 (2H), 3.37 (4H), 3.64 (2H), 3.98 (3H), 4.53 (2H), 7.10 (1H), 8.01 (1H), 8.18 (1H), 8.47 (1H), 8.70 (1H), 12.87 (1H) ppm.
100 mg (381 μmol) 4-chloro-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine hydrochloride (prepared according to US2010/298297) were transformed in analogy to intermediate example 18a using pyrrolidine-1-carbonyl chloride to give after working up and purification 118 mg (86%) of the title compound.
100 mg (284 μmol) N-(6-methoxy-1H-indazol-5-yl)-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-4-amine (prepared according to example 8) were transformed in analogy to example 55 using 1-methyl-1H-pyrrole-2-carboxylic acid to give after working up and purification 2.6 mg (2%) of the title compound.
1H-NMR (DMSO-d6): δ=3.34 (2H), 3.72 (3H), 3.98 (3H), 4.06 (2H), 4.97 (2H), 6.11 (1H), 6.53 (1H), 6.98 (1H), 7.11 (1H), 8.01 (1H), 8.20 (1H), 8.47 (1H), 8.66 (1H), 12.88 (1H) ppm.
75 mg (214 μmol) (4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)(1-methylpiperidin-4-yl)methanone (prepared according to intermediate example 66a) were transformed in analogy to example 3 using 6-(methylsulfanyl)-1H-indazol-5-amine to give after working up and purification 25.5 mg (23%) of the title compound.
1H-NMR (DMSO-d6): δ=1.55-1.70 (4H), 1.94 (2H), 2.15 (3H), 2.44 (3H), 2.67 (2H), 2.78 (2H), 3.19 (1H), 3.86+3.91 (2H), 4.79+4.91 (2H), 7.37 (1H), 7.85+7.87 (1H), 8.05 (1H), 8.23 (2H), 13.02 (1H) ppm.
100 mg (313 μmol) (4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)(1H-imidazol-5-yl)methanone (prepared according to intermediate example 75a) were transformed in analogy to example 60 using 6-methoxy-1H-indazol-5-amine to give after working up and purification 125 mg (85%) of the title compound.
1H-NMR (DMSO-d6): δ=3.33 (2H), 3.97 (3H), 4.03-4.30 (2H), 4.97 (1H), 5.23 (1H), 7.10 (1H), 8.00 (1H), 8.12 (1H), 8.19 (1H), 8.47 (1H), 8.65 (1H), 8.86 (1H), 12.90 (1H) ppm.
790 mg (3.01 mmol) 4-chloro-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine hydrochloride (prepared according to US2010/298297) were transformed in analogy to intermediate example 18a using 1H-imidazole-5-carbonyl chloride to give after working up and purification 812 mg (84%) of the title compound.
100 mg (272 μmol) (4-amino-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)(5-chloro-1-methyl-1H-pyrrol-2-yl)methanone (prepared according to intermediate example 76a) were transformed in analogy to example 60 using 6-methoxy-1H-indazol-5-amine to give after working up and purification 86.5 mg (61%) of the title compound.
1H-NMR (DMSO-d6): δ=3.33 (2H), 3.65 (3H), 3.98 (3H), 4.04 (2H), 4.96 (2H), 6.25 (1H), 6.59 (1H), 7.10 (1H), 8.01 (1H), 8.19 (1H), 8.47 (1H), 8.66 (1H), 12.88 (1H) ppm.
700 mg (2.67 mmol) 4-chloro-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine hydrochloride (prepared according to US2010/298297) were transformed in analogy to intermediate example 18a using 5-chloro-1-methyl-1H-pyrrole-2-carbonyl chloride to give after working up and purification 114 mg (12%) of the title compound.
48 mg (137 μmol) (4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)(1-methylpiperidin-4-yl)methanone (prepared according to intermediate example 66a) were transformed in analogy to example 60 using 1H-pyrazolo[3,4-c]pyridin-5-amine to give after working up and purification 15.6 mg (24%) of the title compound.
1H-NMR (DMSO-d6): δ=1.79-1.96 (4H), 2.72 (3H), 2.84-3.47 (7H), 3.86+3.93 (2H), 4.80+4.94 (2H), 8.24 (1H), 8.43+8.48 (1H), 8.55+8.57 (1H), 8.58+8.67 (1H), 8.85 (1H), 13.58 (1H) ppm.
113 mg (327 μmol) 4-chloro-N-(2-chloroethyl)-N-methyl-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine-7(6H)-carboxamide (prepared according to intermediate example 78a) were transformed in analogy to example 2 using 6-methoxy-1H-indazol-5-amine to give after working up and purification 8.7 mg (5%) of the title compound.
1H-NMR (DMSO-d6): δ=1.18 (3H), 2.56 (3H), 3.15-3.26 (6H), 3.38 (2H), 3.57 (2H), 3.87 (3H), 4.73 (2H), 7.06 (1H), 7.98 (1H), 8.35-8.41 (3H), 12.85 (1H) ppm.
373 mg (1.42 mmol) 4-chloro-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine hydrochloride (prepared according to US2010/298297) were transformed in analogy to intermediate example 18a using (2-chloroethyl)methylcarbamic chloride to give after working up and purification 347 mg (71%) of the title compound.
75 mg (214 μmol) (4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)(1-methylpiperidin-4-yl)methanone (prepared according to intermediate example 66a) were transformed in analogy to example 60 using pyrazolo[1,5-a]pyridin-5-amine to give after working up and purification 10.1 mg (10%) of the title compound.
1H-NMR (DMSO-d6): δ=1.53-1.70 (4H), 1.93 (2H), 2.11-2.18 (3H), 2.66 (1H), 2.77 (2H), 3.22 (1H), 3.32 (1H), 3.76-3.89 (2H), 4.79+4.91 (2H), 6.48 (1H), 7.09-7.15 (1H), 7.90 (1H), 8.08 (1H), 8.45 (1H), 8.52 (1H), 8.61 (1H) ppm.
100 mg (325 μmol) 4-chloro-7-(1,2,4-oxadiazol-3-ylmethyl)-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine (prepared according to intermediate example 80a) were transformed in analogy to example 60 using 6-methoxy-1H-indazol-5-amine to give after working up and purification 78.7 mg (53%) of the title compound.
1H-NMR (DMSO-d6): δ=3.37 (4H), 3.96 (3H), 4.24 (2H), 4.40 (2H), 7.09 (1H), 8.00 (1H), 8.22 (1H), 8.48 (1H), 8.67 (1H), 9.73 (1H), 12.84 (1H) ppm.
1.00 g (3.81 mmol) 4-chloro-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine hydrochloride (prepared according to US2010/298297) were transformed in analogy to intermediate example 60a using 3-(chloromethyl)-1,2,4-oxadiazole to give after working up and purification 866 mg (74%) of the title compound.
100 mg (312 μmol) (4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)(1,3-oxazol-4-yl)methanone (prepared according to intermediate example 81a) were transformed in analogy to example 60 using 6-methoxy-1H-indazol-5-amine to give after working up and purification 45.5 mg (29%) of the title compound.
1H-NMR (DMSO-d6): δ=3.26-3.40 (2H), 3.92-4.32 (2H), 3.96 (3H), 4.88-5.32 (2H), 7.08 (1H), 7.99 (1H), 8.17 (1H), 8.46 (1H), 8.59 (1H), 8.68 (1H), 12.85 (1H) ppm.
695 mg (2.65 mmol) 4-chloro-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine hydrochloride (prepared according to US2010/298297) were transformed in analogy to example 55 using 1,3-oxazole-4-carboxylic acid to give after working up and purification 136 mg (16%) of the title compound.
A mixture comprising 70 mg (203 μmol) 4-chloro-N-(2-chloroethyl)-N-methyl-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine-7(6H)-carboxamide (prepared according to intermediate example 78a), 31.4 mg 6-methoxy-1H-indazol-5-amine and 1.5 mL N,N-dimethylacetamide was heated at 80° C. for 5 hours. 26.8 μL N,N-diethylethanamine were added, the solvents removed and the crude product was purified by chromatography to give 5.9 mg (5%) of the title compound.
1H-NMR (DMSO-d6): δ=2.57 (3H), 3.17-3.40 (6H), 3.48 (2H), 3.90 (3H), 3.91 (3H), 4.61 (2H), 5.64 (1H), 6.62 (1H), 6.90 (1H), 7.08 (1H), 7.66 (1H), 7.99 (1H), 8.34 (1H), 8.36 (1H), 8.44 (1H), 12.51 (1H), 12.85 (1H) ppm.
58.5 mg (166 μmol) 1-[3-(4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)propyl]imidazolidin-2-one (prepared according to intermediate example 83a) were transformed in analogy to example 60 using 6-methoxy-1H-indazol-5-amine to give after working up and purification 66.5 mg (79%) of the title compound.
1H-NMR (DMSO-d6): δ=1.72 (2H), 2.45-2.63 (4H), 2.91 (2H), 3.12 (2H), 3.17-3.27 (4H), 3.74 (2H), 4.00 (3H), 6.25 (1H), 7.10 (1H), 8.01 (1H), 8.20 (1H), 8.49 (1H), 8.79 (1H), 12.87 (1H) ppm.
145 mg (553 μmol) 4-chloro-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine hydrochloride (prepared according to US2010/298297) were transformed in analogy to intermediate example 60a using 1-(3-chloropropyl)imidazolidin-2-one to give after working up and purification 65.3 mg (30%) of the title compound.
87.3 mg (262 μmol) 4-chloro-7-[3-(1H-pyrrol-1-yl)propyl]-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine (prepared according to intermediate example 84a) were transformed in analogy to example 60 using 6-methoxy-1H-indazol-5-amine to give after working up and purification 92.1 mg (69%) of the title compound.
1H-NMR (DMSO-d6): δ=1.99 (2H), 2.55 (2H), 2.91 (2H), 3.21 (2H), 3.74 (2H), 3.97 (2H), 4.00 (3H), 6.00 (2H), 6.78 (2H), 7.11 (1H), 8.01 (1H), 8.20 (1H), 8.49 (1H), 8.78 (1H), 12.87 (1H) ppm.
200 mg (763 μmol) 4-chloro-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine hydrochloride (prepared according to US2010/298297) were transformed in analogy to intermediate example 60a using 1-(3-bromopropyl)-1H-pyrrole to give after working up and purification 97.7 mg (35%) of the title compound.
25.2 mg (75 μmol) 1-[2-(4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)ethyl]pyrrolidin-2-one (prepared according to intermediate example 85a) were transformed in analogy to example 60 using 6-methoxy-1H-indazol-5-amine to give after working up and purification 16.3 mg (45%) of the title compound.
1H-NMR (DMSO-d6): δ=1.92 (2H), 2.21 (2H), 2.70 (2H), 2.95 (2H), 3.17 (2H), 3.42 (4H), 3.80 (2H), 4.00 (3H), 7.11 (1H), 8.01 (1H), 8.20 (1H), 8.48 (1H), 8.77 (1H), 12.87 (1H) ppm.
200 mg (763 μmol) 4-chloro-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine hydrochloride (prepared according to US2010/298297) were transformed in analogy to intermediate example 60a using 1-(2-chloroethyl)pyrrolidin-2-one to give after working up and purification 28.7 mg (10%) of the title compound.
40.5 mg (115 μmol) 1-[3-(4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)propyl]pyrrolidin-2-one (prepared according to intermediate example 86a) were transformed in analogy to example 60 using 6-methoxy-1H-indazol-5-amine to give after working up and purification 21.0 mg (32%) of the title compound.
1H-NMR (DMSO-d6): δ=1.72 (2H), 1.91 (2H), 2.20 (2H), 2.53 (2H), 2.89 (2H), 3.18 (2H), 3.23 (2H), 3.35 (2H), 3.72 (2H), 3.98 (3H), 7.09 (1H), 7.99 (1H), 8.18 (1H), 8.47 (1H), 8.77 (1H), 12.84 (1H) ppm.
200 mg (763 μmol) 4-chloro-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine hydrochloride (prepared according to US2010/298297) were transformed in analogy to intermediate example 60a using 1-(3-chloropropyl)pyrrolidin-2-one to give after working up and purification 45.0 mg (14%) of the title compound.
17.1 mg (47 μmol) 4-[3-(4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)propyl]morpholin-3-one (prepared according to intermediate example 87a) were transformed in analogy to example 60 using 6-methoxy-1H-indazol-5-amine to give after working up and purification 7.9 mg (31%) of the title compound.
1H-NMR (DMSO-d6): δ=1.80 (2H), 2.56 (2H), 2.91 (2H), 3.20 (2H), 3.35-3.43 (4H), 3.74 (2H), 3.83 (2H), 4.00 (3H), 4.02 (2H), 7.11 (1H), 8.01 (1H), 8.21 (1H), 8.49 (1H), 8.79 (1H), 12.87 (1H) ppm.
200 mg (763 μmol) 4-chloro-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine hydrochloride (prepared according to US2010/298297) were transformed in analogy to intermediate example 60a using 4-(3-chloropropyl)morpholin-3-one to give after working up and purification 19.0 mg (6%) of the title compound.
76.5 mg (202 μmol) 5-[(4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)methyl]-N,N-dimethyl-1,2-oxazole-3-carboxamide (prepared according to intermediate example 88a) were transformed in analogy to example 60 using 6-methoxy-1H-indazol-5-amine to give after working up and purification 80.0 mg (74%) of the title compound.
1H-NMR (DMSO-d6): δ=2.97-3.06 (2H), 3.02 (3H), 3.09 (3H), 3.24 (2H), 3.85 (2H), 3.99 (3H), 4.06 (2H), 6.73 (1H), 7.10 (1H), 8.01 (1H), 8.20 (1H), 8.49 (1H), 8.78 (1H), 12.87 (1H) ppm.
136 mg (519 μmol) 4-chloro-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine hydrochloride (prepared according to US2010/298297) were transformed in analogy to intermediate example 60a using 5-(chloromethyl)-N,N-dimethyl-1,2-oxazole-3-carboxamide to give after working up and purification 85.5 mg (41%) of the title compound.
139.5 mg (366 μmol) 4-chloro-7-{3-[(2R,6S)-2,6-dimethylmorpholin-4-yl]propyl}-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine (prepared according to intermediate example 89a) were transformed in analogy to example 60 using 6-methoxy-1H-indazol-5-amine to give after working up and purification 18.9 mg (9%) of the title compound.
1H-NMR (DMSO-d6): δ=1.07 (6H), 1.84 (2H), 2.64 (2H), 2.92-3.87 (14H), 3.98 (3H), 7.10 (1H), 8.00 (1H), 8.19 (1H), 8.48 (1H), 8.76 (1H), 12.85 (1H) ppm.
200 mg (763 μmol) 4-chloro-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine hydrochloride (prepared according to US2010/298297) were transformed in analogy to intermediate example 60a using (2R,6S)-4-(3-chloropropyl)-2,6-dimethylmorpholine to give after working up and purification 164.9 mg (54%) of the title compound.
29.7 mg (84 μmol) 4-chloro-7-[3-(morpholin-4-yl)propyl]-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine (prepared according to intermediate example 90a) were transformed in analogy to example 60 using 6-methoxy-1H-indazol-5-amine to give after working up and purification 6.7 mg (15%) of the title compound.
1H-NMR (DMSO-d6): δ=1.71 (2H), 2.25-2.41 (6H) 2.68 (2H), 2.90 (2H), 3.19 (2H), 3.58 (4H), 3.73 (2H), 4.00 (3H), 7.11 (1H), 8.01 (1H), 8.21 (1H), 8.49 (1H), 8.80 (1H), 12.87 (1H) ppm.
200 mg (763 μmol) 4-chloro-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine hydrochloride (prepared according to US2010/298297) were transformed in analogy to intermediate example 60a using 4-(3-chloropropyl)morpholine to give after working up and purification 33.3 mg (11%) of the title compound.
120 mg (373 μmol) (4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)(cyclopentyl)methanone (prepared according to intermediate example 91a) were transformed in analogy to example 60 using 6-methoxy-1H-indazol-5-amine to give after working up and purification 95.9 mg (57%) of the title compound.
1H-NMR (DMSO-d6): δ=1.50-1.93 (8H), 3.05-3.24 (2H), 3.27 (1H), 3.92+3.97 (2H), 3.98+4.00 (3H), 4.79+4.91 (2H), 7.10 (1H), 8.01 (1H), 8.16+8.18 (1H), 8.48 (1H), 8.72 (1H), 12.87 (1H) ppm.
150 mg (572 μmol) 4-chloro-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine hydrochloride (prepared according to US2010/298297) were transformed in analogy to example 55 using cyclopentanecarboxylic acid to give after working up and purification 122.9 mg (63%) of the title compound.
85 mg (253 μmol) (4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)(cyclohexyl)methanone (prepared according to intermediate example 92a) were transformed in analogy to example 60 using 6-methoxy-1H-indazol-5-amine to give after working up and purification 71.0 mg (61%) of the title compound.
1H-NMR (DMSO-d6): δ=1.18 (1H), 1.29-1.46 (4H), 1.61-1.79 (5H), 2.75 (1H), 3.16+3.28 (2H), 3.90+3.95 (2H), 3.98+3.99 (3H), 4.77+4.91 (2H), 7.10 (1H), 8.00 (1H), 8.16 (1H), 8.47 (1H), 8.65+8.71 (1H), 12.87 (1H) ppm.
150 mg (572 μmol) 4-chloro-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine hydrochloride (prepared according to US2010/298297) were transformed in analogy to example 55 using cyclohexanecarboxylic acid to give after working up and purification 87.9 mg (43%) of the title compound.
70 mg (191 μmol) (4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)[(3R,5R)-3,5-dimethylmorpholin-4-yl]methanone (prepared according to intermediate example 93a) were transformed in analogy to example 60 using 6-methoxy-1H-indazol-5-amine to give after working up and purification 61.4 mg (65%) of the title compound.
1H-NMR (DMSO-d6): δ=0.98 (6H), 3.15 (1H), 3.23-3.44 (5H), 3.53 (1H), 3.73 (2H), 3.96 (3H), 3.99 (1H), 4.70 (2H), 7.08 (1H), 7.99 (1H), 8.15 (1H), 8.44 (1H), 8.62 (1H), 12.84 (1H) ppm.
A mixture comprising 100 mg (347 μmol) 4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine-7(6H)-carbonyl chloride (prepared according to intermediate example 93b), 2.0 mL dichloromethane, 42 mg (3R,5R)-3,5-dimethylmorpholine and 145 μL N,N-diethylethanamine was stirred at 23° C. for 16 hours. The solvent was removed and the residue purified by chromatography to give 73.3 mg (55%) of the title compound.
To a solution comprising 4.00 g (15.26 mmol) 4-chloro-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine hydrochloride (prepared according to US2010/298297), 160 mL dichloromethane and 6.38 mL N,N-diethylethanamine were added 4.75 g bis(trichloromethyl) carbonate at 0° C. The mixture was stirred at 0° C. for one hour, 6.0 mL N,N-diethylethanamine were added and the solvent was removed. The residue was purified by chromatography to give 3.40 g (73%) of the title compound.
120 mg (327 μmol) (4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)[(2S,6S)-2,6-dimethylmorpholin-4-yl]methanone (prepared according to intermediate example 94a) were transformed in analogy to example 60 using 6-methoxy-1H-indazol-5-amine to give after working up and purification 100.1 mg (62%) of the title compound.
1H-NMR (DMSO-d6): δ=1.13 (6H), 2.96 (2H), 3.20-3.34 (4H), 3.60 (2H), 3.92-4.01 (2H), 3.96 (3H), 4.51 (2H), 7.09 (1H), 7.99 (1H), 8.17 (1H), 8.45 (1H), 8.67 (1H), 12.84 (1H) ppm.
100 mg (347 μmol) 4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine-7(6H)-carbonyl chloride (prepared according to intermediate example 93b) were transformed in analogy to intermediate example 93a using (2S,6S)-2,6-dimethylmorpholine to give after working up and purification 123 mg (82%) of the title compound.
125 mg (341 μmol) (4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)[(2R,6R)-2,6-dimethylmorpholin-4-yl]methanone (prepared according to intermediate example 95a) were transformed in analogy to example 60 using 6-methoxy-1H-indazol-5-amine to give after working up and purification 107.5 mg (64%) of the title compound.
1H-NMR (DMSO-d6): δ=1.13 (6H), 2.96 (2H), 3.20-3.34 (4H), 3.60 (2H), 3.92-4.01 (2H), 3.96 (3H), 4.51 (2H), 7.09 (1H), 7.99 (1H), 8.17 (1H), 8.45 (1H), 8.67 (1H), 12.84 (1H) ppm.
100 mg (347 μmol) 4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine-7(6H)-carbonyl chloride (prepared according to intermediate example 93b) were transformed in analogy to intermediate example 93a using (2R,6R)-2,6-dimethylmorpholine to give after working up and purification 128 mg (96%) of the title compound.
137 mg (388 μmol) (4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)[(3R)-3-methylmorpholin-4-yl]methanone (prepared according to intermediate example 96a) were transformed in analogy to example 60 using 6-methoxy-1H-indazol-5-amine to give after working up and purification 105.4 mg (57%) of the title compound.
1H-NMR (DMSO-d6): δ=1.21 (3H), 3.16-3.28 (4H), 3.40-3.79 (7H), 3.96 (3H), 4.51 (2H), 7.09 (1H), 7.99 (1H), 8.16 (1H), 8.45 (1H), 8.65 (1H), 12.84 (1H) ppm.
100 mg (347 μmol) 4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine-7(6H)-carbonyl chloride (prepared according to intermediate example 93b) were transformed in analogy to intermediate example 93a using (3R)-3-methylmorpholine to give after working up and purification 139 mg (max. 100%) of the title compound.
129 mg (366 μmol) (4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)[(3S)-3-methylmorpholin-4-yl]methanone (prepared according to intermediate example 97a) were transformed in analogy to example 60 using 6-methoxy-1H-indazol-5-amine to give after working up and purification 102.1 mg (58%) of the title compound.
1H-NMR (DMSO-d6): δ=1.21 (3H), 3.16-3.28 (4H), 3.40-3.79 (7H), 3.96 (3H), 4.51 (2H), 7.09 (1H), 7.99 (1H), 8.16 (1H), 8.45 (1H), 8.65 (1H), 12.84 (1H) ppm.
100 mg (347 μmol) 4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine-7(6H)-carbonyl chloride (prepared according to intermediate example 93b) were transformed in analogy to intermediate example 93a using (3S)-3-methylmorpholine to give after working up and purification 132 mg (max. 100%) of the title compound.
197 mg (616 μmol) 4-chloro-7-[(1-methyl-1H-pyrazol-3-yl)methyl]-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine (prepared according to intermediate example 98a) were transformed in analogy to example 60 using 6-methoxy-1H-indazol-5-amine to give after working up and purification 5.4 mg (2%) of the title compound.
1H-NMR (DMSO-d6): δ=2.93 (2H), 3.19 (2H), 3.69-3.75 (4H), 3.82 (3H), 3.98 (3H), 6.22 (1H), 7.10 (1H), 7.65 (1H), 8.01 (1H), 8.19 (1H), 8.48 (1H), 8.79 (1H), 12.87 (1H) ppm.
500 mg (1.91 mmol) 4-chloro-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine hydrochloride (prepared according to US2010/298297) were transformed in analogy to intermediate example 60a using 3-(chloromethyl)-1-methyl-1H-pyrazole to give after working up and purification 203 mg (33%) of the title compound.
131 mg (346 μmol) 4-chloro-N-methyl-N-(3,3,3-trifluoropropyl)-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine-7(6H)-carboxamide (prepared according to intermediate example 99a) were transformed in analogy to example 60 using 6-methoxy-1H-indazol-5-amine to give after working up and purification 96.8 mg (55%) of the title compound.
1H-NMR (DMSO-d6): δ=2.54-2.65 (2H), 2.94 (3H), 3.25 (2H), 3.42 (2H), 3.58 (2H), 3.99 (3H), 4.49 (2H), 7.11 (1H), 8.01 (1H), 8.18 (1H), 8.48 (1H), 8.72 (1H), 12.87 (1H) ppm.
100 mg (347 μmol) 4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine-7(6H)-carbonyl chloride (prepared according to intermediate example 93b) were transformed in analogy to intermediate example 93a using 3,3,3-trifluoro-N-methylpropan-1-amine to give after working up and purification 135 mg (92%) of the title compound.
64 mg (175 μmol) 4-chloro-N-(3,3,3-trifluoropropyl)-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine-7(6H)-carboxamide (prepared according to intermediate example 100a) were transformed in analogy to example 60 using 6-methoxy-1H-indazol-5-amine to give after working up and purification 32.6 mg (38%) of the title compound.
1H-NMR (DMSO-d6): δ=2.44 (2H), 3.16 (2H), 3.31 (2H), 3.77 (2H), 3.98 (3H), 4.66 (2H), 7.04 (1H), 7.09 (1H), 7.99 (1H), 8.16 (1H), 8.47 (1H), 8.72 (1H), 12.85 (1H) ppm.
100 mg (347 μmol) 4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine-7(6H)-carbonyl chloride (prepared according to intermediate example 93b) were transformed in analogy to intermediate example 93a using 3,3,3-trifluoropropan-1-amine to give after working up and purification 67 mg (48%) of the title compound.
61 mg (166 μmol) (4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)[(3S,5S)-3,5-dimethylmorpholin-4-yl]methanone (prepared according to intermediate example 101a) were transformed in analogy to example 60 using 6-methoxy-1H-indazol-5-amine to give after working up and purification 44.8 mg (49%) of the title compound.
1H-NMR (DMSO-d6): δ=0.98 (6H), 3.15 (1H), 3.23-3.44 (5H), 3.53 (1H), 3.73 (2H), 3.96 (3H), 3.99 (1H), 4.70 (2H), 7.08 (1H), 7.99 (1H), 8.15 (1H), 8.44 (1H), 8.62 (1H), 12.84 (1H) ppm.
100 mg (347 μmol) 4-Chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine-7(6H)-carbonyl chloride (prepared according to intermediate example 93b) were transformed in analogy to intermediate example 93a using (3S,5S)-3,5-dimethylmorpholine to give after working up and purification 64.9 mg (51%) of the title compound.
60 mg (187 μmol) (4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)(1,2-oxazol-5-yl)methanone (prepared according to intermediate example 102a) were transformed in analogy to example 60 using 6-methoxy-1H-indazol-5-amine to give after working up and purification 20.1 mg (23) of the title compound.
1H-NMR (DMSO-d6): δ=3.34-4.15 (7H), 4.97 (2H), 7.04-7.11 (2H), 7.99 (1H), 8.16 (1H), 8.46 (1H), 8.59+8.67 (1H), 8.78-8.85 (1H), 12.85 (1H) ppm.
696 mg (2.65 mmol) 4-chloro-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine hydrochloride (prepared according to US2010/298297) were transformed in analogy to example 55 using 1,2-oxazole-5-carboxylic acid to give after working up and purification 63 mg (7%) of the title compound.
100 mg (300 μmol) (4-chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)(1-methyl-1H-pyrazol-3-yl)methanone (prepared according to intermediate example 103a) were transformed in analogy to example 60 using 6-methoxy-1H-indazol-5-amine to give after working up and purification 91 mg (63%) of the title compound.
1H-NMR (DMSO-d6): δ=3.23-4.38 (10H), 4.93+5.32 (2H), 6.63 (1H), 7.09 (1H), 7.82 (1H), 7.99 (1H), 8.18 (1H), 8.46 (1H), 8.64+8.69 (1H), 12.86 (1H) ppm.
(4-Chloro-5,8-dihydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-7(6H)-yl)(1-methyl-1H-pyrazol-3-yl)methanone
623 mg (2.38 mmol) 4-chloro-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine hydrochloride (prepared according to US2010/298297) were transformed in analogy to example 55 using 1-methyl-1H-pyrazole-3-carboxylic acid to give after working up and purification 183 mg (23%) of the title compound.
This invention also relates to pharmaceutical compositions containing one or more compounds of the present invention. These compositions can be utilised to achieve the desired pharmacological effect by administration to a patient in need thereof. A patient, for the purpose of this invention, is a mammal, including a human, in need of treatment for the particular condition or disease. Therefore, the present invention includes pharmaceutical compositions that are comprised of a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound, or salt thereof, of the present invention. A pharmaceutically acceptable carrier is preferably a carrier that is relatively non-toxic and innocuous to a patient at concentrations consistent with effective activity of the active ingredient so that any side effects ascribable to the carrier do not vitiate the beneficial effects of the active ingredient. A pharmaceutically effective amount of compound is preferably that amount which produces a result or exerts an influence on the particular condition being treated. The compounds of the present invention can be administered with pharmaceutically-acceptable carriers well known in the art using any effective conventional dosage unit forms, including immediate, slow and timed release preparations, orally, parenterally, topically, nasally, ophthalmically, optically, sublingually, rectally, vaginally, and the like.
For oral administration, the compounds can be formulated into solid or liquid preparations such as capsules, pills, tablets, troches, lozenges, melts, powders, solutions, suspensions, or emulsions, and may be prepared according to methods known to the art for the manufacture of pharmaceutical compositions. The solid unit dosage forms can be a capsule that can be of the ordinary hard- or soft-shelled gelatine type containing, for example, surfactants, lubricants, and inert fillers such as lactose, sucrose, calcium phosphate, and corn starch.
In another embodiment, the compounds of this invention may be tableted with conventional tablet bases such as lactose, sucrose and cornstarch in combination with binders such as acacia, corn starch or gelatine, disintegrating agents intended to assist the break-up and dissolution of the tablet following administration such as potato starch, alginic acid, corn starch, and guar gum, gum tragacanth, acacia, lubricants intended to improve the flow of tablet granulation and to prevent the adhesion of tablet material to the surfaces of the tablet dies and punches, for example talc, stearic acid, or magnesium, calcium or zinc stearate, dyes, colouring agents, and flavouring agents such as peppermint, oil of wintergreen, or cherry flavouring, intended to enhance the aesthetic qualities of the tablets and make them more acceptable to the patient. Suitable excipients for use in oral liquid dosage forms include dicalcium phosphate and diluents such as water and alcohols, for example, ethanol, benzyl alcohol, and polyethylene alcohols, either with or without the addition of a pharmaceutically acceptable surfactant, suspending agent or emulsifying agent. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance tablets, pills or capsules may be coated with shellac, sugar or both.
Dispersible powders and granules are suitable for the preparation of an aqueous suspension. They provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example those sweetening, flavouring and colouring agents described above, may also be present.
The pharmaceutical compositions of this invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil such as liquid paraffin or a mixture of vegetable oils. Suitable emulsifying agents may be (1) naturally occurring gums such as gum acacia and gum tragacanth, (2) naturally occurring phosphatides such as soy bean and lecithin, (3) esters or partial esters derived form fatty acids and hexitol anhydrides, for example, sorbitan monooleate, (4) condensation products of said partial esters with ethylene oxide, for example, polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavouring agents.
Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil such as, for example, arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent such as, for example, beeswax, hard paraffin, or cetyl alcohol. The suspensions may also contain one or more preservatives, for example, ethyl or n-propyl p-hydroxybenzoate; one or more colouring agents; one or more flavouring agents; and one or more sweetening agents such as sucrose or saccharin.
Syrups and elixirs may be formulated with sweetening agents such as, for example, glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, and preservative, such as methyl and propyl parabens and flavouring and colouring agents.
The compounds of this invention may also be administered parenterally, that is, subcutaneously, intravenously, intraocularly, intrasynovially, intramuscularly, or interperitoneally, as injectable dosages of the compound in preferably a physiologically acceptable diluent with a pharmaceutical carrier which can be a sterile liquid or mixture of liquids such as water, saline, aqueous dextrose and related sugar solutions, an alcohol such as ethanol, isopropanol, or hexadecyl alcohol, glycols such as propylene glycol or polyethylene glycol, glycerol ketals such as 2,2-dimethyl-1,1-dioxolane-4-methanol, ethers such as poly(ethylene glycol) 400, an oil, a fatty acid, a fatty acid ester or, a fatty acid glyceride, or an acetylated fatty acid glyceride, with or without the addition of a pharmaceutically acceptable surfactant such as a soap or a detergent, suspending agent such as pectin, carbomers, methylcellulose, hydroxypropylmethylcellulose, or carboxymethylcellulose, or emulsifying agent and other pharmaceutical adjuvants.
Illustrative of oils which can be used in the parenteral formulations of this invention are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, sesame oil, cottonseed oil, corn oil, olive oil, petrolatum and mineral oil. Suitable fatty acids include oleic acid, stearic acid, isostearic acid and myristic acid. Suitable fatty acid esters are, for example, ethyl oleate and isopropyl myristate. Suitable soaps include fatty acid alkali metal, ammonium, and triethanolamine salts and suitable detergents include cationic detergents, for example dimethyl dialkyl ammonium halides, alkyl pyridinium halides, and alkylamine acetates; anionic detergents, for example, alkyl, aryl, and olefin sulfonates, alkyl, olefin, ether, and monoglyceride sulfates, and sulfosuccinates; non-ionic detergents, for example, fatty amine oxides, fatty acid alkanolamides, and poly(oxyethylene-oxypropylene)s or ethylene oxide or propylene oxide copolymers; and amphoteric detergents, for example, alkyl-beta-aminopropionates, and 2-alkylimidazoline quarternary ammonium salts, as well as mixtures.
The parenteral compositions of this invention will typically contain from about 0.5% to about 25% by weight of the active ingredient in solution. Preservatives and buffers may also be used advantageously. In order to minimise or eliminate irritation at the site of injection, such compositions may contain a non-ionic surfactant having a hydrophile-lipophile balance (HLB) preferably of from about 12 to about 17. The quantity of surfactant in such formulation preferably ranges from about 5% to about 15% by weight. The surfactant can be a single component having the above HLB or can be a mixture of two or more components having the desired HLB.
Illustrative of surfactants used in parenteral formulations are the class of polyethylene sorbitan fatty acid esters, for example, sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol.
The pharmaceutical compositions may be in the form of sterile injectable aqueous suspensions. Such suspensions may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents such as, for example, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl-cellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents which may be a naturally occurring phosphatide such as lecithin, a condensation product of an alkylene oxide with a fatty acid, for example, polyoxyethylene stearate, a condensation product of ethylene oxide with a long chain aliphatic alcohol, for example, heptadeca-ethyleneoxycetanol, a condensation product of ethylene oxide with a partial ester derived form a fatty acid and a hexitol such as polyoxyethylene sorbitol monooleate, or a condensation product of an ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride, for example polyoxyethylene sorbitan monooleate.
The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent. Diluents and solvents that may be employed are, for example, water, Ringer's solution, isotonic sodium chloride solutions and isotonic glucose solutions. In addition, sterile fixed oils are conventionally employed as solvents or suspending media. For this purpose, any bland, fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid can be used in the preparation of injectables.
A composition of the invention may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritation excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are, for example, cocoa butter and polyethylene glycol.
Another formulation employed in the methods of the present invention employs transdermal delivery devices (“patches”). Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds of the present invention in controlled amounts. The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art (see, e.g., U.S. Pat. No. 5,023,252, issued Jun. 11, 1991, incorporated herein by reference). Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.
Controlled release formulations for parenteral administration include liposomal, polymeric microsphere and polymeric gel formulations that are known in the art.
It may be desirable or necessary to introduce the pharmaceutical composition to the patient via a mechanical delivery device. The construction and use of mechanical delivery devices for the delivery of pharmaceutical agents is well known in the art. Direct techniques for, for example, administering a drug directly to the brain usually involve placement of a drug delivery catheter into the patient's ventricular system to bypass the blood-brain barrier. One such implantable delivery system, used for the transport of agents to specific anatomical regions of the body, is described in U.S. Pat. No. 5,011,472, issued Apr. 30, 1991.
The compositions of the invention can also contain other conventional pharmaceutically acceptable compounding ingredients, generally referred to as carriers or diluents, as necessary or desired. Conventional procedures for preparing such compositions in appropriate dosage forms can be utilized. Such ingredients and procedures include those described in the following references, each of which is incorporated herein by reference: Powell, M. F. et al., “Compendium of Excipients for Parenteral Formulations” PDA Journal of Pharmaceutical Science & Technology 1998, 52(5), 238-311; Strickley, R. G “Parenteral Formulations of Small Molecule Therapeutics Marketed in the United States (1999)-Part-1” PDA Journal of Pharmaceutical Science & Technology 1999, 53(6), 324-349; and Nema, S. et al., “Excipients and Their Use in Injectable Products” PDA Journal of Pharmaceutical Science & Technology 1997, 51(4), 166-171.
Commonly used pharmaceutical ingredients that can be used as appropriate to formulate the composition for its intended route of administration include:
acidifying agents (examples include but are not limited to acetic acid, citric acid, fumaric acid, hydrochloric acid, nitric acid);
alkalinizing agents (examples include but are not limited to ammonia solution, ammonium carbonate, diethanolamine, monoethanolamine, potassium hydroxide, sodium borate, sodium carbonate, sodium hydroxide, triethanolamine, trolamine);
adsorbents (examples include but are not limited to powdered cellulose and activated charcoal);
aerosol propellants (examples include but are not limited to carbon dioxide, CCl2F2, F2ClC—CClF2 and CClF3)
air displacement agents (examples include but are not limited to nitrogen and argon);
antifungal preservatives (examples include but are not limited to benzoic acid, butylparaben, ethylparaben, methylparaben, propylparaben, sodium benzoate);
antimicrobial preservatives (examples include but are not limited to benzalkonium chloride, benzethonium chloride, benzyl alcohol, cetylpyridinium chloride, chlorobutanol, phenol, phenylethyl alcohol, phenylmercuric nitrate and thimerosal);
antioxidants (examples include but are not limited to ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, hypophosphorus acid, monothioglycerol, propyl gallate, sodium ascorbate, sodium bisulfite, sodium formaldehyde sulfoxylate, sodium metabisulfite);
binding materials (examples include but are not limited to block polymers, natural and synthetic rubber, polyacrylates, polyurethanes, silicones, polysiloxanes and styrene-butadiene copolymers);
buffering agents (examples include but are not limited to potassium metaphosphate, dipotassium phosphate, sodium acetate, sodium citrate anhydrous and sodium citrate dihydrate)
carrying agents (examples include but are not limited to acacia syrup, aromatic syrup, aromatic elixir, cherry syrup, cocoa syrup, orange syrup, syrup, corn oil, mineral oil, peanut oil, sesame oil, bacteriostatic sodium chloride injection and bacteriostatic water for injection)
chelating agents (examples include but are not limited to edetate disodium and edetic acid)
colourants (examples include but are not limited to FD&C Red No. 3, FD&C Red No. 20, FD&C Yellow No. 6, FD&C Blue No. 2, D&C Green No. 5, D&C Orange No. 5, D&C Red No. 8, caramel and ferric oxide red);
clarifying agents (examples include but are not limited to bentonite);
emulsifying agents (examples include but are not limited to acacia, cetomacrogol, cetyl alcohol, glyceryl monostearate, lecithin, sorbitan monooleate, polyoxyethylene 50 monostearate);
encapsulating agents (examples include but are not limited to gelatin and cellulose acetate phthalate)
flavourants (examples include but are not limited to anise oil, cinnamon oil, cocoa, menthol, orange oil, peppermint oil and vanillin);
humectants (examples include but are not limited to glycerol, propylene glycol and sorbitol);
levigating agents (examples include but are not limited to mineral oil and glycerin);
oils (examples include but are not limited to arachis oil, mineral oil, olive oil, peanut oil, sesame oil and vegetable oil);
ointment bases (examples include but are not limited to lanolin, hydrophilic ointment, polyethylene glycol ointment, petrolatum, hydrophilic petrolatum, white ointment, yellow ointment, and rose water ointment);
penetration enhancers (transdermal delivery) (examples include but are not limited to monohydroxy or polyhydroxy alcohols, mono- or polyvalent alcohols, saturated or unsaturated fatty alcohols, saturated or unsaturated fatty esters, saturated or unsaturated dicarboxylic acids, essential oils, phosphatidyl derivatives, cephalin, terpenes, amides, ethers, ketones and ureas)
plasticizers (examples include but are not limited to diethyl phthalate and glycerol);
solvents (examples include but are not limited to ethanol, corn oil, cottonseed oil, glycerol, isopropanol, mineral oil, oleic acid, peanut oil, purified water, water for injection, sterile water for injection and sterile water for irrigation);
stiffening agents (examples include but are not limited to cetyl alcohol, cetyl esters wax, microcrystalline wax, paraffin, stearyl alcohol, white wax and yellow wax);
suppository bases (examples include but are not limited to cocoa butter and polyethylene glycols (mixtures));
surfactants (examples include but are not limited to benzalkonium chloride, nonoxynol 10, oxtoxynol 9, polysorbate 80, sodium lauryl sulfate and sorbitan mono-palmitate);
suspending agents (examples include but are not limited to agar, bentonite, carbomers, carboxymethylcellulose sodium, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, kaolin, methylcellulose, tragacanth and veegum);
sweetening agents (examples include but are not limited to aspartame, dextrose, glycerol, mannitol, propylene glycol, saccharin sodium, sorbitol and sucrose);
tablet anti-adherents (examples include but are not limited to magnesium stearate and talc);
tablet binders (examples include but are not limited to acacia, alginic acid, carboxymethylcellulose sodium, compressible sugar, ethylcellulose, gelatin, liquid glucose, methylcellulose, non-crosslinked polyvinyl pyrrolidone, and pregelatinized starch);
tablet and capsule diluents (examples include but are not limited to dibasic calcium phosphate, kaolin, lactose, mannitol, microcrystalline cellulose, powdered cellulose, precipitated calcium carbonate, sodium carbonate, sodium phosphate, sorbitol and starch);
tablet coating agents (examples include but are not limited to liquid glucose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, ethylcellulose, cellulose acetate phthalate and shellac);
tablet direct compression excipients (examples include but are not limited to dibasic calcium phosphate);
tablet disintegrants (examples include but are not limited to alginic acid, carboxymethylcellulose calcium, microcrystalline cellulose, polacrillin potassium, cross-linked polyvinylpyrrolidone, sodium alginate, sodium starch glycollate and starch);
tablet glidants (examples include but are not limited to colloidal silica, corn starch and talc);
tablet lubricants (examples include but are not limited to calcium stearate, magnesium stearate, mineral oil, stearic acid and zinc stearate);
tablet/capsule opaquants (examples include but are not limited to titanium dioxide);
tablet polishing agents (examples include but are not limited to carnuba wax and white wax);
thickening agents (examples include but are not limited to beeswax, cetyl alcohol and paraffin);
tonicity agents (examples include but are not limited to dextrose and sodium chloride);
viscosity increasing agents (examples include but are not limited to alginic acid, bentonite, carbomers, carboxymethylcellulose sodium, methylcellulose, polyvinyl pyrrolidone, sodium alginate and tragacanth); and
wetting agents (examples include but are not limited to heptadecaethylene oxycetanol, lecithins, sorbitol monooleate, polyoxyethylene sorbitol monooleate, and polyoxyethylene stearate).
Pharmaceutical compositions according to the present invention can be illustrated as follows:
Sterile IV Solution: A 5 mg/mL solution of the desired compound of this invention can be made using sterile, injectable water, and the pH is adjusted if necessary. The solution is diluted for administration to 1-2 mg/mL with sterile 5% dextrose and is administered as an IV infusion over about 60 minutes.
Lyophilised powder for IV administration: A sterile preparation can be prepared with (i) 100-1000 mg of the desired compound of this invention as a lyophilised powder, (ii) 32-327 mg/mL sodium citrate, and (iii) 300-3000 mg Dextran 40. The formulation is reconstituted with sterile, injectable saline or dextrose 5% to a concentration of 10 to 20 mg/mL, which is further diluted with saline or dextrose 5% to 0.2-0.4 mg/mL, and is administered either IV bolus or by IV infusion over 15-60 minutes.
Intramuscular suspension: The following solution or suspension can be prepared, for intramuscular injection:
50 mg/mL of the desired, water-insoluble compound of this invention
5 mg/mL sodium carboxymethylcellulose
4 mg/mL TWEEN 80
9 mg/mL sodium chloride
9 mg/mL benzyl alcohol
Hard Shell Capsules: A large number of unit capsules are prepared by filling standard two-piece hard galantine capsules each with 100 mg of powdered active ingredient, 150 mg of lactose, 50 mg of cellulose and 6 mg of magnesium stearate.
Soft Gelatin Capsules: A mixture of active ingredient in a digestible oil such as soybean oil, cottonseed oil or olive oil is prepared and injected by means of a positive displacement pump into molten gelatin to form soft gelatin capsules containing 100 mg of the active ingredient. The capsules are washed and dried. The active ingredient can be dissolved in a mixture of polyethylene glycol, glycerin and sorbitol to prepare a water miscible medicine mix.
Tablets: A large number of tablets are prepared by conventional procedures so that the dosage unit is 100 mg of active ingredient, 0.2 mg. of colloidal silicon dioxide, 5 mg of magnesium stearate, 275 mg of microcrystalline cellulose, 11 mg. of starch, and 98.8 mg of lactose. Appropriate aqueous and non-aqueous coatings may be applied to increase palatability, improve elegance and stability or delay absorption.
Immediate Release Tablets/Capsules: These are solid oral dosage forms made by conventional and novel processes. These units are taken orally without water for immediate dissolution and delivery of the medication. The active ingredient is mixed in a liquid containing ingredient such as sugar, gelatin, pectin and sweeteners. These liquids are solidified into solid tablets or caplets by freeze drying and solid state extraction techniques.
The drug compounds may be compressed with viscoelastic and thermoelastic sugars and polymers or effervescent components to produce porous matrices intended for immediate release, without the need of water.
The term “combination” in the present invention is used as known to persons skilled in the art and may be present as a fixed combination, a non-fixed combination or kit-of-parts.
A “fixed combination” in the present invention is used as known to persons skilled in the art and is defined as a combination wherein the said first active ingredient and the said second active ingredient are present together in one unit dosage or in a single entity. One example of a “fixed combination” is a pharmaceutical composition wherein the said first active ingredient and the said second active ingredient are present in admixture for simultaneous administration, such as in a formulation. Another example of a “fixed combination” is a pharmaceutical combination wherein the said first active ingredient and the said second active ingredient are present in one unit without being in admixture.
A non-fixed combination or “kit-of-parts” in the present invention is used as known to persons skilled in the art and is defined as a combination wherein the said first active ingredient and the said second active ingredient are present in more than one unit. One example of a non-fixed combination or kit-of-parts is a combination wherein the said first active ingredient and the said second active ingredient are present separately. The components of the non-fixed combination or kit-of-parts may be administered separately, sequentially, simultaneously, concurrently or chronologically staggered.
The compounds of this invention can be administered as the sole pharmaceutical agent or in combination with one or more other pharmaceutical agents where the combination causes no unacceptable adverse effects. The present invention relates also to such combinations. For example, the compounds of this invention can be combined with known chemotherapeutic agents or anti-cancer agents, e.g. anti-hyper-proliferative or other indication agents, and the like, as well as with admixtures and combinations thereof. Other indication agents include, but are not limited to, anti-angiogenic agents, mitotic inhibitors, alkylating agents, anti-metabolites, DNA-intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzyme inhibitors, topoisomerase inhibitors, proteasome inhibitors, biological response modifiers, or anti-hormones.
The terms “chemotherapeutic agent” and anti-cancer agent”, include but are not limited to 131I-chTNT, abarelix, abiraterone, aclarubicin, aldesleukin, alemtuzumab, alitretinoin, altretamine, aminoglutethimide, amrubicin, amsacrine, anastrozole, arglabin, arsenic trioxide, asparaginase, azacitidine, basiliximab, BAY 80-6946, BAY 1000394, BAY 86-9766 (RDEA 119), belotecan, bendamustine, bevacizumab, bexarotene, bicalutamide, bisantrene, bleomycin, bortezomib, buserelin, busulfan, cabazitaxel, calcium folinate, calcium levofolinate, capecitabine, carboplatin, carmofur, carmustine, catumaxomab, celecoxib, celmoleukin, cetuximab, chlorambucil, chlormadinone, chlormethine, cisplatin, cladribine, clodronic acid, clofarabine, crisantaspase, cyclophosphamide, cyproterone, cytarabine, dacarbazine, dactinomycin, darbepoetin alfa, dasatinib, daunorubicin, decitabine, deforolimus, degarelix, denileukin diftitox, denosumab, deslorelin, dibrospidium chloride, docetaxel, doxifluridine, doxorubicin, doxorubicin+estrone, eculizumab, edrecolomab, elliptinium acetate, eltrombopag, endostatin, enocitabine, enzastaurin, epirubicin, epitiostanol, epoetin alfa, epoetin beta, eptaplatin, eribulin, erlotinib, estradiol, estramustine, etoposide, everolimus, exemestane, fadrozole, filgrastim, fludarabine, fluorouracil, flutamide, formestane, fotemustine, fulvestrant, gallium nitrate, ganirelix, gefitinib, gemcitabine, gemtuzumab, glutoxim, goserelin, histamine dihydrochloride, histrelin, hydroxycarbamide, I-125 seeds, ibandronic acid, ibritumomab tiuxetan, idarubicin, ifosfamide, imatinib, imiquimod, improsulfan, interferon alfa, interferon beta, interferon gamma, ipilimumab, irinotecan, ixabepilone, lanreotide, lapatinib, larotaxel, lenalidomide, lenograstim, lentinan, letrozole, leuprorelin, levamisole, lisuride, lobaplatin, lomustine, lonidamine, masoprocol, medroxyprogesterone, megestrol, melphalan, mepitiostane, mercaptopurine, methotrexate, methoxsalen, Methyl aminolevulinate, methyltestosterone, mifamurtide, miltefosine, miriplatin, mitobronitol, mitoguazone, mitolactol, mitomycin, mitotane, mitoxantrone, nedaplatin, nelarabine, nilotinib, nilutamide, nimotuzumab, nimustine, nitracrine, novolimus, ofatumumab, omeprazole, oprelvekin, oxaliplatin, p53 gene therapy, paclitaxel, palifermin, palladium-103 seed, pamidronic acid, panitumumab, pazopanib, pegaspargase, PEG-epoetin beta (methoxy PEG-epoetin beta), pegfilgrastim, peginterferon alfa-2b, pemetrexed, pentazocine, pentostatin, peplomycin, perfosfamide, perifosine, picibanil, pirarubicin, plerixafor, plicamycin, poliglusam, polyestradiol phosphate, polysaccharide-K, porfimer sodium, pralatrexate, prednimustine, procarbazine, quinagolide, raloxifene, raltitrexed, ranimustine, rapamycin, razoxane, regorafenib, risedronic acid, rituximab, romidepsin, romiplostim, sagopilone, sargramostim, selumetinib, sipuleucel-T, sizofiran, sobuzoxane, sodium glycididazole, sorafenib, streptozocin, sunitinib, talaporfin, tamibarotene, tamoxifen, tasonermin, teceleukin, tegafur, tegafur+gimeracil+oteracil, temoporfin, temozolomide, temsirolimus, teniposide, testosterone, tetrofosmin, thalidomide, thiotepa, thymalfasin, tioguanine, tocilizumab, topotecan, toremifene, tositumomab, trabectedin, trametinib, trastuzumab, treosulfan, tretinoin, triciribine, trilostane, triptorelin, trofosfamide, tryptophan, ubenimex, valrubicin, vandetanib, vapreotide, vemurafenib, vinblastine, vincristine, vindesine, vinflunine, vinorelbine, vorinostat, vorozole, yttrium-90 glass microspheres, zinostatin, zinostatin stimalamer, zoledronic acid, zorubicin, zotarolimus, ARRY-162, ARRY-300, ARRY-704, AS-703026, AZD-5363, AZD-8055, BEZ-235, BGT-226, BKM-120, BYL-719, CAL-101, CC-223, CH-5132799, E-6201, GDC-0032, GDC-0068, GDC-0623, GDC-0941, GDC-0973, GDC-0980, GSK-2110183, GSK-2126458, GSK-2141795, INK128, MK-2206, OSI-027, PF-04691502, PF-05212384, PX-866, RG-7167, RO-4987655, RO-5126766, TAK-733, UCN-01, WX-554, XL-147, XL-765, ZSTK-474.
The terms “chemotherapeutic agent” and anti-cancer agent”, also include protein therapeutics such as an interferon (e.g., interferon.alpha., .beta., or .gamma.) supraagonistic monoclonal antibodies, Tuebingen, TRP-1 protein vaccine, Colostrinin, anti-FAP antibody, YH-16, gemtuzumab, infliximab, cetuximab, trastuzumab, denileukin diftitox, rituximab, thymosin alpha 1, bevacizumab, mecasermin, mecasermin rinfabate, oprelvekin, natalizumab, rhMBL, MFE-CP1+ZD-2767-P, ABT-828, ErbB2-specific immunotoxin, SGN-35, MT-103, rinfabate, AS-1402, B43-genistein, L-19 based radioimmunotherapeutics, AC-9301, NY-ESO-1 vaccine, IMC-1C11, CT-322, rhCC10, r(m)CRP, MORAb-009, aviscumine, MDX-1307, Her-2 vaccine, APC-8024, NGR-hTNF, rhH1.3, IGN-311, Endostatin, volociximab, PRO-1762, lexatumumab, SGN-40, pertuzumab, EMD-273063, L19-IL-2 fusion protein, PRX-321, CNTO-328, MDX-214, tigapotide, CAT-3888, labetuzumab, alpha-particle-emitting radioisotope-llinked lintuzumab, EM-1421, HyperAcute vaccine, tucotuzumab celmoleukin, galiximab, HPV-16-E7, Javelin—prostate cancer, Javelin-melanoma, NY-ESO-1 vaccine, EGF vaccine, CYT-004-MelQbG10, WT1 peptide, oregovomab, ofatumumab, zalutumumab, cintredekin besudotox, WX-G250, Albuferon, aflibercept, denosumab, vaccine, CTP-37, efungumab, or 131I-chTNT-1/B.
The terms “chemotherapeutic agent” and anti-cancer agent”, also include monoclonal antibodies useful as the protein therapeutic such as muromonab-CD3, abciximab, edrecolomab, daclizumab, gentuzumab, alemtuzumab, ibritumomab, cetuximab, bevicizumab, efalizumab, adalimumab, omalizumab, muromomab-CD3, rituximab, daclizumab, trastuzumab, palivizumab, basiliximab, and infliximab.
Generally, the use of cytotoxic and/or cytostatic agents in combination with a compound or composition of the present invention will serve to:
In a distinct embodiment of the present invention, a compound of the present invention may be used to sensitize a cell to radiation. That is, treatment of a cell with a compound of the present invention prior to radiation treatment of the cell renders the cell more susceptible to DNA damage and cell death than the cell would be in the absence of any treatment with a compound of the invention. In one aspect, the cell is treated with at least one compound of the invention.
Thus, the present invention also provides a method of killing a cell, wherein a cell is administered one or more compounds of the invention in combination with conventional radiation therapy.
The present invention also provides a method of rendering a cell more susceptible to cell death, wherein the cell is treated with one or more compounds of the invention prior to the treatment of the cell to cause or induce cell death. In one aspect, after the cell is treated with one or more compounds of the invention, the cell is treated with at least one compound, or at least one method, or a combination thereof, in order to cause DNA damage for the purpose of inhibiting the function of the normal cell or killing the cell.
In one embodiment, a cell is killed by treating the cell with at least one DNA damaging agent. That is, after treating a cell with one or more compounds of the invention to sensitize the cell to cell death, the cell is treated with at least one DNA damaging agent to kill the cell. DNA damaging agents useful in the present invention include, but are not limited to, chemotherapeutic agents (e.g., cisplatinum), ionizing radiation (X-rays, ultraviolet radiation), carcinogenic agents, and mutagenic agents.
In another embodiment, a cell is killed by treating the cell with at least one method to cause or induce DNA damage. Such methods include, but are not limited to, activation of a cell signalling pathway that results in DNA damage when the pathway is activated, inhibiting of a cell signalling pathway that results in DNA damage when the pathway is inhibited, and inducing a biochemical change in a cell, wherein the change results in DNA damage. By way of a non-limiting example, a DNA repair pathway in a cell can be inhibited, thereby preventing the repair of DNA damage and resulting in an abnormal accumulation of DNA damage in a cell.
In one aspect of the invention, a compound of the invention is administered to a cell prior to the radiation or other induction of DNA damage in the cell. In another aspect of the invention, a compound of the invention is administered to a cell concomitantly with the radiation or other induction of DNA damage in the cell. In yet another aspect of the invention, a compound of the invention is administered to a cell immediately after radiation or other induction of DNA damage in the cell has begun.
In another aspect, the cell is in vitro. In another embodiment, the cell is in vivo.
As mentioned supra, the compounds of the present invention have surprisingly been found to effectively inhibit MKNK1 and may therefore be used for the treatment or prophylaxis of diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, or inappropriate cellular inflammatory responses, or diseases which are accompanied with uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, or inappropriate cellular inflammatory responses, particularly in which the uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, or inappropriate cellular inflammatory responses is mediated by MKNK1, such as, for example, haematological tumours, solid tumours, and/or metastases thereof, e.g. leukaemias and myelodysplastic syndrome, malignant lymphomas, head and neck tumours including brain tumours and brain metastases, tumours of the thorax including non-small cell and small cell lung tumours, gastrointestinal tumours, endocrine tumours, mammary and other gynaecological tumours, urological tumours including renal, bladder and prostate tumours, skin tumours, and sarcomas, and/or metastases thereof, or pancreatitis.
In accordance with another aspect therefore, the present invention covers a compound of general formula (I), or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, as described and defined herein, for use in the treatment or prophylaxis of a disease, as mentioned supra.
Another particular aspect of the present invention is therefore the use of a compound of general formula (I), described supra, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, for the prophylaxis or treatment of a disease.
Another particular aspect of the present invention is therefore the use of a compound of general formula (I) described supra for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease.
The diseases referred to in the two preceding paragraphs are diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, or inappropriate cellular inflammatory responses, or diseases which are accompanied with uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, or inappropriate cellular inflammatory responses, particularly in which the uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, or inappropriate cellular inflammatory responses is mediated by MKNK1, such as, for example, haematological tumours, solid tumours, and/or metastases thereof, e.g. leukaemias and myelodysplastic syndrome, malignant lymphomas, head and neck tumours including brain tumours and brain metastases, tumours of the thorax including non-small cell and small cell lung tumours, gastrointestinal tumours, endocrine tumours, mammary and other gynaecological tumours, urological tumours including renal, bladder and prostate tumours, skin tumours, and sarcomas, and/or metastases thereof.
The term “inappropriate” within the context of the present invention, in particular in the context of “inappropriate cellular immune responses, or inappropriate cellular inflammatory responses”, as used herein, is to be understood as preferably meaning a response which is less than, or greater than normal, and which is associated with, responsible for, or results in, the pathology of said diseases.
Preferably, the use is in the treatment or prophylaxis of diseases, wherein the diseases are haemotological tumours, solid tumours and/or metastases thereof.
The present invention relates to a method for using the compounds of the present invention and compositions thereof, to treat mammalian hyper-proliferative disorders. Compounds can be utilized to inhibit, block, reduce, decrease, etc., cell proliferation and/or cell division, and/or produce apoptosis. This method comprises administering to a mammal in need thereof, including a human, an amount of a compound of this invention, or a pharmaceutically acceptable salt, isomer, polymorph, metabolite, hydrate, solvate or ester thereof; etc. which is effective to treat the disorder. Hyper-proliferative disorders include but are not limited, e.g., psoriasis, keloids, and other hyperplasias affecting the skin, benign prostate hyperplasia (BPH), solid tumours, such as cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid, parathyroid and their distant metastases. Those disorders also include lymphomas, sarcomas, and leukaemias.
Examples of breast cancer include, but are not limited to invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma in situ, and lobular carcinoma in situ.
Examples of cancers of the respiratory tract include, but are not limited to small-cell and non-small-cell lung carcinoma, as well as bronchial adenoma and pleuropulmonary blastoma.
Examples of brain cancers include, but are not limited to brain stem and hypophtalmic glioma, cerebellar and cerebral astrocytoma, medulloblastoma, ependymoma, as well as neuroectodermal and pineal tumour.
Tumours of the male reproductive organs include, but are not limited to prostate and testicular cancer. Tumours of the female reproductive organs include, but are not limited to endometrial, cervical, ovarian, vaginal, and vulvar cancer, as well as sarcoma of the uterus.
Tumours of the digestive tract include, but are not limited to anal, colon, colorectal, oesophageal, gallbladder, gastric, pancreatic, rectal, small-intestine, and salivary gland cancers.
Tumours of the urinary tract include, but are not limited to bladder, penile, kidney, renal pelvis, ureter, urethral and human papillary renal cancers.
Eye cancers include, but are not limited to intraocular melanoma and retinoblastoma.
Examples of liver cancers include, but are not limited to hepatocellular carcinoma (liver cell carcinomas with or without fibrolamellar variant), cholangiocarcinoma (intrahepatic bile duct carcinoma), and mixed hepatocellular cholangiocarcinoma.
Skin cancers include, but are not limited to squamous cell carcinoma, Kaposi's sarcoma, malignant melanoma, Merkel cell skin cancer, and non-melanoma skin cancer.
Head-and-neck cancers include, but are not limited to laryngeal, hypopharyngeal, nasopharyngeal, oropharyngeal cancer, lip and oral cavity cancer and squamous cell.
Lymphomas include, but are not limited to AIDS-related lymphoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, Burkitt lymphoma, Hodgkin's disease, and lymphoma of the central nervous system.
Sarcomas include, but are not limited to sarcoma of the soft tissue, osteosarcoma, malignant fibrous histiocytoma, lymphosarcoma, and rhabdomyosarcoma.
Leukemias include, but are not limited to acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and hairy cell leukemia.
These disorders have been well characterized in humans, but also exist with a similar etiology in other mammals, and can be treated by administering pharmaceutical compositions of the present invention.
The term “treating” or “treatment” as stated throughout this document is used conventionally, e.g., the management or care of a subject for the purpose of combating, alleviating, reducing, relieving, improving the condition of, etc., of a disease or disorder, such as a carcinoma.
The present invention also provides methods for the treatment of disorders associated with aberrant mitogen extracellular kinase activity, including, but not limited to stroke, heart failure, hepatomegaly, cardiomegaly, diabetes, Alzheimer's disease, cystic fibrosis, symptoms of xenograft rejections, septic shock or asthma.
Effective amounts of compounds of the present invention can be used to treat such disorders, including those diseases (e.g., cancer) mentioned in the Background section above. Nonetheless, such cancers and other diseases can be treated with compounds of the present invention, regardless of the mechanism of action and/or the relationship between the kinase and the disorder.
The phrase “aberrant kinase activity” or “aberrant serin threonin kinase activity,” includes any abnormal expression or activity of the gene encoding the kinase or of the polypeptide it encodes. Examples of such aberrant activity, include, but are not limited to, over-expression of the gene or polypeptide; gene amplification; mutations which produce constitutively-active or hyperactive kinase activity; gene mutations, deletions, substitutions, additions, etc.
The present invention also provides for methods of inhibiting a kinase activity, especially of mitogen extracellular kinase, comprising administering an effective amount of a compound of the present invention, including salts, polymorphs, metabolites, hydrates, solvates, prodrugs (e.g.: esters) thereof, and diastereoisomeric forms thereof. Kinase activity can be inhibited in cells (e.g., in vitro), or in the cells of a mammalian subject, especially a human patient in need of treatment.
Based upon standard laboratory techniques known to evaluate compounds useful for the treatment of hyper-proliferative disorders and angiogenic disorders, by standard toxicity tests and by standard pharmacological assays for the determination of treatment of the conditions identified above in mammals, and by comparison of these results with the results of known medicaments that are used to treat these conditions, the effective dosage of the compounds of this invention can readily be determined for treatment of each desired indication. The amount of the active ingredient to be administered in the treatment of one of these conditions can vary widely according to such considerations as the particular compound and dosage unit employed, the mode of administration, the period of treatment, the age and sex of the patient treated, and the nature and extent of the condition treated.
The total amount of the active ingredient to be administered will generally range from about 0.001 mg/kg to about 200 mg/kg body weight per day, and preferably from about 0.01 mg/kg to about 20 mg/kg body weight per day. Clinically useful dosing schedules will range from one to three times a day dosing to once every four weeks dosing. In addition, “drug holidays” in which a patient is not dosed with a drug for a certain period of time, may be beneficial to the overall balance between pharmacological effect and tolerability. A unit dosage may contain from about 0.5 mg to about 1500 mg of active ingredient, and can be administered one or more times per day or less than once a day. The average daily dosage for administration by injection, including intravenous, intramuscular, subcutaneous and parenteral injections, and use of infusion techniques will preferably be from 0.01 to 200 mg/kg of total body weight. The average daily rectal dosage regimen will preferably be from 0.01 to 200 mg/kg of total body weight. The average daily vaginal dosage regimen will preferably be from 0.01 to 200 mg/kg of total body weight. The average daily topical dosage regimen will preferably be from 0.1 to 200 mg administered between one to four times daily. The transdermal concentration will preferably be that required to maintain a daily dose of from 0.01 to 200 mg/kg. The average daily inhalation dosage regimen will preferably be from 0.01 to 100 mg/kg of total body weight.
Of course the specific initial and continuing dosage regimen for each patient will vary according to the nature and severity of the condition as determined by the attending diagnostician, the activity of the specific compound employed, the age and general condition of the patient, time of administration, route of administration, rate of excretion of the drug, drug combinations, and the like. The desired mode of treatment and number of doses of a compound of the present invention or a pharmaceutically acceptable salt or ester or composition thereof can be ascertained by those skilled in the art using conventional treatment tests.
Preferably, the diseases of said method are haematological tumours, solid tumour and/or metastases thereof.
The compounds of the present invention can be used in particular in therapy and prevention, i.e. prophylaxis, of tumour growth and metastases, especially in solid tumours of all indications and stages with or without pre-treatment of the tumour growth.
Methods of testing for a particular pharmacological or pharmaceutical property are well known to persons skilled in the art.
The example testing experiments described herein serve to illustrate the present invention and the invention is not limited to the examples given.
Examples were tested in selected biological assays one or more times. When tested more than once, data are reported as either average values or as median values, wherein
Examples were synthesized one or more times. When synthesized more than once, data from biological assays represent average values or median values calculated utilizing data sets obtained from testing of one or more synthetic batch.
MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragraphs.
A recombinant fusion protein of Glutathione-S-Transferase (GST, N-terminally) and human full-length MKNK1 (amino acids 1-424 and T344D of accession number BAA 19885.1), expressed in insect cells using baculovirus expression system and purified via glutathione sepharose affinity chromatography, was purchased from Carna Biosciences (product no 02-145) and used as enzyme. As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-IKKRKLTRRKSLKG (C-terminus in amide form) was used which can be purchased e.g. form the company Biosyntan (Berlin-Buch, Germany).
For the assay 50 nL of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 μL of a solution of MKNK1 in aqueous assay buffer [50 mM HEPES pH 7.5, 5 mM MgCl2, 1.0 mM dithiothreitol, 0.005% (v/v) Nonidet-P40 (Sigma)] was added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 μL of a solution of adenosine-tri-phosphate (ATP, 16.7 μM=>final conc. in the μL assay volume is 10 μM) and substrate (0.1 μM=>final conc. in the 5 μL assay volume is 0.06 μM) in assay buffer and the resulting mixture was incubated for a reaction time of 45 min at 22° C. The concentration of MKNK1 was adjusted depending of the activity of the enzyme lot and was chosen appropriate to have the assay in the linear range, typical concentrations were in the range of 0.05 μg/ml. The reaction was stopped by the addition of 5 μL of a solution of TR-FRET detection reagents (5 nM streptavidine-XL665 [Cisbio Bioassays, Codolet, France] and 1 nM anti-ribosomal protein S6 (pSer236)-antibody from Invitrogen [#44921G] and 1 nM LANCE EU-W1024 labeled ProteinG [Perkin-Elmer, product no. AD0071]) in an aqueous EDTA-solution (100 mM EDTA, 0.1% (w/v) bovine serum albumin in 50 mM HEPES pH 7.5).
The resulting mixture was incubated for 1 h at 22° C. to allow the formation of complex between the phosphorylated biotinylated peptide and the detection reagents. Subsequently the amount of phosphorylated substrate was evaluated by measurement of the resonance energy transfer from the Eu-chelate to the streptavidine-XL. Therefore, the fluorescence emissions at 620 nm and 665 nm after excitation at 350 nm were measured in a TR-FRET reader, e.g. a Rubystar (BMG Labtechnologies, Offenburg, Germany) or a Viewlux (Perkin-Elmer). The ratio of the emissions at 665 nm and at 622 nm was taken as the measure for the amount of phosphorylated substrate. The data were normalised (enzyme reaction without inhibitor=0% inhibition, all other assay components but no enzyme=100% inhibition). Usually the test compounds were tested on the same microtiterplate in 11 different concentrations in the range of 20 μM to 0.1 nM (20 μM, 5.9 μM, 1.7 μM, 0.51 μM, 0.15 μM, 44 nM, 13 nM, 3.8 nM, 1.1 nM, 0.33 nM and 0.1 nM, the dilution series prepared separately before the assay on the level of the 100fold concentrated solutions in DMSO by serial 1:3.4 dilutions) in duplicate values for each concentration and IC50 values were calculated by a 4 parameter fit using an inhouse software.
MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET-based MKNK1 high ATP assay as described in the following paragraphs.
A recombinant fusion protein of Glutathione-S-Transferase (GST, N-terminally) and human full-length MKNK1 (amino acids 1-424 and T344D of accession number BAA 19885.1), expressed in insect cells using baculovirus expression system and purified via glutathione sepharose affinity chromatography, was purchased from Carna Biosciences (product no 02-145) and used as enzyme. As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-IKKRKLTRRKSLKG (C-terminus in amide form) was used, which can be purchased e.g. from the company Biosyntan (Berlin-Buch, Germany).
For the assay 50 nL of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 μL of a solution of MKNK1 in aqueous assay buffer [50 mM HEPES pH 7.5, 5 mM MgCl2, 1.0 mM dithiothreitol, 0.005% (v/v) Nonidet-P40 (Sigma)] was added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 μL of a solution of adenosine-tri-phosphate (ATP, 3.3 mM=>final conc. in the 5 μL assay volume is 2 mM) and substrate (0.1 μM=>final conc. in the 5 μL assay volume is 0.06 μM) in assay buffer and the resulting mixture was incubated for a reaction time of 30 min at 22° C. The concentration of MKNK1 was adjusted depending of the activity of the enzyme lot and was chosen appropriate to have the assay in the linear range, typical concentrations were in the range of 0.003 μg/mL. The reaction was stopped by the addition of 5 μL of a solution of TR-FRET detection reagents (5 nM streptavidine-XL665 [Cisbio Bioassays, Codolet, France] and 1 nM anti-ribosomal protein S6 (pSer236)-antibody from Invitrogen [#44921G] and 1 nM LANCE EU-W1024 labeled ProteinG [Perkin-Elmer, product no. AD0071]) in an aqueous EDTA-solution (100 mM EDTA, 0.1% (w/v) bovine serum albumin in 50 mM HEPES pH 7.5).
The resulting mixture was incubated for 1 h at 22° C. to allow the formation of complex between the phosphorylated biotinylated peptide and the detection reagents. Subsequently the amount of phosphorylated substrate was evaluated by measurement of the resonance energy transfer from the Eu-chelate to the streptavidine-XL. Therefore, the fluorescence emissions at 620 nm and 665 nm after excitation at 350 nm were measured in a TR-FRET reader, e.g. a Rubystar (BMG Labtechnologies, Offenburg, Germany) or a Viewlux (Perkin-Elmer). The ratio of the emissions at 665 nm and at 622 nm was taken as the measure for the amount of phosphorylated substrate. The data were normalised (enzyme reaction without inhibitor=0% inhibition, all other assay components but no enzyme=100% inhibition). Usually the test compounds were tested on the same microtiterplate in 11 different concentrations in the range of 20 μM to 0.1 nM (e.g. 20 μM, 5.9 μM, 1.7 μM, 0.51 μM, 0.15 μM, 44 nM, 13 nM, 3.8 nM, 1.1 nM, 0.33 nM and 0.1 nM, the dilution series prepared separately before the assay on the level of the 100fold concentrated solutions in DMSO by serial dilutions, the exact concentrations may vary depending on the pipettor used) in duplicate values for each concentration and IC50 values were calculated. Data are presented in Table 1.
MKNK 2-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK 2 was quantified employing the TR-FRET-based MKNK 2 high ATP assay as described in the following paragraphs.
A recombinant fusion protein of Glutathione-S-Transferase (GST, N-terminally) and human full-length MKNK 2 (Genbank accession number NP_060042.2), expressed in insect cells using baculovirus expression system, purified via glutathione sepharose affinity chromatography, and activated in vitro with MAPK12, was purchased from Invitrogen (product no PV5608) and used as enzyme. As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-IKKRKLTRRKSLKG (C-terminus in amide form) was used which can be purchased e.g. form the company Biosyntan (Berlin-Buch, Germany).
For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 μl of a solution of MKNK 2 in aqueous assay buffer [50 mM HEPES pH 7.5, 5 mM MgCl2, 1.0 mM dithiothreitol, 0.005% (v/v) Nonidet-P40 (G-Biosciences, St. Louis, USA)] was added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 μl of a solution of adenosine-tri-phosphate (ATP, 3.3 mM=>final conc. in the 5 μl assay volume is 2 mM) and substrate (0.1 μM=>final conc. in the 5 μl assay volume is 0.06 μM) in assay buffer and the resulting mixture was incubated for a reaction time of 30 min at 22° C. The concentration of MKNK 2 was adjusted depending of the activity of the enzyme lot and was chosen appropriate to have the assay in the linear range, typical concentrations were in the range of 0.0045 μg/ml. The reaction was stopped by the addition of 5 μl of a solution of TR-FRET detection reagents (5 nM streptavidine-XL665 [Cisbio Bioassays, Codolet, France] and 1 nM anti-ribosomal protein S6 (pSer236)-antibody from Invitrogen [#44921G] and 1 nM LANCE EU-W1024 labeled ProteinG [Perkin-Elmer, product no. AD0071]) in an aqueous EDTA-solution (100 mM EDTA, 0.1% (w/v) bovine serum albumin in 50 mM HEPES pH 7.5).
The resulting mixture was incubated for 1 h at 22° C. to allow the formation of complex between the phosphorylated biotinylated peptide and the detection reagents. Subsequently the amount of phosphorylated substrate was evaluated by measurement of the resonance energy transfer from the Eu-chelate to the streptavidine-XL665. Therefore, the fluorescence emissions at 620 nm and 665 nm after excitation at 350 nm were measured in a TR-FRET reader, e.g. a Pherastar (BMG Labtechnologies, Offenburg, Germany) or a Viewlux (Perkin-Elmer). The ratio of the emissions at 665 nm and at 622 nm was taken as the measure for the amount of phosphorylated substrate. The data were normalised (enzyme reaction without inhibitor=0% inhibition, all other assay components but no enzyme=100% inhibition). Usually the test compounds were tested on the same microtiterplate in 11 different concentrations in the range of 20 μM to 0.1 nM (e.g. 20 μM, 5.9 μM, 1.7 μM, 0.51 μM, 0.15 μM, 44 nM, 13 nM, 3.8 nM, 1.1 nM, 0.33 nM and 0.1 nM, the dilution series prepared separately before the assay on the level of the 100fold concentrated solutions in DMSO by serial dilutions, the exact concentrations may vary depending on the pipettor used) in duplicate values for each concentration and IC50 values were calculated.
EGFR inhibitory activity of compounds of the present invention was quantified employing the TR-FRET based EGFR assay as described in the following paragraphs.
Epidermal Growth Factor Receptor (EGFR) affinity purified from human carcinoma A431 cells (Sigma-Aldrich, # E3641) was used as kinase. As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-AEEEEYFELVAKKK (C-terminus in amid form) was used which can be purchased e.g. form the company Biosynthan GmbH (Berlin-Buch, Germany).
For the assay 50 nL of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 μL of a solution of EGFR in aqueous assay [50 mM Hepes/HCl pH 7.0, 1 mM MgCl2, 5 mM MnCl2, 0.5 mM activated sodium ortho-vanadate, 0.005% (v/v) Tween-20] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 μL of a solution of adenosine-tri-phosphate (ATP, 16.7 μM=>final conc. in the 5 μL assay volume is 10 μM) and substrate (1.67 μM=>final conc. in the 5 μL assay volume is 1 μM) in assay buffer and the resulting mixture was incubated for a reaction time of 30 min at 22° C. The concentration of EGFR was adjusted depending of the activity of the enzyme lot and was chosen appropriate to have the assay in the linear range, typical concentration were in the range of 3 U/ml. The reaction was stopped by the addition of 5 μl of a solution of HTRF detection reagents (0.1 μM streptavidine-XL665 [Cis Biointernational] and 1 nM PT66-Tb-Chelate, an terbium-chelate labelled anti-phospho-tyrosine antibody from Cis Biointernational [instead of the PT66-Tb-chelate PT66-Eu-Cryptate from Perkin Elmer can also be used]) in an aqueous EDTA-solution (80 mM EDTA, 0.2% (w/v) bovine serum albumin in 50 mM HEPES pH 7.5).
The resulting mixture was incubated 1 h at 22° C. to allow the binding of the biotinylated phosphorylated peptide to the streptavidine-XL665 and the PT66-Eu-Chelate. Subsequently the amount of phosphorylated substrate was evaluated by measurement of the resonance energy transfer from the PT66-Eu-Chelate to the streptavidine-XL665. Therefore, the fluorescence emissions at 620 nm and 665 nm after excitation at 337 nm were measured in a HTRF reader, e.g. a Pherastar (BMG Labtechnologies, Offenburg, Germany) or a Viewlux (Perkin-Elmer). The ratio of the emissions at 665 nm and at 622 nm was taken as the measure for the amount of phosphorylated substrate. The data were normalised (enzyme reaction without inhibitor=0% inhibition, all other assay components but no enzyme=100% inhibition). Usually the test compounds were tested on the same microtiterplate in 11 different concentrations in the range of 20 μM to 0.1 nM (e.g. 20 μM, 5.9 μM, 1.7 μM, 0.51 μM, 0.15 μM, 44 nM, 13 nM, 3.8 nM, 1.1 nM, 0.33 nM and 0.1 nM, the dilution series prepared separately before the assay on the level of the 100fold concentrated solutions in DMSO by serial dilutions, the exact concentrations may vary depending on the pipettor used) in duplicate values for each concentration and IC50 values were calculated.
CDK2/CycE inhibitory activity of compounds of the present invention can be quantified employing the CDK2/CycE TR-FRET assay as described in the following paragraphs.
Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, can be purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) can be used which can be purchased e.g. from the company JERINI peptide technologies (Berlin, Germany).
For the assay 50 nL of a 100fold concentrated solution of the test compound in DMSO is pipetted into a black low volume 384well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 μL of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] are added and the mixture is incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction is started by the addition of 3 μL of a solution of adenosine-tri-phosphate (ATP, 16.7 μM=>final conc. in the 5 μL assay volume is 10 μM) and substrate (1.25 μM=>final conc. in the 5 μL assay volume is 0.75 μM) in assay buffer and the resulting mixture is incubated for a reaction time of 25 min at 22° C. The concentration of CDK2/CycE is adjusted depending of the activity of the enzyme lot and is chosen appropriate to have the assay in the linear range, typical concentrations ae in the range of 130 ng/ml. The reaction is stopped by the addition of 5 μL of a solution of TR-FRET detection reagents (0.2 μM streptavidine-XL665 [Cisbio Bioassays, Codolet, France] and 1 nM anti-RB(pSer807/pSer811)-antibody from BD Pharmingen [#558389] and 1.2 nM LANCE EU-W1024 labeled anti-mouse IgG antibody [Perkin-Elmer, product no. AD0077, as an alternative a Terbium-cryptate-labeled anti-mouse IgG antibody from Cisbio Bioassays can be used]) in an aqueous EDTA-solution (100 mM EDTA, 0.2% (w/v) bovine serum albumin in 100 mM HEPES/NaOH pH 7.0).
The resulting mixture is incubated 1 h at 22° C. to allow the formation of complex between the phosphorylated biotinylated peptide and the detection reagents. Subsequently the amount of phosphorylated substrate is evaluated by measurement of the resonance energy transfer from the Eu-chelate to the streptavidine-XL. Therefore, the fluorescence emissions at 620 nm and 665 nm after excitation at 350 nm is measured in a TR-FRET reader, e.g. a Rubystar (BMG Labtechnologies, Offenburg, Germany) or a Viewlux (Perkin-Elmer). The ratio of the emissions at 665 nm and at 622 nm is taken as the measure for the amount of phosphorylated substrate. The data are normalised (enzyme reaction without inhibitor=0% inhibition, all other assay components but no enzyme=100% inhibition). Usually the test compounds are tested on the same microtiterplate in 11 different concentrations in the range of 20 μM to 0.1 nM (20 μM, 5.9 μM, 1.7 μM, 0.51 μM, 0.15 μM, 44 nM, 13 nM, 3.8 nM, 1.1 nM, 0.33 nM and 0.1 nM, the dilution series prepared separately before the assay on the level of the 100fold concentrated solutions in DMSO by serial 1:3.4 dilutions) in duplicate values for each concentration and IC50 values are calculated.
PDGFRβ inhibitory activity of compounds of the present invention can be quantified employing the PDGFRβ HTRF assay as described in the following paragraphs.
As kinase, a GST-His fusion protein containing a C-terminal fragment of human PDGFRβ (amino acids 561-1106, expressed in insect cells [SF9] and purified by affinity chromatography, purchased from Proqinase [Freiburg i.Brsg., Germany] is used. As substrate for the kinase reaction the biotinylated poly-Glu,Tyr (4:1) copolymer (#61GT0BLA) from Cis Biointernational (Marcoule, France) is used.
For the assay 50 nL of a 100fold concentrated solution of the test compound in DMSO is pipetted into a black low volume 384well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 μL of a solution of PDGFRβ in aqueous assay buffer [50 mM HEPES/NaOH pH 7.5, 10 mM MgCl2, 2.5 mM dithiothreitol, 0.01% (v/v) Triton-X100 (Sigma)] are added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction is started by the addition of 3 μL of a solution of adenosine-tri-phosphate (ATP, 16.7 μM=>final conc. in the 5 μL assay volume is 10 μM) and substrate (2.27 μg/ml=>final conc. in the 5 μL assay volume is 1.36 μg/ml [˜30 nM]) in assay buffer and the resulting mixture is incubated for a reaction time of 25 min at 22° C. The concentration of PDGFRβ in the assay is adjusted depending of the activity of the enzyme lot and is chosen appropriate to have the assay in the linear range, typical enzyme concentrations are in the range of about 125 μg/μL (final conc. in the 5 μL assay volume). The reaction is stopped by the addition of 5 μL of a solution of HTRF detection reagents (200 nM streptavidine-XLent [Cis Biointernational] and 1.4 nM PT66-Eu-Chelate, an europium-chelate labelled anti-phospho-tyrosine antibody from Perkin Elmer [instead of the PT66-Eu-chelate PT66-Tb-Cryptate from Cis Biointernational can also be used]) in an aqueous EDTA-solution (100 mM EDTA, 0.2% (w/v) bovine serum albumin in 50 mM HEPES/NaOH pH 7.5).
The resulting mixture is incubated 1 h at 22° C. to allow the binding of the biotinylated phosphorylated peptide to the streptavidine-XLent and the PT66-Eu-Chelate. Subsequently the amount of phosphorylated substrate is evaluated by measurement of the resonance energy transfer from the PT66-Eu-Chelate to the streptavidine-XLent. Therefore, the fluorescence emissions at 620 nm and 665 nm after excitation at 350 nm is measured in a HTRF reader, e.g. a Rubystar (BMG Labtechnologies, Offenburg, Germany) or a Viewlux (Perkin-Elmer). The ratio of the emissions at 665 nm and at 622 nm is taken as the measure for the amount of phosphorylated substrate. The data are normalised (enzyme reaction without inhibitor=0% inhibition, all other assay components but no enzyme=100% inhibition). Normally test compound are tested on the same microtiter plate at 10 different concentrations in the range of 20 μM to 1 nM (20 μM, 6.7 μM, 2.2 μM, 0.74 μM, 0.25 μM, 82 nM, 27 nM, 9.2 nM, 3.1 nM and 1 nM, dilution series prepared before the assay at the level of the 100fold conc. stock solutions by serial 1:3 dilutions) in duplicate values for each concentration and IC50 values are calculated.
C-terminally His6-tagged human recombinant kinase domain of the human T-Fyn expressed in baculovirus infected insect cells (purchased from Invitrogen, P3042) is used as kinase. As substrate for the kinase reaction the biotinylated peptide biotin-KVEKIGEGTYGW (C-terminus in amid form) is used which can be purchased e.g. form the company Biosynthan GmbH (Berlin-Buch, Germany).
For the assay 50 nL of a 100fold concentrated solution of the test compound in DMSO is pipetted into a black low volume 384well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 μL of a solution of T-Fyn in aqueous assay buffer [25 mM Tris/HCl pH 7.2, 25 mM MgCl2, 2 mM dithiothreitol, 0.1% (w/v) bovine serum albumin, 0.03% (v/v) Nonidet-P40 (Sigma)]. are added and the mixture is incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction is started by the addition of 3 μL of a solution of adenosine-tri-phosphate (ATP, 16.7 μM=>final conc. in the 5 μL assay volume is 10 μM) and substrate (2 μM=>final conc. in the 5 μL assay volume is 1.2 μM) in assay buffer and the resulting mixture is incubated for a reaction time of 60 min at 22° C. The concentration of Fyn is adjusted depending of the activity of the enzyme lot and is chosen appropriate to have the assay in the linear range, typical concentration was 0.13 nM. The reaction is stopped by the addition of 5 μL of a solution of HTRF detection reagents (0.2 μM streptavidine-XL [Cisbio Bioassays, Codolet, France) and 0.66 nM PT66-Eu-Chelate, an europium-chelate labelled anti-phospho-tyrosine antibody from Perkin Elmer [instead of the PT66-Eu-chelate PT66-Tb-Cryptate from Cisbio Bioassays can also be used]) in an aqueous EDTA-solution (125 mM EDTA, 0.2% (w/v) bovine serum albumin in 50 mM HEPES/NaOH pH 7.0).
The resulting mixture is incubated 1 h at 22° C. to allow the binding of the biotinylated phosphorylated peptide to the streptavidine-XL and the PT66-Eu-Chelate. Subsequently the amount of phosphorylated substrate is evaluated by measurement of the resonance energy transfer from the PT66-Eu-Chelate to the streptavidine-XL. Therefore, the fluorescence emissions at 620 nm and 665 nm after excitation at 350 nm is measured in a HTRF reader, e.g. a Rubystar (BMG Labtechnologies, Offenburg, Germany) or a Viewlux (Perkin-Elmer). The ratio of the emissions at 665 nm and at 622 nm is taken as the measure for the amount of phosphorylated substrate. The data are normalised (enzyme reaction without inhibitor=0% inhibition, all other assay components but no enzyme=100% inhibition). Normally test compounds are tested on the same microtiter plate at 10 different concentrations in the range of 20 μM to 1 nM (20 μM, 6.7 μM, 2.2 μM, 0.74 μM, 0.25 μM, 82 nM, 27 nM, 9.2 nM, 3.1 nM and 1 nM, dilution series prepared before the assay at the level of the 100fold conc. stock solutions by serial 1:3 dilutions) in duplicate values for each concentration and IC50 values are calculated.
Flt4 inhibitory activity of compounds of the present invention can be quantified employing the Flt4 TR-FRET assay as described in the following paragraphs.
As kinase, a GST-His fusion protein containing a C-terminal fragment of human Flt4 (amino acids 799-1298, expressed in insect cells [SF9] and purified by affinity chromatography, purchased from Proqinase [Freiburg i.Brsg., Germany] is used. As substrate for the kinase reaction the biotinylated peptide Biotin-Ahx-GGEEEEYFELVKKKK (C-terminus in amide form, purchased from Biosyntan, Berlin-Buch, Germany) is used.
For the assay 50 nL of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 μL of a solution of Flt4 in aqueous assay buffer [25 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM dithiothreitol, 0.01% (v/v) Triton-X100 (Sigma), 0.5 mM EGTA, and 5 mM β-phospho-glycerol] are added and the mixture is incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction is started by the addition of 3 μL of a solution of adenosine-tri-phosphate (ATP, 16.7 μM=>final conc. in the 5 μL assay volume is 10 μM) and substrate (1.67 μM=>final conc. in the 5 μL assay volume is 1 μM) in assay buffer and the resulting mixture is incubated for a reaction time of 45 min at 22° C. The concentration of Flt4 in the assay is adjusted depending of the activity of the enzyme lot and was chosen appropriate to have the assay in the linear range, typical enzyme concentrations are in the range of about 120 μg/μL (final conc. in the 5 μL assay volume). The reaction is stopped by the addition of 5 μL of a solution of HTRF detection reagents (200 nM streptavidine-XL665 [Cis Biointernational] and 1 nM PT66-Tb-Cryptate, an terbium-cryptate labelled anti-phospho-tyrosine antibody from Cisbio Bioassays (Codolet, France) in an aqueous EDTA-solution (50 mM EDTA, 0.2% (w/v) bovine serum albumin in 50 mM HEPES pH 7.5).
The resulting mixture is incubated 1 h at 22° C. to allow the binding of the biotinylated phosphorylated peptide to the streptavidine-XL665 and the PT66-Tb-Cryptate. Subsequently the amount of phosphorylated substrate is evaluated by measurement of the resonance energy transfer from the PT66-Tb-Cryptate to the streptavidine-XL665. Therefore, the fluorescence emissions at 620 nm and 665 nm after excitation at 350 nm is measured in a HTRF reader, e.g. a Rubystar (BMG Labtechnologies, Offenburg, Germany) or a Viewlux (Perkin-Elmer). The ratio of the emissions at 665 nm and at 622 nm is taken as the measure for the amount of phosphorylated substrate. The data are normalised (enzyme reaction without inhibitor=0% inhibition, all other assay components but no enzyme=100% inhibition). Normally test compound are tested on the same microtiter plate at 10 different concentrations in the range of 20 μM to 1 nM (20 μM, 6.7 μM, 2.2 μM, 0.74 μM, 0.25 μM, 82 nM, 27 nM, 9.2 nM, 3.1 nM and 1 nM, dilution series prepared before the assay at the level of the 100fold conc. stock solutions by serial 1:3 dilutions) in duplicate values for each concentration and IC50 values are calculated.
TrkA inhibitory activity of compounds of the present invention can be quantified employing the TrkA HTRF assay as described in the following paragraphs.
As kinase, a GST-His fusion protein containing a C-terminal fragment of human TrkA (amino acids 443-796, expressed in insect cells [SF9] and purified by affinity chromatography, purchased from Proqinase [Freiburg i.Brsg., Germany] is used. As substrate for the kinase reaction the biotinylated poly-Glu,Tyr (4:1) copolymer (#61GT0BLA) from Cis Biointernational (Marcoule, France) is used.
For the assay 50 nL of a 100fold concentrated solution of the test compound in DMSO is pipetted into a black low volume 384well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 μL of a solution of TrkA in aqueous assay buffer [8 mM MOPS/HCl pH 7.0, 10 mM MgCl2, 1 mM dithiothreitol, 0.01% (v/v) NP-40 (Sigma), 0.2 mM EDTA] are added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction is started by the addition of 3 μL of a solution of adenosine-tri-phosphate (ATP, 16.7 μM=>final conc. in the 5 μL assay volume is 10 μM) and substrate (2.27 μg/ml=>final conc. in the 5 μL assay volume is 1.36 μg/ml [˜30 nM]) in assay buffer and the resulting mixture is incubated for a reaction time of 60 min at 22° C. The concentration of TrkA in the assay is adjusted depending of the activity of the enzyme lot and is chosen appropriate to have the assay in the linear range, typical enzyme concentrations are in the range of about 20 pg/μL (final conc. in the 5 μL assay volume). The reaction is stopped by the addition of 5 μL of a solution of HTRF detection reagents (30 nM streptavidine-XL665 [Cis Biointernational] and 1.4 nM PT66-Eu-Chelate, an europium-chelate labelled anti-phospho-tyrosine antibody from Perkin Elmer [instead of the PT66-Eu-chelate PT66-Tb-Cryptate from Cis Biointernational can also be used]) in an aqueous EDTA-solution (100 mM EDTA, 0.2% (w/v) bovine serum albumin in 50 mM HEPES/NaOH pH 7.5).
The resulting mixture is incubated 1 h at 22° C. to allow the binding of the biotinylated phosphorylated peptide to the streptavidine-XL665 and the PT66-Eu-Chelate. Subsequently the amount of phosphorylated substrate is evaluated by measurement of the resonance energy transfer from the PT66-Eu-Chelate to the streptavidine-XL665. Therefore, the fluorescence emissions at 620 nm and 665 nm after excitation at 350 nm is measured in a HTRF reader, e.g. a Rubystar (BMG Labtechnologies, Offenburg, Germany) or a Viewlux (Perkin-Elmer). The ratio of the emissions at 665 nm and at 622 nm is taken as the measure for the amount of phosphorylated substrate. The data are normalised (enzyme reaction without inhibitor=0% inhibition, all other assay components but no enzyme=100% inhibition). Normally test compound are tested on the same microtiter plate at 10 different concentrations in the range of 20 μM to 1 nM (20 μM, 6.7 μM, 2.2 μM, 0.74 μM, 0.25 μM, 82 nM, 27 nM, 9.2 nM, 3.1 nM and 1 nM, dilution series prepared before the assay at the level of the 100fold conc. stock solutions by serial 1:3 dilutions) in duplicate values for each concentration and IC50 values are calculated.
AlphaScreen SureFire eIF4E Ser209 Phosphorylation Assay
The AlphaScreen SureFire eIF4E Ser209 phoshorylation assay can be used to measure the phosphorylation of endogenous eIF4E in cellular lysates. The AlphaScreen SureFire technology allows the detection of phosphorylated proteins in cellular lysates. In this assay, sandwich antibody complexes, which are only formed in the presence of the analyte (p-eIF4E Ser209), are captured by AlphaScreen donor and acceptor beads, bringing them into close proximity. The excitation of the donor bead provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in the emission of light at 520-620 nm.
Surefire EIF4e Alphascreen in A549 Cells with 20% FCS Stimulation
For the assay the AlphaScreen SureFire p-eIF4E Ser209 10K Assay Kit and the AlphaScreen Protein A Kit (for 10K assay points) both from Perkin Elmer are used.
On day one 50.000 A549 cells are plated in a 96-well plate in 100 μL per well in growth medium (DMEM/Hams' F12 with stable Glutamin, 10% FCS) and incubated at 37° C. After attachment of the cells, medium is changed to starving medium (DMEM, 0.1% FCS, without Glucose, with Glutamin, supplemented with 5 g/L Maltose). On day two, test compounds are serially diluted in 50 μL starving medium with a final DMSO concentration of 1% and are added to A549 cells in test plates at a final concentration range from as high 10 μM to as low nM depending on the activities of the tested compounds. Treated cells are incubated at 37° C. for 2 h. 37 ul FCS is added to the wells (=final FCS concentration 20%) for 20 min. Then medium is removed and cells are lysed by adding 50 μL lysis buffer. Plates are then agitated on a plate shaker for 10 min. After 10 min lysis time, 4 μL of the lysate is transferred to a 384well plate (Proxiplate from Perkin Elmer) and 5 μL Reaction Buffer plus Activation Buffer mix containing AlphaScreen Acceptor beads is added. Plates are sealed with TopSeal-A adhesive film, gently agitated on a plate shaker for 2 hours at room temperature. Afterwards 2 μL Dilution buffer with AlphaScreen Donor beads are added under subdued light and plates are sealed again with TopSeal-A adhesive film and covered with foil. Incubation takes place for further 2 h gently agitation at room temperature. Plates are then measured in an EnVision reader (Perkin Elmer) with the AlphaScreen program. Each data point (compound dilution) is measured as triplicate.
The tumor cell proliferation assay which can be used to test the compounds of the present invention involves a readout called Cell Titer-Glow® Luminescent Cell Viability Assay developed by Promega® (B. A. Cunningham, “A Growing Issue: Cell Proliferation Assays, Modern kits ease quantification of cell growth”, The Scientist 2001, 15(13), 26; S. P. Crouch et al., “The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity”, Journal of Immunological Methods 1993, 160, 81-88), that measures inhibition of cell proliferation. Generation of a luminescent signal corresponds to the amount of ATP present, which is directly proportional to the number of metabolically active (proliferating) cells.
Cultivated tumour cells (MOLM-13 (human acute myeloid leukemia cells obtained from DSMZ # ACC 554), JJN-3 (human plasma cell leukemia cells obtained from DSMZ # ACC 541), Ramos (RA1) (human Burkitt's lymphoma cells obtained from ATCC # CRL-159)) are plated at a density of 2,500 cells/well (JJN-3), 3,000 cells/well (MOLM-13), 4,000 cells/well (Ramos (RA1)), in a 96-well multititer plate (Costar 3603 black/clear bottom) in 100 μL of their respective growth medium supplemented with 10% fetal calf serum. After 24 hours, the cells of one plate (zero-point plate) are measured for viability. Therefore, 70 μL/well CTG solution (Promega Cell Titer Glo solution (catalog # G755B and G756B)) is added to zero-point plate. The plates are mixed for two minutes on orbital shaker to ensure cell lysis and incubated for ten minutes at room temperature in the dark to stabilize luminescence signal. The samples are read on a VICTOR 3 μlate reader. In parallel, serially test compounds are diluted in growth medium, and 50 μL of 3× dilutions/well are pipetted into the test plates (final concentrations: 0 μM, as well as in the range of 0.001-30 μM). The final concentration of the solvent dimethyl sulfoxide is 0.3-0.4%. The cells are incubated for 3 days in the presence of test substances. 105 μL/well CTG solution (Promega Cell Titer Glo solution (catalog #G755B and G756B)) is added to the test wells. The plates are mixed for 2 minutes on an orbital shaker to ensure cell lysis and incubated for 10 min at room temperature in the dark to stabilize luminescence signal. The samples are read on a VICTOR 3 μlate reader. The change of cell number, in percent, is calculated by normalization of the measured values to the extinction values of the zero-point plate (=0%) and the extinction of the untreated (0 μm) cells (=100%).
Thus the compounds of the present invention effectively inhibit one or more kinases and are therefore suitable for the treatment or prophylaxis of diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, or inappropriate cellular inflammatory responses, particularly in which the uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, or inappropriate cellular inflammatory responses is mediated by MKNK, more particularly in which the diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, or inappropriate cellular inflammatory responses are haemotological tumours, solid tumours and/or metastases thereof, e.g. leukaemias and myelodysplastic syndrome, malignant lymphomas, head and neck tumours including brain tumours and brain metastases, tumours of the thorax including non-small cell and small cell lung tumours, gastrointestinal tumours, endocrine tumours, mammary and other gynaecological tumours, urological tumours including renal, bladder and prostate tumours, skin tumours, and sarcomas, and/or metastases thereof.
| Number | Date | Country | Kind |
|---|---|---|---|
| 14169842.3 | May 2014 | EP | regional |
| 14190622.2 | Oct 2014 | EP | regional |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2015/061358 | 5/22/2015 | WO | 00 |
